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Cancer metastasis is responsible for 90% of cancer deaths.  It is well known that metabolic 
reprogramming, which is one of the hallmarks of cancer, plays an important role in 
increasing cancer cell migration and metastasis. Changes in mitochondrial morphology are 
thought to affect their function; however the mechanism is still unclear. Moreover, it is not 
known whether changes in mitochondrial morphology and their metabolism can affect cell 
migration or not. The overall aim of this study was to investigate the link between 
mitochondrial morphology and their metabolism with cancer cell migration.  
Several factors such as different glucose levels, PGC-1α activator, hydrogen peroxide, and 
anti-metabolic agents that can affect mitochondrial morphology has been used to 
investigate the effect of mitochondrial morphologic changes on their metabolism and cell 
migration. Furthermore, p66shc and TRAP1, the function of which are related to 
mitochondria, have been identified as novel components related to reprogramming 
metabolism and cell migration. Using confocal and time-lapse microscopy, as well as 
through measuring ATP production, lactate production, and estimation of ROS generation 
in MDA-MB-231 breast cancer cells, HT1080 fibrosarcoma cells, and HeLa cells.  
This study has been found that mitochondria fragmentation induces metabolic 
reprogramming from oxidative phosphorylation to glycolysis, due to reducing 
mitochondrial inner membrane surface area which required for mitochondrial oxidative 
phosphorylation enzyme activity, which in turn led to increases in cancer cell migration. 
Inhibition of mitochondrial fragmentation using a mitochondrial division-1 inhibitor has 
led to significant decreases in glycolysis and cell migration. 
This study has also shown that the function of pro-apoptotic p66shc and cytoprotective 
TRAP1 are correlated strongly to each other. Increasing the expression of p66shc can 
trigger metabolic reprogramming and enhance cancer cell migration, whereas, increasing 
TRAP1 expression inhibits apoptosis, which can be induced by activated p66shc.  
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In conclusion, mitochondrial fragmentation can alter cancer cell metabolism to glycolysis 
and activated p66shc is a main cause of this metabolic reprogramming, which controls 
cancer cell migration. In addition, TRAP1 and mitochondrial fragmentation can increase 
resistance to apoptosis induced by oxidative stress. This finding could be exploited in the 
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Chapter One: General introduction  
1.1 Cancer  
Cancer is considered to be a leading cause of death worldwide. According to a WHO 
report in 2015 cancer deaths are projected to increase from 8.2 million deaths in 2012 to 
more than 13million deaths per year in 2030. There are more than 100 types of cancer with 
different risk factors, which can originate from different cell types and organs. These cells 
can proliferate uncontrollably and migrate and invade normal surrounding tissue and 
metastasize to distant organs (Hanahan and Weinberg, 2000; Stratton et al., 2009).  
Transformation of normal cells to cancerous cells is a multistep process which is started by 
mutations in genetic material that accumulate over time. This can lead to changes in gene 
expression and function, and this will reflect on the growth and behaviour of cells 
(Hanahan and Weinberg, 2000; Lopez-Saez et al., 1998). Unlimited capacity for cell 
division and the ability to migrate and colonise in distant parts of body makes cancer a 
dangerous disease that threatens life (Martin et al., 2013; Sudheer Shenoy P, 2014) 
In general cancer cells acquire several biological capabilities that enable them to develop 
from normal cells. Hanahan and Weinberg (2000) described six Hallmarks of cancer cells 
which are self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue 
invasion and metastasis, limitless replicative potential, sustained angiogenesis and evading 
apoptosis and these are illustrated in Figure 1.1. Then they address two new enabling 
characteristic of cancer which is genomic instability in cancer cells, and tumour-promoting 
inflammation, which promotes tumour progression via a variety of ways (Hanahan and 




Figure 1.1: The Hallmarks of cancer. The characteristics are believed to govern  
the transformation of normal cells to a malignant cancer.  
Cited from (Hanahan and Weinberg, 2011). 
They also address other two additional emerging Hallmarks, which play an important role 
in the development of cancer cells. The first includes reprogramming of cellular energy 
metabolism and the second includes the ability of cancer cells to avoid the immune system. 
Figure 1.2 shows the new emerging hallmarks and enabling characteristics of cancer cells. 
 
Figure1.2: emerging hallmarks and enabling characteristics 
Cited from (Hanahan and Weinberg, 2011) 
The Hallmarks of cancer cell can be summarized in the following points: 
I. Sustaining Proliferative Signaling: Proliferation of normal cells requires growth 
factors, which bind with receptors on cell surface and trigger cell division. Cancer 
cells have the ability to sustain proliferative signaling by several ways: they can 
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generate their own growth factors that ligand its receptors, thus resulting in autocrine 
proliferative stimulation. In some cases cancer cells increase their growth factor 
receptors. Cell surface receptors can also be deregulated as a result of mutation 
leading to hyper-responsive of growth factor ligand and constant cell division, 
permitting cancer cells to survive beyond its normal life span (Feitelson et al., 2015; 
Hanahan and Weinberg, 2011). 
II. Evading Growth Suppressors: There are several anti-growth signals that limit growth 
and proliferation in normal cells called tumour suppressor proteins such as 
suppressor protein RB (retinoblastoma-associated) and TP53 (tumor protein p53) that 
code for either inhibiting cell cycle or promoting apoptosis, and sometimes do both. 
Cancer cells evade these mechanisms as a consequence of mutations in tumour 
suppressor genes (Hanahan and Weinberg, 2000; Nahta et al., 2015). 
III. Evading apoptosis: Apoptosis is a normal process that removes abnormal cells when 
their DNA is damaged and cannot be repaired. Cancer cells can evade apoptosis 
through downregulating or inhibiting pro-apoptotic proteins and/or upregulating of 
anti-apoptotic proteins (Fernald and Kurokawa, 2013; Fulda, 2010; Hanahan and 
Weinberg, 2011). 
IV. Enabling Replicative Immortality: Cell growth and division in normal cells is limited 
by telomeres, which are terminal ends of chromosomes. During the cell cycle 
telomeres progressively shorten, until cells reach their senescence and die. It has 
been observed that normal cells have capacity for only 60-70 doublings. While, 
cancer cells are able to overcome this barrier through telomere maintenance through 
up-regulating expression of the telomerase enzyme that adds to the end of telomere 
DNA hexa-nucleotide repeats. As a result, the cancer cells can continue to proliferate 
without senescence and death (Hanahan and Weinberg, 2000; Yaswen et al., 2015). 
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V. Inducing Angiogenesis: As cells divide and the number of them increases, there will 
be more requirements for oxygen and nutrients which are essential for cell growth. 
Cancer cells have the ability to encourage the formation of new blood vessels to 
supply developed tumour tissue with essential growth requirements and to ensure 
their survival and expansion. This is achieved by changes in the regulated balance 
between angiogenesis induction factors and inhibitors of it (Broertjes, 2015; Hanahan 
and Weinberg, 2011). 
VI. Activating Invasion and Metastasis: one of most important characteristics of cancer 
cells is their ability to migrate and spread from their origin location to other parts of 
the body, where they may succeed to form a secondary tumour. Cancer cells acquire 
this ability by modification in their membrane proteins, which reduces cell to cell 
adhesion, also they secret extracellular proteolytic enzymes that digest surrounding 
barriers (Broertjes, 2015; Fouad and Aanei, 2017) 
VII. Evading the immune system: it is clear that the immune system is constantly 
monitoring cells and tissues and plays an essential role in the detection and 
eradication of any abnormal growth of incipient neoplasia. However, cancer cells can 
escape from immune-mediated detection and limit immunologic killing using several 
mechanisms especially in non-virus inducing cancer. One strategy to evade the 
immune system is by impairing antigen presentation that fails to activate an immune 
response (Hanahan and Weinberg, 2011; Igney and Krammer, 2002). 
VIII. Genomic Instability: One characteristic of most cancer cells is genomic instability. 
There are different forms of genomic instability. However, chromosomal instability 
(CIN) is considered a major form, which is characterized by high rate of changes in 
chromosome structure and number over time in cancer cells compared with normal 
cells. Microsatellite instability is another form of genomic instability. This is 
characterized by the expansion or contraction of the number of oligonucleotide 
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repeats present in microsatellite sequences (Microsatellites refer to 2-5 nucleotide 
repeats in DNA sequences) (Broertjes, 2015).  
There are several components of the genomic maintenance machinery, tumor 
suppresser 53 (p53) is an essential protein that controls DNA damage either through 
inducing DNA repair or apoptosis if the damage is excessive, however, cancer cells 
through a breakdown in repairing machinery can increase the rates of mutation for 
tumor progression (Ferguson et al., 2015; Negrini et al., 2010). 
IX. Tumour promoting inflammation: Inflammation is an immune response in a specific 
microenvironment that reflects an attempt of the immune system to eradicate infected 
cells, injured cells, or neoplasia. There are several evidences that indicate that in the 
earliest stages of neoplastic progression, inflammation has an important role in 
development of incipient neoplasia into cancer (de Visser et al., 2006; Qian and 
Pollard, 2010). Inflammatory cells through release of chemicals which include 
growth factors, survival factors, pro-angiogenic factors, extracellular matrix-
modifying enzymes that facilitate angiogenesis, invasion, and cell migration, and 
inductive signals that lead to activation of epithelial-mesenchymal transition EMT 
and other characteristics that facilitating programs into the tumor microenvironment 
can contribute in accelerating the tumor growth (de Visser et al., 2006; Grivennikov 
et al., 2010). 
X. Reprogramming energy metabolism: Usually normal cells obtain ATP energy 
through the oxidative phosphorylation process, in which cells metabolize glucose to 
pyruvate in the glycolysis process in cytoplasm, then pyruvate completely oxidizes in 
the citric acid cycle in mitochondria into CO2 and the reduced molecules of NADH 
and FADH2. The electron transport system that includes a series of oxidation – 
reduction reactions, transfer the electrons from NADH and FADH2 to O2 leading to 
production of H2O and generation of ATP. However, cancer cells reprogram the 
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pathway of energy production: they convert pyruvate to lactate in the cytosol. The 
ATP energy produced in glycolysis is only 2ATP which is less by 18 times the 
energy yield in oxidation phosphorylation. However the consumption of glucose and 
production of ATP in cancer cell is more than 100 times faster than non-cancer cells 
(Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). 
Although most developed anti-cancer drugs are designed to target the hallmarks of cancer, 
their effectiveness are still limited (Cree and Charlton, 2017). This issue may be due to that 
majority of anticancer therapy has specific molecular targets which have role in one 
hallmark, and such specificity with cancer cells maybe not effective since each hallmark 
can be regulated by more than one pathway. This allowing cancer cells to survive and 
adapted to applied therapy through mutation, reprogramming, epigenetic, and remodeling 
of the stromal microenvironment, which can give the capability to renew tumor growth and 
progress resistance (Cree and Charlton, 2017; Hanahan and Weinberg, 2011). 
To overcome this issue, it will be more effective if targeting multiple signaling pathways 
that modulate the same hallmark or targeting more than one hallmark to get better results 
from cancer treatment. However, despite difficulty studying this strategy, the concept 
remains important to improve the efficacy of cancer treatment. 
1.2 Cancer Metastasis  
Metastasis, which is the process of invasion and spreading of neoplastic cells from the 
original site of the tumor to other distant organs, is the biggest challenge for treatment and 
is responsible for the majority of cancer deaths (Khan and Mukhtar, 2010; Labelle and 
Hynes, 2012). In order to metastasize successfully, tumor cells must complete several 
sequential events, called the metastatic cascade (Gupta and Massagué, 2006; Martin et al., 
2013). This process as shown in Figure 1.3 includes; detachment of cancer cells from the 
extracellular matrix in the original site, which is called the primary tumor (1), migration to 
invade surrounding stroma, which is called the process of invasion (2), successful 
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penetration into lumina of blood vessels or lymphatic channels, which is called 
intravasation (3), successful transport via vasculature (4), arrest and colonization in distant 
organ sites (5), extravasation into the surrounding parenchyma tissue (6), initiation of 
growth, colonization and  survival the new microenvironment, this step is called  
metastatic colonization (Labelle and Hynes, 2012; Martin et al., 2013; Ray and Jablons, 
2010; Valastyan and Weinberg, 2011). 
 
Figure1.3: Sequential events of the metastatic cascade. 
Cited from (Alsarraj and Hunter, 2012) 
 
1.3 Cell Migration 
Cell migration plays a crucial role in several important processes in the multicellular 
organisms such as, formation, development and maintenance of new tissues, wound 
healing, and immune responses (Franz et al., 2002; Trepat et al., 2012; Weaver, 2017).  
However, changes in the signaling pathways can lead to many pathologic states such as 
mental disorders (Horwitz and Webb, 2003) and progression of cancer (Sever and Brugge, 
2015). In fact, it is considered as one of the main factors that affect the cell invasion and 
metastatic character of cancer cells (Aguiar et al., 2014; Martin et al., 2013). 
The process of cell migration involves changes in cell shape as a result of cytoskeletal 
modifications, changes in the cell-cell and cell-extracellular matrix (ECM) adhesion, and 
responses to stimulus (Chen et al., 2013). The migration of single cells is initiated by 
extending protrusions in the direction of movement, which is driven by polymerization of 
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actin and filament elongation at the leading edge, forming a lamellipodia and/or filopodia 
that attach to the specific ECM protein on the substrate. Since, attachment of the cells to 
the ECM at the leading edge is tighter than at the rear of the cell (trailing edge) and as a 
result of cell contraction, the cell body extends forward; this process is coupled with 
detachment of the trailing edge of the cell from substrate, as shown in Figure 1.4 (Chen et 
al., 2013; Lauffenburger and Horwitz, 1996; Martin et al., 2013; Schmidt et al., 1993). 
 
Figure 1.4: Mechanism of cell migration. Migrating cells extends a protrusion in direction of motion by 
actin polymerization at the leading edge, then adheres its leading edge to the surface on which it is moving 
and detached at the trailing edge. Finally, it pulls the whole cell body forward by contractile forces generated 
at the cell body and rear of the cell. Cited from (Ananthakrishnan and Ehrlicher, 2007). 
 
It has been documented that a migrating cell secretes protease enzymes such as matrix 
metalloproteinases (MMP), which degrade the extracellular matrix proteins at trailing edge 
(Lu et al., 2011) leading to increased cell migration speed (DiMilla et al., 1993; Nabeshima 
et al., 2002). 
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Several molecules and pathways have been documented that can play an important role in 
the signaling processes that  enhance or supress cell migration (Martin et al., 2013). 
Metabolism reprogramming, which is known as the Warburg effect, and changes in 
mitochondrial morphology are two important factors that can control cell migration (Caino 
and Altieri, 2015; Campello and Scorrano, 2010; Han et al., 2013; Marelli-Berg and 
Jangani, 2018; Wang et al., 2015b).  
1.4 Mitochondria  
Mitochondria are important organelles in cells due to their essential role in regulating 
several processes and pathways. They are considered a powerhouse of the cell; since they 
supply the cells with more than 90% of required ATP energy (Marchi et al., 2012; Vyas et 
al., 2016). They also have a crucial role in apoptosis, production of reactive oxygen species 
(ROS), biosynthesis of required molecules for proliferation, calcium signaling, and aging 
(Bratic and Larsson, 2013; Jeong and Seol, 2008; Vandecasteele et al., 2001). Therefore, it 
is not surprising that mitochondria are implicated in range of disorders and diseases 
including progression of tumors (Hsu et al., 2016; McInnes, 2013; Ridge and Kauwe, 
2018) .  
1.4.1 Mitochondrial structure and morphology 
Mitochondria are unique organelles within the cells; they are surrounded by double 
membrane, which are the outer and inner mitochondrial membrane. In general, 
mitochondria are composed of four compartments and each of them has different 
functions. The outer membrane (OM) contains many porins, which are protein like 
channels that allow free diffusion of molecules into the intermembrane space. The 
intermembrane space (IMS) is a space located between the two membranes and contains 
proteins such cytochrome c that play a fundamental role in apoptosis. The inner membrane 
(IM) is inwardly folded forming several cristae expanding the inner surface area of the 
mitochondrial membrane and is also characterized by its impermeability for most ions and 
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molecules. However, it contains transporter proteins that allow crossing of selected 
molecules and ions, in addition to the electron transport chain enzymes and ATP synthase. 
And the last mitochondrial compartment is the  matrix, which contain about 65% of the 
total mitochondrial proteins, including enzymes and proteins participating in tricarboxylic 
acid cycle (TCA cycle), as shown in Figure 1.5 (Kühlbrandt, 2015; Mannella, 2006; 
McCarron et al., 2013).  
The number of mitochondria are varies widely by cell types, tissue types, and organism 
depending on metabolic demands. Some cells, such as immune cells have only few 
mitochondria, whilst, others such as hepatocytes contain hundreds to thousands (Zeviar et 
al., 2014). Their shape is typically range from spherical to tubular networks, with the size 
ranging from 1-10µm (McCarron et al., 2013). The number and shape of mitochondria in 
the cell can be changed as a response to different physiological, pathological, and 
environmental conditions (Knez et al., 2016; Verschoor et al., 2013). 
 
Figure 1.5: Basic mitochondrial structure. Typically mitochondria composed of four compartments; 
 outer membrane, intermembrane space, inner membrane, and matrix 
 
Mitochondria contain their own DNA (mtDNA). In humans this genome, which is 
inherited from the mother, consists of 16,569 base pairs and encodes 37 genes; 13 genes 
are for electron transport chain proteins, 22 genes are for transfer RNA (tRNA), and two 







 copies and this number can vary by cell type. Replication of mtDNA is carried 
out by DNA polymerase γ, which is found only in the mitochondria, and is independent 
from nuclear DNA (Hu et al., 2016; Rooney et al., 2015).  
Mutation in mtDNA is linked to many diseases including type 2 diabetes (Rolo and 
Palmeira, 2006) neurodegenerative diseases such as Parkinson and Alzheimer Disease 
(Coskun et al., 2012), and several  cancers  (Yu, 2011). This is may be due to the fact that 
mtDNA lack introns and histones that protect them from mutation induced by oxidative 
stress and other sources of genotoxic damage, as well as the fact that the DNA repair 
mechanisms are inefficient. Therefore, mtDNA mutations can lead to defects in oxidative 
phosphorylation (Gredilla, 2011). Recently, changes in mtDNA copy number have been 
used as a biomarker for studying many diseases related to mitochondria. These changes in 
mtDNA can be measured through quantitative real-time PCR (qPCR) method (Mei et al., 
2015; Memon et al., 2017). 
1.4.2 Mitochondrial dynamics 
Mitochondria are highly dynamic organelles and continuously undergo morphological 
changes through mitochondrial fission, fusion, and movement of mitochondria in the 
cytosol (van der Bliek et al., 2013). The balance between fission and fusion is necessary 
for cell survival and several physiological functions including cell growth, cell death, and  
cell migration,  and they are tightly related to metabolic function (Hu et al., 2017; Mishra 
and Chan, 2014; Simula et al., 2017; Zemirli et al., 2018). These processes require co-
ordinated synthesis and import of more than 1000 proteins which are encoded by the 
nuclear genome and mitochondrial genome. In addition to that, mitochondrial fission 
requires an additional step, which is mitochondrial DNA replication (Mishra and Chan, 
2014). 
The balance between fission and fusion processes is regulated through specialized protein 
machinery. As summarized in Figure 1.6, the fission of mitochondria is induced by 
12 
 
dynamin-related protein1 (Drp1) (Frank et al., 2001). This protein, which is a large 
GTPase and localized in the cytosol, translocates to the mitochondrial outer membrane 
(OMM) during mitochondria fission where it binds to OMM through several receptors 
such as mitochondrial fission 1 protein (Fis1), mitochondrial fission factor (Mff), and 
mitochondrial dynamics proteins of 48 and 51 kDa (MiD48/51), leading to polymerization 
and formation of a ring-like structure around the mitochondria (Gao et al., 2017; Trewin et 
al., 2018), which divides the mitochondria into two separate organelles upon hydrolysis of 
guanosine triphosphate (GTP) (Mishra et al., 2010).  
In contrast to fission, the mitochondrial fusion process involves fusion of both outer and 
inner membrane. This process is regulated by three large GTPase proteins, which includes; 
Mitofusin 1 (Mfn1), Mitofusin 2 (Mfn2), and optic atrophy protein 1 (OPA1) (Ni et al., 
2015). During mitochondria fusion, Mfn1/Mfn2 proteins dimerise at the OMM between 
two individual mitochondria, which are drawn to each other upon GTP hydrolysis. After 
fusion of the outer membrane of two adjacent mitochondria, OPA1 starts to fuse the IMM, 
depending on the GTPase activity and hydrolysis of GTP (Santel and Fuller, 2001; Trewin 
et al., 2018).  
1.4.3 Mitochondrial morphology and function 
It has been documented that changes in mitochondrial morphology accompany changes in 
metabolic function (Shin et al., 2016). The relationship between mitochondrial size and 
metabolic activity has revealed that elongated, network-like mitochondria are characteristic 
metabolically active cells, whereas, small size mitochondria are common  in inactive cells 




Figure 1.6: Mitochondrial fission and fusion. Mitochondria alter their morphology toward fusion or fission 
to maintain cellular homeostasis depending on physiological conditions. Mfn1, Mfn2, and OPA1 proteins are 
the major regulators of mitochondrial fusion. The mitochondrial fission process is mainly conducted by 
Drp1, and Fis1. 
Mitochondrial morphology can be maintained via the balance between fission-fusion 
continuously, however, several factors that can cause a stress on the cells such as exercise, 
temperature, U.V., hyperglycaemia, H2O2, anti-cancer agents can disrupt this balance 
leading to hyperfragmentation of mitochondria (Aung et al., 2017; Van Beersel et al., 
2013; Yu et al., 2011; Yu et al., 2006), which can lead to reduced capacity for ATP 
production via oxidative phosphorylation (Alecu et al., 2017); this is implicated in several 
pathological conditions including cardiovascular disease, neurodegenerative disease, 
diabetes mellitus, and  cancer progression (Bordi et al., 2017; Rosdah et al., 2016; Suárez-
Rivero et al., 2017).  In contrast, it has been shown that conditions such as starvation, 
which can lead to elongation of mitochondria, enhance resistance to oxidative stress and 
apoptosis (Mai et al., 2010; Rambold et al., 2011), and stimulates  the cell  to shift their 


















Figure 1.7.  However, the mechanism responsible for the initiation and changes in 
mitochondrial morphology is still not entirely clear. 
1.4.4 Mitochondrial biogenesis 
Mitochondrial biogenesis is the mechanism through which the cell can adapt to increased 
energy demands through increasing their individual mitochondrial mass and increasing 
mitochondrial copy number (Fabian et al., 2014; Jornayvaz and Shulman, 2010). It can be 
stimulated by distinct signaling pathways in response to exercise, to development, and in 
several diseases (Hood, 2009; Sanchis-Gomar et al., 2014; Vaarmann et al., 2016).  
It has been suggested that increasing mitochondrial biogenesis in cancer cells can 
impair carcinogenesis, and decrease growth rates since it boosts oxidative phosphorylation 
for ATP production and decreases dependence on aerobic glycolysis, which is essential for 
high proliferation in cancer cells. Moreover, it was found that mitochondrial 
biogenesis leads cancer cells to be less invasive due to reduction in lactate production 
(Wang and Moraes, 2011). Other studies have demonstrated that mitochondrial biogenesis 
can promote cancer tumor growth via increased energy production and protects cancer 
cells from autophagy as a result of increasing role of antioxidant which neutralized 
mitochondrial-released ROS(Salem et al., 2012). It was reported that  increasing 
mitochondrial mass via mitochondrial biogenesis can enhance carcinogenesis of epithelial 
cells (Sotgia et al., 2013). Despite that, the role of mitochondrial biogenesis in  cancer cell 
proliferation  as well as in migration and metastasis of cancer cells remains controversial 
and requires more investigation. 
1.4.5 Mitochondrial mitophagy 
Human cells can selectively remove damaged or unnecessary mitochondria through 
mitochondrial autophagy, which is called mitophagy. This process is crucial in maintaining 
mitochondrial quality, as well as for maintaining cellular homeostasis. Damaged 
mitochondria can generate a high amount of stress signals which can lead to cellular 
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dysfunction and induction of apoptosis (Hamacher-Brady and Brady, 2016; Novak, 2012). 
Reducing this process can lead to several diseases such as metabolic disease, 
neurodegenerative diseases, and cancer (Song et al., 2015; Um and Yun, 2017). 
 
 
Figure 1.7: Mitochondrial morphology and activity depending on the conditions. Under normal 
condition mitochondria undergo frequent cycles of fusion and fission to allow spreading of metabolites and 
macromolecules throughout the entire compartment. When the bioenergetics state becomes critical, for 
example under nutrient deprivation, highly fused mitochondria are formed to optimize mitochondrial 
function. Mitochondrial fission is required for removal of damaged and inactive organelles by autophagy or 
for resistant abnormal condition. Fragmented mitochondria constitute the preferred morphological state when 
respiratory activity is low. Modified from (Westermann, 2012). 
The process of mitophagy starts when factors such as ROS, aging, and lack of nutrients 
cause mitochondrial dysfunction, this leads to accumulation of high levels of ROS as a 
result, mitochondria become depolarized and damaged. Damaged mitochondria can then 
fuse with lysosomes forming autophagosome, which degrades damaged mitochondria 
completely, as shown in Figure 1.8 (Song et al., 2015). This process usually leads to 





1.4.6 Effect of glucose level on mitochondrial morphology 
Mitochondrial morphology is highly dynamic; it can be shift between small, 
fragmented and large, elongated network-like shape. Several factors such as high glucose 
level (Trudeau et al., 2011) , anticancer agents (Cao et al., 2017), U.V. (Sanjuán Szklarz 
and Scorrano, 2012), and H2O2 (Iqbal and Hood, 2014) can affect mitochondrial 
morphology. 
 
Figure 1.8:  Mitophagy process.  Defective mitochondria will damage themselves 
then fused with lysosomes forming autophagosome, which degraded 
mitochondria completely. Cited from(Song et al., 2015). 
 
It has been demonstrated that high glucose level affects mitochondrial morphology and 
shifts them toward fragmentation (Trudeau et al., 2011) which may be due to activation of 
Drp1 protein (Filippi et al., 2017). There is evidence that hyperglycaemia, which is 
characterized by high glucose levels in the blood, is implicated in several diseases such as 
neurodegenerative diseases, cardiovascular disease, diabetes mellitus, and cancer (Knott et 
al., 2008; Ong and Hausenloy, 2010; Rolo and Palmeira, 2006; Ryu et al., 2014). 
Elevated levels of glucose exerts oxidative stress on the cells, which can lead to mtDNA 
mutation and changes in ROS scavenger enzymes, leading to mitochondrial dysfunction 
and increasing ROS generation. This state can lead to fragmentation of mitochondria and 
induce apoptosis (Hou et al., 2015). However, despite the fact that it is well known that 
17 
 
high glucose is essential for maintaining high cancer cell proliferation and metastasis; it is 
still not clear how cancer cells avoid the apoptotic effect of high glucose.   
In contrast, it has been reported that low glucose levels support an elongation shape of 
mitochondria due to inhibition of Drp1 protein (Rambold et al., 2011). However, it does            
not seem that this protein, which is essential in mitochondrial fission, plays any role in 
mitochondrial fusion and in mitochondrial biogenesis.   
1.4.7 Effect of H2O2 on mitochondrial morphology 
While, generation of low concentrations of ROS is necessary for the regulation of several 
biological processes in the cell such as cellular proliferation and differentiation, high level 
of ROS exerts several damaged outcomes including accumulation of mtDNA mutation, 
mitochondrial dysfunction, growth inhibition and apoptosis (Chen et al., 2010; Cribbs and 
Strack, 2007)   
It has been shown that exposure to exogenous hydrogen peroxide (H2O2) promotes several 
defense mechanisms by the cells including changes in mitochondrial morphology toward 
fragmentation through enhancing Drp1activation (Fan et al., 2010). Despite that the exact 
mechanism is not clear as H2O2 can interact with several proteins and pathways (Gough 
and Cotter, 2011; Lennicke et al., 2015). 
Contrary to normal cells, cancer cells might exploit increases in H2O2 for their 
reprogramming metabolism, proliferation, angiogenesis and metastasis(Lopez-Lazaro, 
2007).   
1.4.8 Effect of PGC-1α on mitochondrial morphology 
The peroxisome proliferator-activated receptor γ activator-1 alpha (PGC-1α) is a 
transcription factor that is involved in the regulation of mitochondrial biogenesis through 
stimulation of several transcription factors such as nuclear respiratory factors-1 (NRF-1) 
and NRF-2, which interact and promote the expression of mitochondrial transcription 
factor A (Tfam). This leads to activation of mitochondrial enzymes that induce 
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transcription and replication of mtDNA (Jornayvaz and Shulman, 2010). It can be activated 
in response to several factors including cold exposure, nutrient deprivation, exercise, 
chemotherapy, and oxidative stress (Tan et al., 2016).  
PGC-1 α regulates oxidative metabolism through increasing metabolic enzymes required 
for glycolysis and oxidative phosphorylation, as well as through increasing mitochondrial 
mass and number in order to generate a  greater amount of required ATP energy by the cell 
(LeBleu et al., 2014). Moreover, it can play a protective role against apoptotic effects of 
ROS generation via increasing ROS scavenger enzymes in mitochondria(Chen et al., 
2011). 
It was documented that exercise elevates expression of PGC-1α in skeletal muscle, which 
partially switch to glycolysis. Upon expression, it reduces the expression of lactate 
dehydrogenase A (LDH A), which converts pyruvate and L-lactate, and enhances oxidative 
phosphorylation (Summermatter et al., 2013).  It has been reported that PGC-1α promotes 
metastasis and its silencing reduces invasive ability (LeBleu et al., 2014). 
Recently, it has been shown that PGC-1α plays an important role in mitochondrial fission-
fusion processes through controlling expression of the mitochondrial fission protein, Drp1, 
and its overexpression can induce mitochondrial fragmentation and cell death (Dabrowska 
et al., 2015). The evidence suggests that excessive mitochondrial fragmentation in some 
diseases such as Parkinson's disease is due to overexpression of PGC-1α, which is 
increased as a result of increasing ROS level, which in- turn can induce expression of Drp1 
protein (Peng et al., 2017; Santos et al., 2015).  
1.4.9 Role of mitochondria in apoptosis 
Apoptosis or programmed cell death is a highly organized process in which cells signal to 
their self-destruction in order for proper homeostasis, embryonic development,  or to 
prevent abnormal cell growth (Elmore, 2007). This process is characterized by certain 
morphological changes, which includes membrane blebbing, cell shrinkage, protein 
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cleavage, chromatin condensation, nuclear and DNA fragmentation, then the dying cells 
will be eliminated by phagocytic cells (Xiong et al., 2014). 
Apoptosis is regulated via two pathways called death receptor (extrinsic) and 
mitochondrial (intrinsic) pathways (Jin and El-Deiry, 2005). The first pathway is activated 
by external signals, which are called death inducing ligands such as, Fas ligand, tumor 
necrosis factor (TNF) ligand, and TNF-related apoptosis-inducing ligand (TRAIL), which 
bind to death receptors such as Fas, TNFR1, and DR4/DR5. This pathway is mainly 
activated by other cells such as immune cells. Whereas, the second pathway is initiated by 
endogenous signals such as oxidative stress, DNA damage, chemical agents. An essential 
event in this pathway is mitochondrial outer membrane permeabilization (MOMP) and 
formation of the permeability transition pore complex (PTPC) (Jin and El-Deiry, 2005; 
Wang and Youle, 2009). 
A set of caspase enzymes, which are widely expressed in the cell as an inactive proenzyme 
form, can be activated following initiation of external or internal pathway and then cleave 
proteins at aspartic acid residues. Once proenzyme caspase is activated, it can activate 
other procaspases, leading to initiation of a protease cascade. This leads to amplifying the 
apoptotic signaling pathway and promotes rapid cell death. There are 10 major identified 
caspases, which can be categorized into initiators includes (caspase 2, 8, 9, 10), effectors or 
executioners includes (caspase 3, 6, 7) and inflammatory caspases includes (caspase 1, 4, 
5). There are four more inflammatory caspases (caspase 11, 12, 13, and 14), which are 
activated in apoptosis in specific cells or tissues, as shown in Table 1.1 (Bratton et al., 















In humans, oxidative stress, which can be induced by many factors including 
hyperglycaemia, has been implicated in several disorders and diseases including cancer, 
and diabetes mellitus. Exposure to strong or prolonged oxidative stress can induce 
mitochondrial induced apoptosis via elevation of intracellular ROS (Nita and Grzybowski, 
2016).  
Initiation of mitochondrial apoptosis is controlled by a family of proteins known as Bcl-2 
family (Chipuk and Green, 2008). As summarized in Table 1.2,  the Bcl-2 family consists 
of three groups; pro-apoptotic Bcl-2 proteins, which include Bax, Bak, and Bok, Anti- 
apoptotic Bcl-2 proteins includes Bcl-XL, Bcl-w, Mcl-1, A1, Bcl-Rambo, Bcl-L10, and 
Bcl-G, and heterogeneous group of proteins which known as BH3 only protein and  
includes Puma, Noxa, Bid, Bad, Bim, Bik, Hrk, and Bmf. Proteins of the third group hence 
act as proapoptotic proteins through suppression of anti-apoptotic Bcl-2 proteins and 
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The apoptotic stimulus such as ROS can change the balance between pro-apoptotic and 
anti-apoptotic proteins of Bcl-2 family, and lead to activation of apoptotic effector 
Bax/Bak proteins. Bax is present in the cytosol as a monomer, upon activation, it will 
translocate to mitochondria where oligomers form, while, Bak present on the mitochondria 
constantly, after activation undergoes a series of conformational changes forming 
oligomers. This conformational change of Bax/Bak is essential for mitochondrial outer 
membrane permeabilization which allows release of intermembrane space proteins into the 
cytosol including; cytochrome c, SMAC/DIABLO, and Omi/Htra2, which induce caspase 
activation, as well as Apoptosis inducing factor (AIF), and endonuclease G, which act in a 
caspase-independent manner (Griffiths et al., 1999; Hata et al., 2015; Kuwana and 
Newmeyer, 2003).  
In the cytosol, released cytochrome c binds with apoptotic protease activating factor-1 
(Apaf-1) and pro-caspase-9 forms together a complex known as an apoptosome, as shown 
in Figure 1.9. The apoptosome cleaves the pro-caspase to active caspase 9, which in turn 
propagates the apoptotic signal  through  activating downstream effector caspases 3, 6, and 
7  by proteolytic cleavage (Schafer and Kornbluth, 2006). 
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Bax/Bak can be activated via two models; the direct activation model through Bim/ Bid/ 
Puma or by other BH3-only proteins when they releasing Bim/Bid/Puma from association 
with anti-apoptotic Bcl-2 proteins, and indirect activation model when the anti-apoptotic 
Bcl-2 proteins are supressed by BH3-only protein (Kim et al., 2006; Willis et al., 2007).  
Another group of proteins known as inhibitor of apoptosis proteins (IAPs), which includes:  
XIAP, ILP-2, c-IAP1, c-IAP2, ML-IPA, NAIP, Survivin, and Apollon, also play an 
essential role in the regulation of apoptosis. IAPs inhibit apoptosis through binding with 
effector caspases. These proteins can be inhibited by SMAC/DIABLO proteins, which are 
released from mitochondria and prevent their association with caspases, as shown in 
Figure. 1.9 (Wang and Youle, 2009). 
 
Figure 1.9: Death receptor and mitochondrial pathways of apoptosis. 
External pathway activated by external ligand, whereas, internal pathway activated by internal stress, it also 




The mitochondrial apoptosis pathway can cross-talk with extrinsic pathways through 
activated caspase 8, which cleaves and activates BID to tBID; a pro-apoptotic member of 
Bcl-2 family proteins. Activated tBID protein can activate pro-apoptotic Bax/Bak protein 
through inhibition anti-apoptotic Bcl-2 proteins (Marquez et al., 2013). 
One hallmark of cancer cells, is their ability to evade apoptosis (Hanahan and Weinberg, 
2011). Inhibition of apoptosis is fundamental for cancer cell survival, progression and 
metastasis (Fernald and Kurokawa, 2013).  Indeed, cancer cells have several mechanisms 
to circumvent apoptosis at multiple stages. Deviation of normal apoptotic pathways, 
caspases inhibition, and loss of tumour suppressor protein, p53, as well as changing the 
expression of Bcl-2 family proteins thereby preventing MOMP can be effective 
mechanisms for suppression of apoptosis (Koff et al., 2015; Lopez and Tait, 2015; Renault 
et al., 2015).  
There is evidence that cancer cells reduce  reliance on mitochondrial activity as a strategy 
for surviving apoptosis (Palorini et al., 2013), since  mitochondria  are a main regulator  of 
apoptosis as well as being considered a main sources for ROS generation, which is a strong 
apoptosis stimulator (Giampazolias and Tait, 2016).  
A link has been suggested between mitochondrial morphology and apoptosis (Suen et al., 
2008). Several studies have postulated that mitochondrial fragmentation is related to 
apoptosis, and it enhances mitochondrial outer membrane permeabilization (MOMP) and 
release of cytochrome c (Landes and Martinou, 2011; Youle and Karbowski, 2005). By 
contrast, several studies found that MOMP can occur before mitochondrial fragmentation 
(Arnoult, 2007), and even apoptosis can occur independently from mitochondrial 
fragmentation(Parone et al., 2006; Sheridan and Martin, 2010). 
Furthermore, research has shown that cancer cells can increase resistance to apoptosis 
through changes in mitochondrial morphology toward fragmentation, which is leads to 
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reducing surface area required for activation of pro-apoptotic Bax protein and 
mitochondrial outer membrane permeabilization, as shown in Figure 1.10 (Renault et al., 
2015). Whereas, another study has reported that elongation of mitochondria exhibits 
apoptosis resistance which may be due to inhibiting translocation of pro-apoptotic Bax 
protein to mitochondria, and prevention of release of cytochrome c from mitochondria 
(Jeong and Seol, 2008). However, the exact relationship between mitochondrial 
morphology and apoptosis is still not clear.  
 
Figure 1.10: Role of mitochondrial morphology in apoptosis. In contrast to tubular-like shape 
mitochondria, small size mitochondria prevent MOMP, an essential initial step for mitochondrial apoptosis. 
Cited from (Renault et al., 2015)  
1.4.10 Inhibition of mitochondrial fragmentation with mdivi-1 
Mitochondrial fragmentation is the result of excessive mitochondrial fission, which is 
mediated by several proteins including Mff, MiD49/51, Fis1, and Drp1 (Rosdah et al., 
2016). It has been reported that mitochondrial fragmentation leads to mitochondrial 
dysfunction (Jheng et al., 2012), and apoptosis (Young et al., 2010), and it is responsible 
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for several diseases related to mitochondria such as Parkinson's disease and 
Alzheimer's disease (Burte et al., 2015; Itoh et al., 2013; Wang et al., 2017b; Winklhofer 
and Haass, 2010). 
Recently, several compounds including P110, and mdivi-1 have been designed for 
targeting Drp1 protein and preventing mitochondrial fragmentation (Rovira-Llopis et al., 
2017). Mdivi-1inhibitor, which is a small chemical molecule, can inhibit mitochondrial 
fission protein Drp1 selectively and reversibly through binding with it at allosteric site, 
suppressing its ability to hydrolyse GTP and assembly around mitochondria to form ring-
like structures, as seen in Figure 1.11 (Cassidy-Stone et al., 2008; Rosdah et al., 2016). 
 
Figure 1.11: Mechanism of mdivi-1 inhibitor effect.  Targeting of Drp1 protein with 
 mdivi-1 inhibitor can prevent mitochondrial fragmentation through inhibition of fission process.  
Modified from (Kornfeld et al., 2015). 
26 
 
Studies has shown that targeting mitochondrial fragmentation with mdivi-1 inhibitor could 
prevent apoptosis in different cell types, especially in nerve and cardiovascular cells 
through declining ROS production (Reddy, 2014), whereas, it has been revealed that 
targeting  Drp1 with mdivi-1 inhibitor can affect cell proliferation via increasing apoptosis 
(Qian et al., 2013; Rosdah et al., 2016). However, its effect on mitochondrial metabolism 
and cell migration in cancer cells is still unknown. 
1.5 Cancer cell metabolism 
Unlike normal cells, which depend on mitochondrial oxidative phosphorylation for 
generation ATP, most cancer cells have enhanced glycolysis and reduced oxidative 
phosphorylation even in the presence of oxygen. This metabolic shift was suggested first 
by Otto Warburg in 1924 and is known as the Warburg effect (Vander Heiden et al., 2009). 
It was believed for a long time that shifting to aerobic glycolysis in cancer cells is due to a 
permanent defect in mitochondrial oxidative phosphorylation (Zheng, 2012). However, 
several investigations have found that mitochondrial oxidative phosphorylation in many 
cancers is intact (Hsu and Sabatini, 2008; Scott et al., 2011). 
Cancer cells can reprogram their metabolism to aerobic glycolysis as a result of different 
factors such as oncogenes such as RAS, MYC,  mtDNA and genomic DNA mutation, loss 
of tumor suppressors such as p53, and hypoxic microenvironment (Hanahan and 
Weinberg, 2011; Zheng, 2012). Recently, changes in mitochondrial morphology have been 
identified as an inducer of metabolic reprogramming in some cancers (Guido et al., 2012; 
Mishra and Chan, 2016).  
1.5.1 Aerobic glycolysis 
Metabolic reprogramming from oxidative phosphorylation to glycolysis even in the 
presence of oxygen considered an important hallmark of cancers (Hanahan and Weinberg, 
2011).  The glycolysis process, which is carried out in cytosol and generates only 2ATPs, 
include a number of steps starting with uptake of glucose and end with pyruvate 
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production, as shown in Figure 1.12.  In aerobic conditions, pyruvate transported into the 
mitochondria for complete oxidation via the Krebs cycle. Whilst, in the absence of oxygen, 
pyruvate reduced to lactate in cytosol by lactate dehydrogenase A (LDH-A), then exported 
through monocarboxylate transporters (MCTs) into extracellular space. Most cancer cells 
converts pyruvate to lactate even in oxygen availability, and this phenomenon is called 
aerobic glycolysis or the Warburg effect (Hanahan and Weinberg, 2011; Lopez-Lazaro, 
2008).   
 
Figure1.12: Aerobic glycolysis. Show glycolysis steps and 
intermediates for macromolecule synthesis in pentose phosphate pathway. HKII; hexokinase II, PKF; 
phosphofructokinase, PDK1; pyruvate dehydrogenase kinase, LDH-A; lactate dehydrogenase kinase, GLUT; 
glucose transporter, MCT; monocarboxylate transporter 
Cancer cells reprogram their metabolism from oxidative phosphorylation to aerobic 
glycolysis for several reasons. First, high proliferation rates of cancer cells require a high 
amount of energy, which can be obtained through aerobic glycolysis. Despite that 
generated energy in glycolysis is less by 18 times than oxidative phosphorylation, aerobic 
glycolysis can generate  much more ATP than oxidative phosphorylation through 
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producing ATP  faster by 10-100 times (Liberti and Locasale, 2016; Lunt and Vander 
Heiden, 2011). Second, mitochondrial oxidative phosphorylation is accompanied by  
reactive oxygen species  (ROS) production, therefore, reducing oxidative phosphorylation 
by cancer cells decreases ROS levels, which has cytotoxic effect on the cells (Kang and 
Pervaiz, 2012; Nogueira et al., 2008). Third, several intermediates from glycolysis can be 
used for macromolecule biosynthesis such as ribose-5- phosphate for nucleotide, and  
glycerol for lipid, which  are essential for cell  division  and  cancer proliferation, as 
illustrated in Figure 1.12 (Kroemer and Pouyssegur, 2008; Lunt and Vander Heiden, 2011).  
Forth, lactic acid, the end product of glycolysis that is secreted to the tumor 
microenvironment through monocarboxylate transporter (particularly MCT1 and MCT4) 
decreases the pH of the microenvironment. which is crucial for increasing cancer cell 
migration and metastasis (Doherty and Cleveland, 2013; Jiang, 2017). Finally, acidification 
of the tumor microenvironment can suppress an immune responses. For example, acidic 
pH can weaken T-helper cells and cytokines, which activate  effector T-cells; which are an 
essential for cancer immune response (Huber et al., 2017; Jiang, 2017).  
1.5.2 Pentose phosphate pathway and its role in antioxidant response  
The pentose phosphate pathway (PPP), which branches out from glycolysis at first 
committed step of glucose metabolism (Sreedhar and Zhao, 2018), is an important pathway 
in order to synthesize precursors for nucleotides and amino acids which are required in 
large quantities for building new cells (Sreedhar and Zhao, 2018; Stincone et al., 2014), it 
is also an exclusive source of NADPH generation, which plays an essential role in 
detoxification of intracellular reactive oxygen species (ROS) (Jiang et al., 2014; Riganti et 
al., 2012). 
In the cell, hexokinase (HK) enzyme catalyses phosphorylation of glucose to glucose-6-
phosphate (G6P) which can be further metabolized through glycolysis or dehydrogenated 
by glucose-6-phosphate dehydrogenase (G6PD) in the PPP (Tsouko et al., 2014).  
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The PPP comprises of two branches: the oxidative branch and the non-oxidative branch.  
The oxidative branch includes series of irreversible reactions starting with G6P generating 
ribulose-5-phosphate that converts later to ribose-5-phosphate, and two molecules of 
NADPH. While, the non-oxidative branch includes a series of reversible reactions in which 
intermediates in glycolysis such as fructose-6-phosphate (F6P) and glyceraldehyde-3-
phosphate (G3P) convert to ribose-5-phosphate and xylulose-5- Phosphate and vice versa, 
creating a reversible link between glycolysis and PPP (Jiang et al., 2014; Patra and Hay, 
2014; Stincone et al., 2014) as shown in Figure 1.13.  
Produced NAPDH in PPP is crucial for glutathione reductase function as a cofactor to 
reduce oxidized glutathione. Oxidized glutathione consists of two molecules of disulfide 
linked together (GSSG). Upon reducing, disulfide breaks and two molecules of reduced 
GSH will form, as shown in Figure 1.14. Reduced GSH then will be used by glutathione 
peroxidase as an electron donor for reducing reactive oxygen species such as hydrogen 





Figure 1.13: A schematic representation shows the pentose phosphate pathway and it crosslink with 
glycolysis. The oxidative branch of the PPP generates NADPH, whereas, the non-oxidative branch produces 
ribose-5-phosphate from oxidative branch as well as glycolytic intermediates.  G6PD: glucose-6-phosphate 
dehydrogenase, 6PGD: 6-phosphogluconate dehydrogenase, 6PGL: 6-Phosphogluconolactonase. 
 
Figure 1.14: Scheme representation shows the role of NADPH in reducing of 
 oxidized glutathione GSSG by glutathione reductase. 
Although oxidative stress in cancer cells is higher than normal cells (Schumacker, 2006), 
cancer cells can tolerate these increases in oxidative stress through several 
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mechanisms(Thorpe et al., 2004). One of the effective ways is through increasing activity 
of the antioxidant systems including glutathione to keep generated reactive species that can 
induces apoptosis at non-toxic levels (Redza-Dutordoir and Averill-Bates, 
2016).Therefore, the PPP plays a critical role in cancer progression since it provides cancer 
cells with large amount of macromolecules required for nucleotide biosynthesis, a building 
unit for repair and synthesis of DNA and RNA (Jiang et al., 2014; Tsouko et al., 2014), it 
has also been reported that cancer cells, which reprogram their metabolism, direct most of 
glucose flux into PPP (Jiang et al., 2014). Furthermore, PPP produces the reducing agent; 
NADPH that maintains the redox homeostasis in cancer cells through glutathione 
production, and serves as a cofactor in lipids and amino acids biosynthesis (Ayala et al., 
2014; Lushchak, 2012; Sreedhar and Zhao, 2018), hence, this pathway could be effective 
strategy for treatment of cancer cells.  
1.5.3 Targeting glycolysis with 3-Bromopyruvic acid 
Targeting glycolysis can provide a promising strategy for cancer therapy since glycolysis 
plays an important role in cell transformation, cancer cell proliferation, and metastasis 
(Finley and Thompson, 2015; Pascual et al., 2018). There is evidence that expression of 
several proteins and enzymes, which are related to glycolysis pathway, such as HKII, 
MCTs, GLUTs, LDH, and PFK-B, are raised significantly in most cancers (Ganapathy-
Kanniappan and Geschwind, 2013; Li et al., 2014). Many chemicals and antimetabolites 
have been developed to be used as anticancer drugs through targeting glycolysis pathway, 
however, the majority of them are unsuccessful due to development of resistance, lack of 
specificity, low efficiency, or toxicity to normal cells (Ganapathy-Kanniappan, 2016; 
Scholar, 2007). 3-Bromopyruvic acid (3BrPA), can inhibit glycolysis through targeting 
HKII, GAPDH, and pyruvate, as shown in Figure 1.12 (Ganapathy-Kanniappan et al., 
2010; Leni et al., 2013). Moreover, it was reported that 3BrPA can affect oxidative 
phosphorylation through inhibiting succinate dehydrogenase(Sanborn et al., 1971).  
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It was demonstrated that chemotherapy can induce oxidative stress, which can affect 
cancer cells. However, the mechanism by which these drugs promote ROS production as 
well as their effect is not clear yet (Molavian et al., 2016; Yokoyama et al., 2017). 3BrPA 
like other anticancer drugs can induce ROS production. In fact, it was reported that treating 
breast cancer cells; MDA-MB-435 and MDA-MB-231 cells, with 3-BrPA has induced 
autophagy through stimulating ROS production (Zhang et al., 2014). Despite that, the 
effect of 3BrPA on the mitochondrial shape and the cell migration remains unclear. 
1.5.4 Oxidative phosphorylation in cancer cells 
According  to the Warburg hypothesis, cancer cells reprogram their metabolism due to 
defect in mitochondrial oxidative phosphorylation (Vander Heiden et al., 2009). However, 
it has been proved that oxidative phosphorylation in most cancer cells is intact (Moreno-
Sanchez et al., 2007), despite the fact that cancer cells prefer to rely on glycolysis for ATP 
production (Jiang, 2017). The Warburg theory has been modulated by some authors who 
consider that metabolic reprogramming in cancer cells is due to suppression of 
mitochondrial oxidative phosphorylation by enhanced glycolysis rather than defect in 
oxidative phosphorylation, and it can be restored if glycolysis is inhibited (Fantin et al., 
2006; Moreno-Sanchez et al., 2007; Smolkova et al., 2011).  
A key of metabolic reprogramming in cancer cells is pyruvate dehydrogenase (PDH), 
which is converts pyruvate to acetyl CoA  (Eyassu and Angione, 2017). This enzyme can 
be inhibited by pyruvate dehydrogenase kinase (PDK), which was found to be 
overexpressed in hypoxic conditions and in many cancers, leading to reprogram 
metabolism toward glycolysis (Sradhanjali and Reddy, 2018; Waters et al., 2014). 
Therefore, targeting PDK can enhances PDH activity and reverse metabolism from 
glycolysis to oxidative phosphorylation (Saunier et al., 2017). 
Despite this metabolic reprogramming in cancer cells, evidence shows that oxidative 
phosphorylation contributes to total ATP by 30%. This ratio is varying depending on 
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cancer cell and microenvironment condition. For example, it was reported that oxidative 
phosphorylation contributes to ATP production by 79 and 91% in HeLa cells and MCF-7 
cells, respectively. While, this ratio reduced to 29 and 36% respectively under hypoxic 
condition (Rodríguez-Enríquez et al., 2010; Zu and Guppy, 2004). 
Mitochondrial structure and shape especially inner mitochondrial membrane can play an 
important role in mitochondrial function. It was reported that reducing inner mitochondrial 
membrane can affect ETC function, thereby ATP production (Mannella, 2006). which is  
essential in cancer progression (Maiuri and Kroemer, 2015), including cell migration 
(Hüttemann et al., 2007). In contrast, many studies linked mitochondrial dysfunction to 
cancer cell proliferation and cell migration (Antico Arciuch et al., 2012; Ma et al., 2013).  
Despite that the effect of mitochondrial metabolism on cancer cells remains controversial. 
  1.5.5 Targeting oxidative phosphorylation with Antimycin A 
AMA is a secondary metabolite produced by Streptomyces kitazawensis (Ma et al., 2011), 
and is considered a potent inhibitor of cytochrome c oxidoreductase complex (complex III) 
of electron transport chain in mitochondria.  It binds to the Qi site of complex III inhibiting 
the oxidation of ubiquinol, which blocks transfer of electron between 
cytochrome bL and bH in complex III, as shown in Figure 1.15 (Alexandre and Lehninger, 
1984; Pham et al., 2000). 
Targeting complex III inhibits transport of electrons between ETC proteins, which results 
in a collapse of the proton gradient across the inner membrane.  This can lead to the loss of 
the mitochondrial membrane potential, which is essential for synthesis of ATP (Ma et al., 
2011; Quinlan et al., 2011). 
It was reported that treating cancer cells such as HeLa cells, which mainly depend on the 
mitochondrial oxidative phosphorylation (Rodríguez-Enríquez et al., 2010), can lead to 
significant decreases in ATP production (Maguire et al., 1992; Pham et al., 2000). 
However, its effect on glycolytic cancer cells is not known. 
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Increasing ROS level is considered one consequence of targeting complex III with AMA 
(Balaban et al., 2005; Panduri et al., 2004). It was found that treating FRTL, thyroid 
normal cell of rat, with 10 μM AMA induced mitochondrial superoxide production without 
inducing apoptosis (Wang et al., 2015a).    
Recent evidence suggests that treating plant roots of Tritium aestivum with AMA showed 
a change in mitochondrial morphology, it may be due to high level of ROS production 
(Rakhmatullina et al., 2016). However, no previous study has investigated the effect of 
AMA on mitochondrial morphology in mammalian cells. 
 
 
Figure 1.15: Target site of Antimycin A in Electron Transport Chain. AMA inhibit transport of electron 
from cytochrome bL to cytochrome bH thereby inhibition of mitochondrial oxidative phosphorylation. 
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1.6 Pro-apoptotic protein p66shc  
P66shc protein is 66kDa isoform of adaptor protein shc 1 (or shc A) (Src homology 2 
domain containing transforming protein 1). In mammals shc protein is encoded by three 
shc genes: shc A,   shc B, and shc C (Ravichandran, 2001). Whereas shc B and shc C 
expression are limited to the neuronal cells, shc A has ubiquitous expression and has 3 
isoforms p46shc, p52shc, and p66shc
 
with molecular weight 46, 52, 66 kDa, respectively. 
They share a Src-homology 2 domain (SH2), a collagen homology region (CH1), and 
phosphotyrosine-binding domain (PTB).  p66shc contains an additional CH-like domain 
termed (CH2) that contains a serine phosphorylation site (Ser36), which is critical for its 




Figure1.16: Organization of Shc A isoforms.  
Cited from http://www.atlasgeneticsoncology.org 
 
The shc proteins function as phosphotyrosine adaptor molecules in different receptor 
mediated signalling cascades. Whereas both protein p46shc and p52shc participate in the 
transmission of mitogenic signals from cell surface receptor tyrosine kinases to RAS 
proteins that lead to rising cell proliferation, the protein p66shc functions as a critical redox 
enzyme involved in mitochondrial reactive oxygen species (ROS) generation and inducer 
of apoptosis (Ravichandran, 2001; Trinei et al., 2002). 
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In normal cells, ROS production is maintained at a low level by various enzyme systems 
and this small ratio has an essential role in cell signalling and homeostasis. However, a 
number of external and internal factors can raise the level of ROS production and disturb 
this balance that leads to the state known as oxidative stress, which is responsible for 
damage of DNA, proteins, and lipids (Bhattacharyya et al., 2014; Stanczyk et al., 2005).  
It is well established that in response to DNA damage induced by oxidative stress, protein 
53 will activate and induce arrest in the cell cycle until DNA damage repairs, in case repair 
is impossible, it will induce apoptosis through activation of several pro-apoptotic proteins 
(Amundson et al., 1998). Trinei and co-workers (2002) suggested that p66shc, which is a 
downstream target of the p53, is essential for stress-activated p53 that induces the elevation 
of intracellular oxidants, releases of cytochrome c, and apoptosis. It has also been shown 
by Tomita and co-workers (2012) that p53 deficiency suppresses the enhanced p66Shc 
signaling which causes apoptosis during oxidative stress. However, others believe that 
p66shc also can induce apoptosis independently from p53 (Orsini et al., 2004; Tiberi et al., 
2006; Xiong et al., 2013). 
Giorgio and co-workers (2005) have suggested a mechanism that describes the role of 
p66shc in mitochondria-dependent apoptosis. According to this mechanism in normal 
conditions protein p66shc is inactive and 44% of total p66shc is localized to the 
mitochondria, while 32% and 24% are localized in the cytoplasm and the endoplasmic 
reticulum, respectively. Oxidative stress enhances translocation of protein p66shc into 
mitochondria. 
According to Pinton and co-workers (2007), p66shc translocates into the mitochondria 
through a signal pathway. Upon exposure to oxidative stress, PKCβ is activated, and this 
leads to p66Shc phosphorylation at Ser36. This phosphorylation allows it to transfer from 
the cytoplasm into mitochondrial intermembrane space. Giorgio and co-workers (2005) 
found that p66shc can translocate through the TIM-TOM import system. In the 
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mitochondria, the protein p66shc is inactive and binds with TIM-TOM complex through 
mtHsp70. Pro-apoptotic stimuli can dissociate it from the complex, the monomeric form of 
p66shc is active and can oxidize cytochrome c and catalyse production of H2O2 through 
reduction of O2, this leads to permeability-transition pore formation that allow entering of 
ions, solutes, and water into mitochondria and release the cytochrome C into the cytosol, 
which is the initiator of apoptosome assembly, and caspase activation that lead to 
apoptosis, as shown in Figure 1.17. 
 
Figure 1.17: Mechanism of p66shc activation and translocation to mitochondria. 
Phosphorylation of p66Shc at Ser36 is essential for its translocation from cytosol to mitochondria via TIM-
TOM complex. In mitochondria, activated p66Shc can oxidizes cytochrome c and catalyzes the reduction of 
O2 to H2O2, which can induce opening of the mitochondrial permeability transition pore (PTP), as a result 
mitochondrial membrane permeability to ions, solutes and water will increase and this lead to swelling and 
disruption of mitochondrial outer membrane, which allow to release of cytochrome c into cytosol that induce 





1.7 Role of p66shc in cancer cell metabolism and cell migration 
It has been demonstrated that p66shc plays important roles in many biological processes 
and it is implicated in various pathological processes including cancer development, 
progression, and metastasis, and mostly related to the cellular responses to oxidative stress 
(De Marchi et al., 2013).  
In normal cells, oxidative stress induced by external factors can cause cellular damage and 
trigger cancer progression. Pro-apoptotic p66shc can play a protective role through 
removing of damaged cells via ROS induced apoptosis (Lebiedzinska-Arciszewska et al., 
2015). However, cancer cells can avoid apoptosis, which is considered one of cancer 
hallmarks (Hanahan and Weinberg, 2011). Moreover, cancer cells can exploit normal 
cellular mechanisms and proteins including p66shc for their proliferation and progression 
(Rajendran et al., 2010). 
Oxidation of cytochrome c, which is an essential enzyme that transfers electrons from 
reduced Cytc to molecular oxygen in electron transport system, can lead to defects 
mitochondrial ATP production (Tsukihara et al., 1996). Moreover, increased ROS levels, 
which can be induced by several factors including high glucose levels, can induce mutation 
of mtDNA and inhibition of several mitochondrial enzymes. This leads to significant 
depletion of ATP levels, which can affect most cellular processes (Wallace, 2012). To 
compensate these decreases in ATP level, cancer cells enhance reprogramming metabolism 
to glycolysis, which can leads to increasing cell migration due to raising lactic acid 
production, the end product of glycolysis (Zheng, 2012). In fact, previous research has 
established that ROS induced by hyperglycaemia, which is an important characteristic of 
several diseases including diabetes and obesity, can increase p66shc expression 
(Berniakovich et al., 2008; De Marchi et al., 2013; Xi et al., 2010).  
It has been found that p66shc levels increased in several cancer cell lines especially highly 
metastatic  variants, suggesting a possible role of p66shc in cancer cell migration and 
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metastasis (Jackson et al., 2000). Despite that, there remains a paucity of evidence on its 
role in cell migration and metastasis. 
Apoptosis induced by mitochondrial ROS, which can increased as a result of 
overexpressed p66shc, remains a major challenge for cancer cells (Bhat et al., 2015). 
Increased ROS levels in cancer cells can induce several changes within the cell including 
mitochondrial morphologic changes (Wu et al., 2011)  and increasing the expression of 
protein TRAP1 (Kadye et al., 2014), which can play important role in apoptotic resistance. 
Despite the well characterized role of p66shc in inducing ROS generation,  its relationship 
to TRAP1, which can be induced under oxidative stress condition (Basit et al., 2017; 
Yoshida et al., 2013), has not been investigated. 
1.8 Role of cytoprotective TRAP1 protein in cancer cells  
Tumor necrosis factor (TNF) receptor associated protein 1 (TRAP1) is a mitochondrial 
chaperone protein that belongs to the heat shock protein 90 (HSP90) family. This protein 
has ATPase activity and interacts with TNF1. It plays an important role in regulation of 
several biological processes specifically, in regulation of mitochondrial integrity, 
protection from DNA damage and cell death induced by oxidative stresses (Kang, 2012; 
Matassa et al., 2012; Ou et al., 2014). It has been found that the majority of cancers exploit 
TRAP1 protein for their survival and metastasis, therefore, its expression is upregulated 
dramatically in cancer cells compared to the normal cells (Gao et al., 2012; Guzzo et al., 
2014). 
Previous research has demonstrated that the antioxidant activity of TRAP1 protects cancer 
cells from apoptosis through avoiding lethal opening of the mitochondrial permeability 
transition pore (mPTP) (Guzzo et al., 2014). The mechanism of opening this channel has 
been described by Tsujimoto and co-workers (2006). They suggested that this channel 
consists of the voltage-dependent anion channel (VDAC), located at mitochondrial outer 
membrane, the adenine nucleotide translator (ANT), which is located at the inner 
40 
 
membrane of mitochondrial, and Cyclophilin D (Cyp D) that is located in the 
mitochondrial matrix.  
Cyp D, which is show peptidyl-prolyl cis-trans isomerase activity and able to catalyse 
protein folding, can be activated under oxidative stress induced by several pathological 
conditions such diabetes and obesity (Karamanlidis et al., 2013; Yan et al., 2016). Upon 
activation, it can interacts with the PTP complex forming non-selective pore in the 
mitochondrial inner membrane  that allow free movement of molecules smaller than 
1500 Daltons,  leading  to mitochondrial swelling and  cell death (Elustondo et al., 2016; 
Marzo et al., 1998). However, cancer cells can prevent activation of Cyp D thereby 
inhibiting apoptosis through increasing the expression of TRAP1, which binds and inhibits 
the Cyp-D function (Kang, 2012), as illustrated  in Figure 1.18. 
 
Figure 1.18: CypD control mitochondrial permeability transition pore opening. Under normal 
conditions, the CypD in a mitochondrial matrix is inactive and the PTP is closed. Under stress conditions, the 
Cyp D is activated and interacts with the PTP, which triggers opening of the pore and results in the increase 
permeability, leading to swelling of the mitochondria and rupturing of the mitochondrial outer membrane, 
this lead to release of cytochrome c and thus induction of cell death. Cancer cells, under same conditions 
overexpressed TRAP1 which inhibits the function of the Cyp-D and prevent formation of   PTP. Cited from 





1.9 Role of TRAP1 in cancer cells metabolism and cell migration 
In addition to cytoprotective role of mitochondrial chaperone TRAP1, it has been 
demonstrated that TRAP1 also play an important role in the growth and spreading of 
cancer cells through binding to and inhibiting SDH, which induces reprogramming of 
mitochondrial metabolism to aerobic glycolysis (Amoroso et al., 2014; Briere et al., 2005; 
Sciacovelli et al., 2013), and it is well known that aerobic glycolysis promote cell 
migration (Jiang, 2017). 
It was reported that silencing TRAP1 can suppress cancer cell migration and invasion 
significantly without any effect on cell proliferation (Caino et al., 2013). In contrast, others 
found that TRAP1 knockdown can inhibit proliferation and induce apoptosis (Tain et al., 
2014). Similarly, Zhang and co-workers (2015) found that TRAP1 knockdown can inhibit 
cell growth in MDA-MB-231 and MCF-7 breast cancer cells. They suggested that TRAP1 
can play an important role in the regulation of mitochondrial morphology.  They also had 
suggested that low expression of TRAP1 gene is related to the small and rod-shape 
mitochondria in metastatic cancer cells, whereas, high levels of TRAP1 expression  are 
related to elongated shape mitochondria in non-metastatic cancer cells. Moreover, they 
found that overexpression of TRAP1 can induce elongation of mitochondria and supress 
cell migration and invasion ability. This finding may be contradictory with the role of 
TRAP1 in cancer cells, since TRAP1 can be overexpressed when the cells encountered 
oxidative stress such as being induced by hyperglycaemia, diabetes, and obesity (De 
Marchi et al., 2013; Hall and Martinus, 2013; Montesano Gesualdi et al., 2007; Pridgeon et 
al., 2007), and this leads to inhibiting SDH that defects oxidative phosphorylation and 
enhances cancer cells to reprogram their metabolism to glycolysis(Guzzo et al., 2014; 
Sciacovelli et al., 2013), which in turn enhances cell migration. Despite that, the role of 




1.10 Link between p66shc and TRAP1 
Many studies have demonstrated that oxidative stress can induce expression of both p66shc 
and TRAP1 (Kadye et al., 2014; Lebiedzinska-Arciszewska et al., 2015); however, they 
show different effects on the cells. While, activation of p66shc can induce apoptosis and 
enhance metabolic reprograming due to inhibition of mitochondrial oxidative 
phosphorylation as a results of cytochrome c oxidation (Ott et al., 2007), increasing 
TRAP1 expression can inhibit apoptosis induced by ROS and inhibit mitochondrial 
oxidative phosphorylation (Yoshida et al., 2013). Despite the high expression of both 
p66shc and TRAP1 proteins in cancer cells, the link between them has not been 
investigated. 
1.11 Effect of microenvironment on the mitochondrial morphology  
The tumor microenvironment (TME), which is  in addition to cancer cells  include  stromal 
cells, signaling molecules, immune cells, nerve cells, extracellular matrix (ECM), and 
blood vessels, has an important  role in the initiation, progression, and migration of cancer 
cells (Weber and Kuo, 2012, Kamińska et al., 2015).  
The interaction between cancer cells and microenvironment is a very complex process, in 
which several tumor microenvironment components play critical roles in cancer cell 
survival, proliferation, and successful metastasis (Jayappa et al., 2016). In turn, cancer cells 
can affect the microenvironment through secreting many enzymes and factors that remodel 
surrounding ECM making it more suitable for their growth, progression, migration and 
colonization at distant organs (Lu et al., 2012, Xiong and Xu, 2016). Moreover, cancer 
cells through secretion of H2O2 into microenvironment can promote neighbouring stromal 
cells to reprogram their metabolism to glycolysis and efflux by-products to the 
microenvironment, which can be used by cancer cells for generation of energy and/or 
affect microenvironment acidity (Kato et al., 2013; Rofstad et al., 2006; Sotgia et al., 2012; 
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Xing et al., 2015). These interactions between cancer cells and their microenvironment 
pose a challenge in cancer cell investigation in the artificial micro-environments.  
Two-dimensional (2D) cell culture technique have been used for long time as an essential 
tool in studying cancer cells and molecular biology (Lee et al., 2008, Edmondson et al., 
2014, Antoni et al., 2015). However, it differs from true microenvironment that is present 
in vivo, where cell-cell and cell-extracellular matrix (ECM) interaction occur (Aljitawi et 
al., 2014, Edmondson et al., 2014).  Three dimensional (3D) cell culture model, which is 
also known as scaffolds, has been developed to allow the cells to grow and interact with 
surrounding artificial microenvironment that resembles to some extent to human tissues 
and tumor microenvironments (Lee et al., 2008; Vinci et al., 2012). However, there are 
limitations, since artificial 3D cell culture lacks the vascular system which is essential to 
support tissues with oxygen, nutrients, and to remove waste as in vivo (Yamada and 
Cukierman, 2007). 
Recently, several models have been designed to be used as 3D cell culture more 
resembling to tumor microenvironments such as Alvetex scaffolds and decellularised 
tissue. Indeed, using decellularised tissue, in which biomedical engineering is used to 
isolate the ECM of specific tissues such as lung, and liver tissues from their cells, leaving 
only an ECM scaffold, to be used as 3D cell culture, has taken important consideration 
since it overcomes the limitations of uses of 3D cell cultures in-vitro (Aljitawi et al., 2014; 
MacDonald et al., 2014; Mazza et al., 2015; Mishra et al., 2012; Mokhtari-Jafari et al., 
2015).  Therefore, it will be of a great value to investigate the impact of mitochondrial 
morphologic changes on metabolism and cell migration in 3D environments such as 
collagen matrices, Alvetex scaffolds and Decellularised lung tissue which have 




1.12 Aim of the study 
As described above, mitochondrial morphology is highly dynamic and it can be shifted 
easily between small, fragmented and large, elongated network-like shape as a response to 
oxidative stress  that can be induced by many factors such as high glucose level, anticancer 
agents, and ROS. However, the effect of  mitochondrial morphological changes on the 
metabolism and the cell migration, which is critical for metastasis, is not clear. In this 
study, we hypothesized that mitochondrial fragmentation induced by factors including high 
glucose level, H2O2, PGC1α coactivaitor, and anticancer drugs targeting metabolism, can 
induce metabolic reprogramming from oxidative phosphorylation to aerobic glycolysis that 
play essential role in accelerating cancer cell migration.   
To achieve this goal we treated MDA-MB-231 breast cancer cells with different glucose 
concentrations (1, 5.5, and 25mM), Hydrogen peroxide, ZLN005 activator (PGC-1α 
coactivator), and anti-metabolic anticancer drugs including Antimycin A (Sigma) and 3-
Bromopyruvic acid (Sigma) to study changes in mitochondrial morphology, mitochondrial 
metabolism, and cell migration.  
Over the past decade investigation added valuable information concerning role of p66shc 
and TRAP1in cancer cells. However, to date, no evidence has been found associating 
p66shc with TRAP1 and their effect on cancer cell migration. We hypothesized that 
expression and activation of cytoprotective protein TRAP1 are strongly affected by 
activation of pro-apoptotic protein p66shc since the function of both are related to 
mitochondria and both activated under oxidative stress that can be induced by several 
factors such as hyperglycaemic condition. 
To fill this gap in information and for a better understanding, we investigated the 
relationship between p66shc and TRAP1 through silencing the expression of their genes, 
as well as their effect on the metabolism and cell migration were investigated. Using three 
45 
 
cell lines: breast cancer cell line MDA-MB-231, fibrosarcoma cell line HT1080, and 
cervical cancer HeLa cells, for this study.   
Finally, in this study, we aimed to uncover the impact of mitochondria in 3D 
environments, which mimic tissue culture in vivo, on cell migration in MDA-MB-231 
cells, to determine whether growing these cells in 3D culture nulled in different 
























Chapter two: Material and Methods 
2.1 Materials 
2.1.1 Reagent and Kits  
All chemicals and reagents used in the study were of analytical grade. 
Reagents used in cell culture including; Dulbecco’s modified Eagle medium (DMEM; 
Catalog no. 11880-028 and A14430-01), Eagle's Minimum Essential Medium (EMEM;  
Catalog no.51200-046), Fetal bovine serum (FBS; Catalog no.10500-064), Penicillin-
Streptomycin (Catalog no. 15140-122), L-Glutamine (Catalog no. 25030-081), 0.05% 
Trypsin-EDTA (Catalog no. 25300-054) , D-glucose (Catalog no.A13275-04), Phosphate 
buffer saline (PBS) (Catalog no.10010-023), Hank’s Balanced Salt Solution ( Catalog 
no.14175-095), were purchased from Fisher Scientific, UK. 
Reagents used for total protein harvesting including; RIPA buffer, 1X (Catalog 
no.10230544), and the Protease Inhibitor Cocktail (Catalog no. 539131) were purchased 
from Fisher Scientific, UK, and Merck Millipore, UK respectively. The protein 
quantification was performed using the Pierce Bradford assay kit (Catalog no.  23246), it 
was purchased from Fisher Scientific, UK.   
Reagents used for western blot; Precision plus Protein™ Dual Color Standards (Catalog 
no.161-0374) and Clarity TM Western ECL Blotting Substrate (Catalog no. 17050-61) 
were purchased from Bio-Rad Laboratories, Inc., UK. ReBlot Plus Mild Antibody 
Stripping Solution, 10X (Catalog no. 2502) was purchased from Merck Millipore. All 
primary antibodies used are listed in Table 2.1, as well as their respective Catalog number 
and brand.  
Chemicals used for hand cast SDS-PAGE gel: Sodium dodecyl sulfate (SDS) (99%) 
(Catalog no. 10593335), Ammonium persulfate (Catalog no. 17874), Proto Gel 30% 
Solution (Catalog no. 12381469), Tris-Base (Catalog no. BP 152-500), NaCl, KCl, Glycine, 
and Gelatine were purchased from Fisher Scientific, UK. N, N, N′, N′-
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Tetramethylethylenediamine (Catalog no. T9281-25ML) and methanol were purchased 
from Sigma-Aldrich, UK. 
4-20% Mini-Protein® TGX™ Precast Protein Gels (Catalog no. 4561094) and Trans-
Blot® Turbo™ Mini PVDF Transfer Packs (Catalog no. 1704156) were purchased from 
Bio-Rad Laboratories, Inc., UK. 
Reagents used for studying mitochondrial dynamics including; Hydrogen peroxide solution 
(H2O2) 30% (Catalog no. 7722-84-1), ZLN005 (Catalog no. 49671-76-3), Mdivi-1 
inhibitor (Catalog no. M0199), Antimycin A (Catalog no. A8674), and 3-bromopyruvic 
acid (Catalog no. 16490) were purchased from Sigma-Aldrich, UK. 
All primers used were purchased from Sigma-Aldrich and are listed in Table 2.2. Total 
DNA was isolated using DNeasy Blood & Tissue Kit (Catalog no. 69504) which was 
purchased from Qiagen, UK. QuantiTect SYBR Green PCR Kit (SYBR Green PCR master 
mix) (Catalog no. 204141) was also purchased from Qiagen, UK. 
To confirm primer specificity, agarose gel electrophoresis was performed using Agarose I 
(17850), Blue Juice Gel loading buffer (Catalog no. 10816-015), TAE Buffer (Tris-acetate-
EDTA) (50X) (Catalog no.  B49), and a 1000bp plus GeneRuler DNA Ladder (Catalog no. 
SM0321) which were all purchased from Fisher Scientific, UK. 
Metabolism Assay Kits used in metabolic studying include; ATP Assay Kit (Catalog no. 
ab83355) was purchased from Abcam LTD, UK. Glycolysis Cell-Based Assay Kit 
(Catalog no. CAY600450-1 ea) and OxiSelect™ ROS Assay Kit (Catalog no. STA-342) 
were purchased from Cambridge bioscience LTD, UK.  
Reagent and siRNA used in transfection: DharmaFECT 1 Transfection Reagent and 
DharmaFECT 4 Transfection reagent were purchased from Thermo Scientific, UK. ON-
TARGET plus Non-targeting control siRNA and ON-TARGET plus SMART pool TRAP1 
siRNA were purchased from Dharmacon GE Company. Designed SMART pool P66shc 
siRNA was   purchased from Sigma-Aldrich, UK.  
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MitoTracker Orange (M7510) and Alexa Fluor 488 Phalloidin were purchased from 
Invitrogen-Thermo Fisher Scientific, UK. Vectashield-Mounting Medium with DAPI was 
obtained from Vector laboratories, UK.  
Collagen Type 1 (Catalog no 2561888) was purchased from Millipore. Goat serum was 
purchased from Life Technologies. UK. Triton X-100, DMSO and TWEEN
®
 20 were 
purchased from Sigma-Aldrich. Paraformaldehyde was purchased from Agar Scientific.  




 cell culture flasks, and Nunc™ Micro Well™ 
96-Well Optical-Bottom Plates with Polymer Base (Catalog no. 12-566-70) were 
purchased from Fisher Scientific, UK. Alvetex Scaffold 12-well plate (Catalog no. 
AMS.AVP002-10) was purchased from AMS Biotechnology (Europe) Limited.  







Catalog no. Manufacturer 
P66shc 1:1000 Rabbit 66 2432 Cell signaling 
TRAP1 1:200 Mouse 80 Sc-13134 Santa Cruz 
Drp1 1:1000 Mouse 82 ab56788 abcam 
PGC-1α 1:1000 Mouse 92 ab54484 abcam 
β-actin 1:2500 Mouse 45 3700 Cell signaling 
β-actin 1:2500 Rabbit 45 4970S Cell signaling 
 
Table 2.2: list of primers used in real-time qPCR 











tRNA CACCCAAGAACAGGGTTTGT TGGCCATGGGTATGTTGTTA 107 






2.1.2 Preparation of stock solutions:  
1mM (w/v) of Mito-Tracker® Orange CM-H2TMRos stock solution was prepared by 
dissolving the contents of one vial (50μg) in 127μl of Dimethyl sulfoxide (DMSO). 10 mM   
(w/v) of Antimycin A stock solution from Antimycin A (90%) was prepared by dissolving 
it in Ethanol (100%). 20 mM (w/v) of 3- Bromopyruvate stock solution from 3-
Bromopyruvate (98%) was prepared by dissolving it in sterilized ultra-pure water. 20 mM 
(w/v) of ZLN005 stock solution from ZLN005 (95%) and 20 mM (w/v) of mdivi-1 
inhibitor stock solution from mdivi-1 inhibitor (98%) were prepared by dissolving them in 
DMSO. Working solutions for the above mentioned chemicals were prepared by diluting 
stock solutions in DMEM just before using them in experiments.  
2.2 Methods 
2.2.1 Cell culture  
In the present study, three cell lines from American Type Culture Collection (ATCC) were 
used. 
MDA-MB-231            human breast cancer cell line 
HT1080                      human fibrosarcoma cell line 
HeLa cell                    cervical carcinoma cell line 
Depending on ATCC guidelines, MDA-MB-231 cells were grown in Dulbecco’s modified 
Eagle medium (DMEM) (Gibco, UK), whereas, HT1080, and HeLa cells were grown in 
Eagle's Minimum Essential Medium (EMEM) (Gibco, UK), in humidified atmosphere 
supplemented with 5% CO2 at 37℃. The media were supplemented with  
 Fetal bovine serum (FBS)     (Gibco, UK)             (10% V/V) 
 Penicillin                              (Gibco, UK)             (100 IU/mL) 
 Streptomycin                        (Gibco, UK)             (100 µg/mL) 




The glucose concentration in the medium was modified to (1, 5.5 and 25mM) using               
D-glucose (Gibco) and cells were continuously cultured in medium with relevant glucose 
levels. 
2.2.2 Counting cells  
It is important to seed equal numbers of the cells in all experimental units in order to obtain 
optimum results from experimental replicates. Cells were counted using a haemocytometer 
slide. A clean coverslip was put over the haemocytometer slide and a small amount of cell 
suspension (about 10 μL) was placed in the space between the haemocytometer slide and 
the cover slip, later cells were counted with an inverted light microscope (Leitz Labovert) 
using 10x objective lens. Depending on the following equation the number of cells/ml was 
calculated:   
No. of cells / mL = (No. of Cells counted / No. of Square counted) x 10
4 
x dilution factor 
Cell suspensions were made directly from fresh flasks with 70-80% cell confluence after 
being washed twice with sterilized PBS and de-attached by using Trypsin-EDTA (0.05%). 
During all experiments cells were seeded 24-48 hours earlier and were washed with 
sterilized PBS before exposing them to any sort of treatments.  
2.2.3 Preparing cell lysates 
At the end of the experiments cells that were grown in T-25 culture flasks (25 cm
2
) or T-75 
culture flasks (75 cm
2
) were collected and lysates were extracted. The growth media were 
removed and cells were washed once using chilled PBS. Immediately cells were scraped 
into PBS and moved into 15 ml tubes then centrifuged in 4º C at 2000 rpm (Eppendorf 
centrifuge 5804 R) for 15 minutes. Supernatant was discarded and 400 μL of protein 
inhibitor cocktail; A cocktail containing six protease inhibitors: which are AEBSF (Amino-
ethyl benzene-sulfonyl fluoride hydrochloride), Aprotinin, E-64, Leupeptin, Pepstatin A 
and Bestatin hydrochloride, to inhibit a broad range of proteases, and Radio-immuno-
precipitation assay (RIPA) buffer (25mM Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% 
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sodium deoxy cholate, 0.1% SDS) mixture (1:100), was added to the pellets and mixed 
well. Lysates were then passed through 21 gauge needles several times to shear the DNA. 
The suspension was incubated in 4ºC for 30 minutes then transferred into 1.5ml Eppendorf 
tubes and centrifuged in 4ºC at 13000 rpm for 15 minutes. Supernatants were collected and 
stored in freezer (-20º C).  
2.2.4 Bradford Protein Assay  
A Bradford protein assay was used to measure the quantity of protein in the samples. The 
principle of this assay depends on the reaction of protein with the Bradford reagent, which 
contains Coomassie Brilliant Blue G-250, forming a stable blue solution that has a 
maximum absorbency at 595nm, the intensity of this blue solution increases with 
increasing  protein concentration and vice versa (Bradford, 1976). This assay was carried 
out in 96 well plates. Three replicates from each lysate were tested. In the first column of 
the plate, 195 μL of blank Bradford reagent was applied. While, in columns two and three 
5 μL of ascending concentrations of bovine serum albumin standards (25-2000 μg/ml) and 
195 μL of Bradford reagent were applied. Columns two and three were used to produce a 
standard curve to reveal protein concentration in each of the lysates. Finally 5 μL of lysates 
with 195 μL of Bradford reagent were added to the remaining wells. Details were recorded 
in a data sheet as shown in Figure 2.1 
 A plate reader, E max Molecular Device, was used to read the absorbance at 600 nm. 
From the data provided by the plate reader the concentration of protein in each well and 
average protein concentration for each sample was displayed in μg/ml. 
A linear regression equation was then obtained by plotting absorbance versus protein 
amount. An unknown amount of protein was then estimated by measuring the absorbance 






Figure 2.1: Data sheet shows a standard 96 well plate. Used for loading standard protein and sample with 
unknown concentration of protein to be measure by a plate reader at 595nm. 
 
 
Figure 2.2: Standard curve for protein with known concentrations and absorbance. 





2.2.5 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)/ 
Western Blot Analysis  
2.2.5.1 Protein Running  
After performing Bradford protein assay, 25 μL of 5X (v/v) loading buffer was added to 
100 μL of sample lysate, to ensure the loading lysate protein ran consistently. Later this 
mixture was boiled for 3-5 minutes at 95 ℃. The mixture could be stored at -20℃ until the 
next step.  
After processing lysates with loading buffer, samples were run on a pre-casted SDS-
PAGE, 4-20% Mini-PROTEAN® TGX™ gel or 12% hand cast SDS-PAGE gel, in order 
to dissociate the proteins into their individual polypeptide subunits, depending on their size 
and molecular weight. Running buffer was added to the gel tank, and then a molecular 
weight marker and samples between 50-75µg were loaded in stacking gel wells (after been 
filled with running buffer). Electrical current was applied to the running tank, 100mA with 
a constant voltage (250V) during running through the stacking gel and at 50mA through 
the resolving gel for one hour. After separation of the proteins, the gel was removed from 
the running tank and transferred to transfer buffer and left to equilibrate in western blot 
transfer buffer for 15-20 minutes. The gel was transferred to Trans-Blot® Turbo™ Mini 
PVDF Transfer Packs, which have 0.2 mm pore size, the transfer pack was a pre-processed 
ready to use product with a PVDF membrane in-between two stacks of filtered papers. The 
stacks were pre-treated with transfer buffer by the manufacturer. The gel was put on top of 
the PVDF membrane and the sandwich was packed and transferred into the Trans Blot 
Turbo Transfer System Bio-Rad cassette. A roller was used to remove bubbles and the 
cassette was assembled. Electric current; 2.5A and Voltage 25V, was applied for 7 
minutes. After transfer was complete the PVDF membrane was blocked with 5% (w/v) of 
bovine serum albumin (BSA) or low fat milk solution dissolved in Tris-buffered saline 
Tween (TBST), for 1 hour at room temperature with agitation.  After that the membrane 
was washed three times with TBST, 10 minutes for each with agitation. Primary antibody 
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was added to the membrane after dilution 1:1000 in 5% (w/v) BSA or 5% low fat milk 
powder (dissolved in TBST) and incubated overnight at 4ºC with slow agitation on plate 
shaker. The membrane was then washed in TBST three times. Secondary antibody, after 
dilution 1:4000 in 1% (w/v) low fat milk powder (dissolved in TBST), was applied to the 
membrane for one hour at room temperature with agitation.  
Three washings were applied to the membrane each for 10 minutes with agitation, and then 
covered with Clarity TM Western ECL Blotting Substrate (reagents were mixed 5 minutes 
before use) and protein bands were detected by using Image-Quant LAS 4000 mini - GE 
Healthcare machine. All protein bands were quantified by using Image-Quant TL 8.1 
software.  
2.2.5.2 Preparation of SDS-PAGE 
SDS gels were cast using two glass plates which were separated by 1.5mm spacers. The 
gels consisted of a stacking gel of 5% and resolving gel of 12%. The concentration of the 
resolving gel depended on the protein being investigated ensuring sufficient separation of 
proteins. For preparing a gel 25ml of 12% resolving gel and 5ml of 5% stacking gel were 












Preparing 25ml of  12% Resolving gel   10ml of 30% acrylamide 
 6.3ml 1.5M Tris base pH 8.8  
 8.2ml distilled H2O 
 0.25ml of 10% SDS 
 0.25ml of 10% ammonium persulfate (APS) 
 0.01ml of TEMED 
 
Preparing 5ml of  5% Stocking gel  0.83ml of 30% acrylamide 
 0.63ml 1M  Tris base pH 6.8 
 3.4ml distilled H2O 
 0.05 of 10% SDS 
 0.05ml of 10% ammonium persulfate (APS) 




After assembling the cassette, the resolving gel was added and left to polymerize for 20 
minutes, then the stacking gel was added above resolving gel and left for 10-15minutes.  A 
comb of 2.5cm depth with10 wells was inserted into the stacking solution to make wells 
before the gel solution polymerized.  























1L 5X  Running buffer  
 15.1 g Tris base 
 72.1 g  glycine 
 50ml of  10% SDS 
 Making up 1L by ddH2O 
For preparation 1X running buffer take 200ml of 5X running buffer  and volume 
complete to 1L with ddH2O 
 
1L 1 X  Transfer Buffer  
 2.8g Tris base 
 2.9g Glycine 
 200ml Methanol 
 Making up 1L by ddH2O 
 
1L 10X Tris Buffer Saline  
 30g Tris base 
 80g of NaCl 
 2g KCl 
 Add 800ml of ddH2O 
 Adjust to the pH to 7.4 using concentrated HCl    
 Complete to 1 litter by ddH2O 
 
1L 1X Tris Buffer Saline Tween (TBST) 
 100ml of 10X Tris Buffer Saline 
 900ml of ddH2O 




2.2.6 Preparing collagen coated surfaces 
2mg/ml (v/v) of collagen type 1 was prepared according to a protocol provided by the 
supplier (Millipore, UK). 0.75ml of 2mg/ml of collagen solution was added to each well of 
a six well plate. The plates placed in an incubator for 20-30minutes for polymerization of 
the collagen. Later cells were seeded onto the collagen gel and left for 24hrs. 
2.2.7 Mitochondrial Staining  
Clean cover slips were transferred into six well plates, submerged within methanol for 30 
minutes. The methanol was removed and coverslips /plates were left to air dry. Later they 
were covered with sterilized gelatin solution (0.1 % w/v) for 30 minutes and then the 
gelatine was removed from the wells and plates were left to air dry. Depending on the 
experiments, cells were seeded on these coverslips at 10
4
cells/well density. After 24 hours 
the cells were treated and incubated for a further 24-48 hrs. At the end of the experiment, 
the medium was replaced with 2 mL of pre-warmed serum and antibiotic free growth 
medium containing reduced mitochondrial- selective fluorescent probe (MitoTracker® 
Orange CMTMRos, Invitrogen Cat. no. M7510)  with a final concentration 300-400 nM, 
then plates incubated for 15-30 minutes. The probe was designed to enter actively respiring 
cells and to be sequestered permanently in the mitochondria, reacting with thiols groups on 
proteins and peptides to form an aldehyde-fixable conjugate. The cells were washed twice 
using pre-warmed PBS. Cells were fixed with 4.0 % (w/v) paraformaldehyde - PBS for 20 
minutes. The fixative was aspirated and cells were washed twice with PBS, one minute 
each, and covered with 0.1% (v/v) Triton X100 - PBS for 10 minutes (to permeabilize the 
cells) then washed twice, for one minute each time with PBS. Cover slips were mounted on 
glass slides using VECTASHIELD mounting medium with DAPI and the edges of the 
cover slips were sealed with nail polish. Z-stack images were captured at 100x oil 
immersion lens using Nikon A1R confocal microscope running NIS Elements AR imaging 
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software, then Images were processed and analysed using NIS elements AR (Nikon) and 
ImageJ (Fiji, 64bit) software.  
 
2.2.8 Immunostaining  
This technique depends on an antibody to detect a specific protein in a sample, in which 
cells were seeded on coated cover slips with sterilized gelatin, as described in the 
mitochondrial staining section above. Cells were seeded at density 2.5 X 10
4
cells/well in 
six well plates and incubated overnight, and then cells were treated with different 
treatments depending on the experiment. At the end of each experiment, cells were washed 
with PBS and fixed with 4.0 % (w/v) paraformaldehyde for 20 minutes. After fixing the 
cells, the fixative was aspirated and cells were washed twice with PBS, for one minute 
each time. Then cells were covered with 0.1% v/v Triton X100 - PBS for 10 minutes and 
washed twice with PBS, one minute each time. After that cells were covered with blocking 
solution (10% v/v goat serum – PBS) and washed twice with PBS. Primary antibody 
solution (1:100 v/v diluted in 1% goat serum – PBS) was applied for one hour. Later 
primary antibody solution was removed and followed by 3-5 washings, one minute each, 
with PBS. Secondary fluorescent antibody solution (1:500 v/v in 1% goat serum – PBS) 
was applied in dark for one hour and later it was aspirated and cells were washed with PBS 
three times (five minutes each). Then, cover slips were recovered from six the well plates 
and mounted on glass slides using VECTASHIELD Mounting Medium with DAPI and the 
edges of the cover slips were sealed with nail polish. Slides were either stored in the 
refrigerator at 4℃ or examined immediately by confocal microscopy. Later Image J 





2.2.9 Gene Knockdown with siRNA  
After overnight seeding, cells were transfected with 25nM of either Non-target siRNA, 
TRAP1 siRNA, or p66shc siRNA. Dharma-FECT 1 or Dharma-FECT 4 Transfection 
reagent and siRNA were added to serum and antibiotic-free media in separate sterile tubes, 
then both solutions were incubated at room temperature for 5 minutes, after that, they were 
mixed well and incubated at room temperature for 20 minutes. The final volume of 
working solution was achieved by adding antibiotic-free media. For each of normal and 
high glucose controls, only Dharma-FECT 1 or Dharma-FECT 4 Transfection was added 
to serum and antibiotic free media. Concentrations and volumes of reagents were 
determined by the manufacturer’s protocol (DharmaFECT Transfection protocol), 
depending on the cell type and the surface area of the wells.  
For western blot analysis, cells were seeded in 75 cm
2 
flask with a density of 10
6
 cells / 
flask; at the end of the experiments (48 hrs after transfection) cells were collected.  For 
time-lapse microscopy, cells were seeded in 12-well plates at a density of 10
4
 cells/ well, 
while, for measuring ROS, ATP, and glycolysis, cells were seeded in 96-well plates at a 
density 2.5x 10
4
 cells/ well. After 24 hrs of silencing a gene, medium containing siRNA + 
transfection reagent was replaced with fresh medium without antibiotics.  
2.2.10 Quantitative Real- Time PCR (qRT-PCR) 
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to investigate the 
changes of mitochondrial DNA (mtDNA) copy number in treatment cells compared to 
non-treated control cells. Total DNA including mtDNA was isolated from cultured cells 
and purified using DNeasy Blood & Tissue kit (Qiagen) according to manufacturer’s 
instructions. The DNA concentration of samples was measured using a Nano-drop 
Spectrophotometer then from each sample an equal amount of DNA (10 ng) was used. 
(qPCR) primers for the t-RNA gene (a mitochondrial gene) and the β-actin gene locus (for 
nuclear) were designed using the NCBI website tool called Primer-Blast, each one 
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designed to be 18-22bp (details of (qPCR) primers are in Table 2.2).  The primer 
efficiencies were tested prior to the experiments by running them on an agarose gel 
electrophoresis using DNA Ladder to verify the size and singularity of amplified segments 
as shown in Figure 2.3.  
All (qPCR) experiments were conducted in 96-well plates and the reaction for each well 




The plate was sealed then centrifuged briefly. The reactions were incubated in an AB 
StepOne Plus real time PCR machine (Applied Biosystems) at 50℃ for 2 min and 95℃ for 
15 min (initial cycle), followed by 40 cycles of 95℃ for15 sec, 60℃ for 1 min and 72℃ for 
1 min. PCR products were visualized using gel electrophoresis in a 1% agarose gel and 
stained with ethidium bromide (1µg/ml) for visualisation. 
The threshold cycle (Ct) is defined as the fractional cycle number at which fluorescence 
pass the threshold. The expression of each gene was defined from the threshold cycle (Ct).  
The copy number of mtDNA was calculated using the delta Ct (ΔCt) which is equal to 
average Ct of t-RNA gene subtracted from average Ct value of β-actin, depending on the 
following formula  
ΔCT = (β-actin DNA Ct)-(t-RNA DNA Ct) 
mtDNA copy number = 2 X 2
ΔCT 
 
 0.3 µL primers mix (5µM)  
 7µL 2X quantiTect SYBR Green Master Mix (Qiagen) and 





Figure 2.3: Agarose gel electrophoresis. Shows nuclear DNA gene; β-actin with size 101 bp, and 
mitochondrial DNA gene; t-RNA with size 107 bp. Samples taken from results of glucose level effect on 
mtDNA copy number in MDA-MB-231 cells for verification of the qPCR results. 
2.2.11 Cell viability assay (MTT assay)  
We used an MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay 




 cells/well were seeded in 96-well microtiter plates and 
incubated for 24 hours in a humidified atmosphere at 37℃ and 5% CO2. Cells were then 
treated depending on the experiment with either an inhibitor, an activator, or with 
chemotherapy drugs and plates incubated for further 24 - 48hrs depending on the 
experiment. Next, the MTT reagent was added directly to the culture medium. Viable cells 
with active metabolism can reduce MTT tetrazolium, which has yellow colour, into 
formazan, which has a purple colour, by Nicotinamide adenine dinucleotide; NADH, as 
seen in Figure 2.4. The quantity of formazan (assumed to be directly proportional to the 
number of viable cells) is measured by recording changes in absorbance at 570nm using a 
plate reading spectrophotometer. The viable cells are quantified depending on the 
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following equation and a histogram of cell viability plotted on Y axis and treatments on the 
X axis  
Cell viability = (OD of treated sample – OD of blank) / (OD of control-OD of blank) x 100% 
 
Figure 2.4: Yellow colour MTT tetrazolium changed to purple colour formazan 
 in metabolic active cells. 
2.2.12 Quantification of Reactive Oxygen Species (ROS) 
OxiSelect™ Intracellular ROS Assay Kit (Green Fluorescence) (Cell Biolabs, STA-342) 
was used to measure intracellular ROS level according to the manufacturer’s instructions. 
In brief, 2.5 X 10
4
 cells/well were cultured in black 96-well cell culture plate and incubated 
overnight, and then the medium was replaced with 2’, 7’-dichloro dihydro fluorescin 
diacetate (DCFH-DA) (100μL) and incubated for 60 min at 37℃. After washing with 
Hank’s buffered salt solution (HBSS), cells were treated depending on the experiment. 
Intracellular generated ROS can oxidize non-fluorescent DCFH into highly fluorescent 2’, 
7’-Dichlorodihydrofluorescein (DCF), as shown in Figure 2.5, which can be read with 
fluorescent microplate reader at 485 nm (excitation) and 535 nm (emission). Results were 





Figure 2.5: Mechanism of quantification of intracellular ROS. 
 Generated ROS within the cell can oxidize non-fluorescent DCFH into fluorescent DCF 
2.2.13 Quantification of L-Lactate production (Glycolysis) 
The concentration of lactate in culture media, which represents glycolytic activity of the 
cells, was measured by colorimetric-based method using a Glycolysis Cell-Based Assay 
Kit (Cayman Chemical Company) according to the manufacturer’s instructions.  
In the assay, lactate dehydrogenase catalyzes the oxidation of lactate to pyruvate, in which 
the formed NADH reduces a tetrazolium substrate (INT) to a highly-coloured formazan 
which absorbs strongly at 490-520 nm. The amount of formazan produced is proportional 
to the amount of lactate released into the culture medium and could be used as an indicator 





Figure 2.6: Mechanism of L-Lactate quantification. The colorimetric assay for measuring L-Lactate, the 
end product, formazan is proportional to the amount of lactate released into the culture medium. 
 
In brief, 2.5 X 10
4
 cells / well were cultured in 96-well cell culture plate overnight in 5% 
CO2 at 37°C, and then the cells were treated depending on the experiment and incubated for a 
further 24-48 hrs depending on the experiment. At the end of the experiment, the plate was 
centrifuged at1000 rpm for 5 minutes, and then 10µL of supernatant from each sample was 
added to 90µL of assay buffer in a new 96-well plate, and 100µL of reaction solution 
added. The plate was then incubated for 30minutes after shaking, and the absorbance was 
read at 490 nm. The amount of generated lactate was calculated using standard curve 
equation, based on the obtained absorbance value for each sample.   
2.2.14 Quantification of ATP production  
An ATP Assay Kit (abcam, ab83355) was used to determine the total generated ATP,   
according to manufacturer’s instructions. The assay is based on the phosphorylation of 
glycerol to generate a product that can be measured by colorimetric methods at 570 nm. 
Briefly, 5X10
5 
cells / well were seeded in 6-well plates and allowed to attach overnight. 
The cells were treated depending on the experiment. Later 1X10
6
 cells from each sample 
were harvested and suspended in 100µL of ATP buffer. After homogenization and 
centrifugation at 1000 rpm for 2minutes, 50µL of supernatant from each sample was mixed 
with 50µL of reaction mix in 96-well plate. A SpectraMax microplate reader was used to 
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read the optical density at 570 nm. A standard curve equation was used to determine the 
concentration of each treatment based on the optical density. 
2.2.15 Time-lapse microscopy analysis 




 cells /well 
respectively in a humidified atmosphere at 37℃ and 5% CO2 overnight. After treating cells 
with different treatments depending on the experiment, the plates were put on a Nikon 
Eclipse TiE Time-lapse microscope with automated stage and environmental chamber 
running NIS Elements software and Plan 10x / 0.25  ph1 DL  lens was selected to monitor 
cellular response to treatments. Three locations from each well were selected randomly and 
the microscope software was programmed in a way that a series of photos was taken every 
15 minutes (for single cell tracking and monitoring apoptosis) or every 1 hour (for wound 
healing assay) for 24 hours. Images were analysed using Image J Software. The MtrackJ 
plugin was used to track and measure the speed of cell migration, and the cell counter 
plugin was used to measure apoptosis. Whereas, Measure Analyze plugin was used for 
wound healing analysis. Data was then analysed using Microsoft excel and Graph pad 
Prism.  
2.2.16 Confocal microscopy analysis 
Nikon A1R confocal microscope was used to obtain series of high quality 3D images of 
mitochondria with 1024 X 1024 pixel format at 400 Hz speed in xyz plane. To obtain 3D 
images, a z-stack was taken from the top to the bottom and 3 colours (Laser) were used: 
Alexa 405, 488, and 561nm for the blue, green and orange respectively. Images were 
analyzed using ImageJ Software to measure the number, size, and volume of mitochondria 





2.2.17 Measuring cancer cell migration  
Two techniques were used for measuring cancer cell migration: a wound healing assay and 
single cell tracking. For wound healing assays, cells were seeded in twelve well plates at a 
density 2.5X10
5
 cells / well and incubated in a humidified atmosphere at 37℃ and 5% CO2 
and left to grow until the confluence of the cells reached 90-95%.  Then the cell monolayer 
cells were scratched in a straight line using a sterilized pipette tip. After washing wounded 
monolayer with PBS or medium to remove non-adherent and scratched cells, fresh medium 
with a treatment agent was added. Plates were placed on the stage of the phase contrast 
time-lapse microscope and a series of photos was taken every 1 hour for 24 hours, as seen 
in Figure 2.7, and from each well three locations were selected randomly. ImageJ software 
(Polygon selections / Analyze measure) was used to measure the wound area at  beginning 
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of experiment and at the end of experiment and the following equation was used to 
calculate wound closure are, which is represent cell migration.  
% Wound closure area = {Wounded area at 0h – Wounded area at 24h / Wounded area at 0h } X 100 
       
         Wound area at 0 hour                                  Wound area at 24hrs 
For measuring cancer cell migration through tracking single cell migration, cells were 




cells / well 
respectively, and incubated overnight. Cell migration was monitored, after treating the 
cells with different treatments depending on the experiment, with time-lapse microscopy 
for 24 hrs. ImageJ software (MtrackJ plugin) was used to track cells and to measure the 
speed and distance of migrating cells; at least twenty cells were tracked randomly for each 
location 
2.2.18 Measuring apoptosis 
For measuring apoptosis, cells were seeded in six or twelve-well plates with a density of 
5X104 and 1x104 cells / well respectively in a humidified atmosphere at 37℃ and 5% CO2 
overnight. Cells were treated with different treatments depending on the experiment. Nikon 
TiE Time-lapse microscope running NIS Elements software and Plan 10x / 0.25 ph1 DL 
lens was used to monitor cells death tacking a series of images every 15 minutes for 24hrs.  
From each well three locations were selected randomly and all cells/location were tracked 
(Al-Gubory, 2005; Huh et al., 2012; Röttgermann et al., 2016). ImageJ software (counter 
plugin) was used to analyse data and following steps were done with ImageJ  
 
Figure 2.7: Micrographs 
showing wound healing 
in MDA-MB-231 cells 
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Open ImageJ file 
 Plugin                  Analyze            cell counter 
 In new window press initialize then choose type 1 under counters 
 During run of video image point on apoptotic cells for measuring dead cells, then 
count total cells. 
The rate of cell death during the 24hrs was calculated using the following equation. 
% cell death = (number of dead cells per location / total number of cells per location) X 100 
Apoptotic cells can be distinguished from live cells and other forms of cell death in time-
lapse video microscopy by observing shrinkage of cell that is followed by blebbing, 
fragmentation and cell rupture, as seen in Figure 2.8.  
 
   Figure 2.8: Morphological changes of apoptotic cells enable differentiating them from other cells. 
 
2.2.19 Quantifying p66shc  
Activated p66shc was measured using confocal microscopy. First, cells were seeded in a 




 cells / well respectively in a 
humidified atmosphere at 37℃ and 5% CO2 overnight. Cells were then transfected with 
p66shc siRNA and /or TRAP1 siRNA for 48hrs, next, cells were subjected to staining with 
a mitochondrial probe, and the immunofluorescence with anti-p66shc antibody as detailed 
above in 2.2.7 and 2.2.8 respectively.  A series of z-stack images was taken using confocal 
microscope and ImageJ software was used to measure activated p66shc (Steps described in 




2.2.20 Statistical analysis 
Data were expressed as mean ± standard error of mean (M ± SE) and statistical analysis 
was carried out using Microsoft Excel and Graph Pad Prism version 5.01 software. One-
way analysis of variance (ANOVA) followed by Tukey (to compare between the mean of 
treatments) or Dunnett (to compare between the mean of treatments with control mean) 
multiple comparison test, and significance level was expressed as following:  
(*)  represent P values < 0.05 statistically significant 
(**)  represent P values < 0.01 statistically highly significant 











Chapter Three: Investigating the impact of glucose levels on 
mitochondrial dynamics, metabolism, and cell migration in MDA-MB-
231 cells 
3.1 Introduction  
Mitochondria mediate several essential functions in the cell and are highly dynamic 
organelles (Rambold et al., 2011). Through fission and fusion process, they continuously 
regulate their morphology and structure between a fragmented, small size and tubular, 
network-like shapes. The balance between these two processes is essential for exchange of 
the damaged mitochondrial DNA, lipid, and protein with healthy mitochondria to maintain 
the normal function and structure of mitochondria (Scott and Youle, 2010, Otera et al., 
2013, van der Bliek et al., 2013, Guitart-Mampel et al., 2017). 
Many factors such as hyperglycaemia, hypoxemia, heat, U.V., and chemotherapy which 
cause oxidative stress through increase in ROS levels can shift mitochondrial dynamics 
toward the fission process resulting in hyper-fragmented mitochondria (Yu et al., 2006, Yu 
et al., 2011, Van Beersel et al., 2013, Aung et al., 2017). There are several published 
studies (Yu et al., 2006, Yu et al., 2008, Jheng et al., 2012, Kumari et al., 2012, Li et al., 
2017) that reported the responsibility of hyperglycaemia on mitochondrial fragmentation 
and cell death in patients with diabetes mellitus (DM) and cardiovascular disease.  
In contrast to the normal cells, cancer cells can tolerate high level of ROS.  Indeed, cancer 
cells are able to exploit high levels of ROS to enhance their function,  processes and 
pathways; it can induce  overexpression, secretion, or inhibition of several enzymes that 
participate  in cell motility, cell metabolism, and cell death (Fiaschi and Chiarugi, 2012). 
One of the enzymes that is overexpressed and activated at high ROS levels is Dynamin-
related protein 1 (Drp1), which is translocated from cytosol to mitochondrial surface where 
it interacts with fission 1 (Fis1) protein forming a ring around mitochondria that leads to 




Figure 3.1: Mechanism of inducing mitochondrial fragmentation in high glucose level. High glucose 
generates cellular ROS mainly through mitochondrial metabolism, elevated ROS activate dynamin-related 
protein 1 (Drp1) which bind with Fis1 on the surface of mitochondria. Assembling of Drp1 around 
mitochondria drives the fission process. Graph made using Motifolio - Scientific illustration Toolkits. 
It has been reported that during early steps of apoptosis, mitochondria encounters 
fragmentation through participation of the mitochondrial fission machinery, which can 
induce mitochondrial outer membrane permeabilization (MOMP) and cell death. 
Therefore, it is postulated that mitochondrial fragmentation is related to  apoptosis (Youle 
and Karbowski, 2005, Perfettini et al., 2005). However, several studies suggest that 
apoptosis can occur independently from mitochondrial fragmentation or activation of 
MOMP (Tondera et al., 2004, Parone et al., 2006, Arnoult, 2007, Sheridan and Martin, 
2010). Incontrast , it has been reported that fragmentation of mitochondria can increase 
resistance to apoptosis. Renault and co-workers (2015) investigated the relationship 
between mitochondrial shape and BCL2-associated X protein (BAX) induced MOMP for 
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apoptosis. They concluded that small mitochondrial size can restrict BAX from inducing 
MOMP and apoptosis (Renault et al., 2015).  
Many studies have suggested that the morphology of mitochondria plays important roles in 
the normal function of mitochondria (Jeong and Seol, 2008, Picard et al., 2013). In an 
investigation by Jheng and co-workers (2012), they found an association between 
mitochondrial fragmentation and mitochondrial dysfunction. They induced mitochondrial 
fragmentation by using palmitate (PA) in C2CL mouse myoblast cell line and it led to 
mitochondrial depolarization and loss of ATP production which is characteristic of 
mitochondrial dysfunction. They also found that prevention of mitochondrial 
fragmentation can inhibit mitochondrial dysfunction (Jheng et al., 2012). It appears that 
fragmentation of mitochondria can reduce the surface area of the inner mitochondrial 
membrane which plays an important role in oxidative phosphorylation (Mannella, 2006).  
Unlike normal cells, cancer cells prefer to rely on aerobic glycolysis to enhance rapid 
proliferation and metastasis which is also known as the Warburg Effect (Cantor and 
Sabatini, 2012, Li et al., 2016). There are studies that have found that growth of A549 lung 
cancer cells can be inhibited using Antimycin A; an inhibitor of mitochondrial electron 
transport chain (Han et al., 2008), this means that cancer cells  may not be depending on 
glycolysis completely to obtain required energy.  
It should be remembered that measuring metabolic changes including O2 consumption, 
ATP and lactate production directly in live cells using Seahorse XF Analyzer can show 
better understand of changes in glycolysis as well as changes in oxidative phosphorylation 
rate. However, due to unavailability of Seahorse XF Analyzer during studying time had 





Upon exposure of cancer cells to extrinsic oxidative stress, levels of ROS increase and this 
can cause mitochondrial oxidative damage and cell death.  To avoid apoptosis and the 
effect of excess ROS, cancer cells switch metabolism from oxidative phosphorylation to 
glycolysis. This reprogramming of metabolism leads to acidification of the 
microenvironment which can enhance cell migration (Pani et al., 2010, Fiaschi and 
Chiarugi, 2012). 
Previous studies have found that mitochondrial dynamics are linked to cell migration,  it 
was found that up-regulation of Dynamin-related Protein (Drp1) and fission of 
mitochondria increase migration and invasion of metastatic breast cancer cells (Zhao et al., 
2013a). Also in the study by Takatani and co-workers (2014), they found that 
hyperglycaemia can promote motility of MCF-7 breast cancer trough  increasing uptake of 
zinc (Takatani-Nakase et al., 2014). In contrast, another study reported that vascular 
smooth muscle cell (VSMC) migration can be limited by controlling mitochondrial fission 
(Wang et al., 2015b). Despite that, the effect of changes in mitochondrial morphology on 
cancer cell migration remains unclear. 
We hypothesize that morphological changes of mitochondria can affect glucose 
metabolism in cancer cells, which inturn affect cell migration and cancer metastasis. 
In this chapter we used different concentrations of glucose; low glucose (1mM), normal 
glucose (5.5mM), and high glucose (25mM), to investigate the link between mitochondrial 
dynamics; through measuring mitochondrial number, size, volume and total mitochondrial 
mass, and mitochondrial metabolism through measuring generated ATP and lactate; end 
product of glycolysis, and cell migration through tracking single cell movements and 
wound healing assay. 
In order to understand the effect of generated ROS on the mitochondrial dynamics 
changes, we investigated the effect of exogenous hydrogen peroxide (H2O2), which causes 
oxidative stress, on the mitochondrial dynamics, metabolism, and the cell migration. 
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Inhibition of mitochondrial fission using mitochondrial division-1 (mdivi-1) inhibitor, will 
be another point that focusing on it in this investigation as a confirmation of the link 






















3.2 Material and methods: 
3.2.1 Cell culture 
MDA-MB-231 breast cancer cells were continuously cultured in Dulbecco’s Modified 
Eagles Media (DMEM) with relevant glucose levels (1, 5.5, and 25mM) and  
supplemented with 10% FBS, 1% L-glutamine, 100 Unit/ml of penicillin and 100 µg/ml of 
streptomycin (Gibco), at 37°C in a humidified atmosphere containing 5% CO2. 
For preparation medium with different glucose concentrations, D-glucose was added to 
glucose free medium to final (1, 5.5 and 25mM) concentrations. 
In H2O2 study, the cells were treated in normal glucose DMEM medium with different 
concentrations of H2O2 (50, 100, 250, and 500µM) for 24hrs after overnight seeding. 
In the mdivi-1 inhibitor study, the cells were seeded overnight in high glucose DMEM 
medium then treated with different concentrations of mdivi-1 inhibitor (10, 30, 50µM) for 
24hrs.   
3.2.2 Mitochondrial staining 
A selective fluorescent probe (MitoTracker® Orange) was used to stain mitochondria. At 
the end of the experiments, the cells were incubated for 15 minutes with probe in serum 
free DMEM medium. The probe enters an actively respiring cell and sequestered 
permanently in the mitochondria. Then the cells washed twice using pre-warmed PBS. 
Later cells were fixed by using 4.0 % w/v paraformaldehyde for 20 minutes. After fixing 
the cells, fixative was aspirated and cells were washed twice, one minute each, and covered 
with 0.1% v/v Triton X100 - PBS for 10 minutes (to permeabilize the cells) and washed 
twice, for one minute each time with PBS. Then coverslips were mounted on glass slides 
using VECTASHIELD Mounting Medium with DAPI and the edges of the cover slips 
were sealed with nail polish. Z-stack images were captured at 100x objective lens using 
Nikon A1R confocal microscope running NIS Elements AR imaging software, then Images 
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were processed and analysed using NIS elements AR (Nikon) and ImageJ (Fiji, 64bit) 
software.  
3.2.3 Confocal microscopy images analysis  
The mitochondrial z-stack images were acquired by a Nikon A1R confocal microscopy 
using 100 X Oil immersion objectives with a format of 1024x1024 at 0.25µm intervals, 
which provides steady state 3D information about mitochondrial morphology. Then 
obtained 3D z-stack video images were analyzed using Image J (Fiji) Software to measure 
the number, size, and volume of mitochondria in control and treatments. The steps for 
analyse images were as follow  
Opening image  
Image Colour                           split channels  
Image                       Adjust                         brightness/contrast  
Set contrast of image under maximum slider to middle 
Image                        Lookup Tables                         Grays  
Process                        Find edges 
Analyze                     3D Object Counter                       3D object counter  
      Set threshold slider in such a way that only mitochondrial appear with fully stain if needed 
(Without over saturation of mitochondria with stain) 
 
Under size filter space 
Write 0.1 in Min. and 200 in Max 
        It takes 2-5 minutes to analyse images 
 
Copy displayed results and paste it into an Excel spreadsheet  
In the results we used only the number, size (μm^2), and volume size (μm^3), whereas 
total mitochondrial mass calculated by multiplying the number of mitochondria to the 





3.2.4 Quantitative Real- Time PCR (qRT-PCR) 
The Quantitative real time polymerase chain reaction (qRT-PCR) used for investigation the 
changes of mitochondrial DNA (mtDNA) copy number in MDA-MB-231 cells treated 
with different glucose levels, H2O2, or Mdivi-1 inhibitor. The total DNA including mtDNA 
was isolated and purified using DNeasy Blood & Tissue kit (Qiagen) according to 
manufacturer’s instructions, and concentration of DNA samples were measured using 
Nano-drop Spectrophotometer, then from each sample an equal amount of DNA (10 ng) 
was used. As described in section 2.2.10, mtDNA copy number was calculated through 
measuring t-RNA gene which represent mitochondrial gene and housekeeping gene β-actin 
which represent nucleus gene as control using AB StepOne Plus real time PCR machine 
(Applied Biosystems). Then PCR products were run through 1% agarose gel 
electrophoresis to visualized purity and singularity of amplified segments. 
3.2.5 Western blot analysis 
Immunoblotting was performed as described in section 2.2.8, to measure quantitative 
changes in expression of Drp1 and PGC-1α proteins, which normalized to housekeeper 
protein β-actin, between different treatments or between treatments compare to control. In 
brief, Cellular extracted proteins were fractionated using SDS-page gels (4-20% Mini-
PROTEAN® TGX™ Precast Protein Gels, Bio-Rad) and transferred to polyvinylidene 
difluoride (PVDF) membranes (Bio-Rad). Immunoblot analysis was visualized using the 
secondary antibody conjugated with horseradish peroxidase followed by the ECL Western 
blotting detection system (Amersham Biosciences), through Image-Quant LAS 4000 mini - 
GE Healthcare machine .The   protein bands were quantified using Image-Quant TL 8.1 
software. 
 3.2.6 Measurement of glycolysis activity  
Glycolytic activity in MDA-MB-231 breast cancer cells was determined by colorimetric-
based method for measuring lactate levels using Glycolysis Cell-Based Assay Kit (Cayman 
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Chemical Company) according to manufacturer’s instructions. In the assay, lactate 
dehydrogenase catalyzes the oxidation of lactate to pyruvate, in which the formed NADH 
reduces a tetrazolium substrate (INT) to a highly-coloured formazan which absorbs 
strongly at 490-520 nm. The amount of formazan produced is proportional to the amount 
of lactate released into the culture medium and could be used as an indicator of cellular 
glycolytic rate as shown in Figure 3.2. In brief, 2.5X10
4
 cells/well were cultured in 96-well 
cell culture plate overnight in 5% CO2 at 37°C, then depending on experiment the cells were  
treated and incubated either with glucose level, H2O2 or mdivi-1 inhibitor.  
 
Figure3.2: The illustration shows principle of glycolysis assay kit. The colorimetric assay for assessing of 
L-Lactate, it based on glycolysis activity. The end product, formazan is proportional to the amount of lactate 
released into the culture medium. 
 
Then 10µL of supernatant from each sample, after centrifugation of cell cultured plate at 
1,000 rpm for five minutes, transferred to 90µL of assay buffer in new 96-well plate, and 
added to them 100µL of reaction solution. The plate was incubated for 30minutes after 
shaking. The absorbance was read at 490nm, and amount of generated lactate was 
calculated through standard curve equation using obtained absorbance value.   
3.2.7 Measurement of ATP  
ATP levels were determined using ATP Assay Kit (abcam, ab83355) according to the 
manufacturer’s instructions. The assay is based on the phosphorylation of glycerol to 
generate a product that can be measured by colorimetric methods at 570 nm. Briefly, 
5X10
5
 cells / well were plated in 6-well plates and allowed for attachment overnight. Then 
the cells treated depending on the experiments. Later 1X10
6
 cells from each sample were 
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harvested and suspended in 100µL ATP buffer. After homogenization and centrifugation at 
1000 rpm for 2minutes, 50µL of supernatant from each sample were mixed with 50µL of 
reaction mix in 96-well plate.  Microplate read used to read optical density at 570nm. 
Through standard curve equation, concentration of each treatment was calculated using an 
obtained OD. 
3.2.8 Measurement of intracellular ROS 
Intracellular ROS generation was assessed using OxiSelect™ Intracellular ROS Assay Kit 
(Cell Biolabs, STA-342) according to manufacturer’s instructions. In brief, 2.5X10
4
 
cells/well were cultured in black 96-well cell culture plate and incubated with 2’, 7’-
Dichloro dihydro fluorescin diacetate (DCFH-DA) (100µL) for 60 min at 37℃. After 
washing with Hank’s buffered salt solution (HBSS), cells were incubated with different 
glucose level, or treated either with H2O2 or mdivi-1 inhibitor. Generated ROS by cells can 
oxidize non-fluorescent DCFH-DA into highly fluorescent 2’,7’-
Dichlorodihydrofluorescein (DCF), which can be read with fluorescent microplate reader 
at 485 nm (excitation) and 535 nm (emission).  Results are presented as relative 
fluorescence unit (RFU). 
3.2.9 Wound Healing Assay 
1.5 X10
5 
cells were added to each well of 12 well plates and cultured overnight at 37℃ in 
5% CO2. Then cells were treated and incubated with different glucose levels, H2O2, or 
mdivi-1 inhibitor for 24hrs.  Next cell monolayer  scratched with a standard 200 ml pipette 
tip to create a narrow wound-like gap (confluency should be reach to more than 80% 
before scratching).  Wounded monolayers were washed twice to remove non-adherent cells 






3.2.10 Cell migration  
MDA-MB-231 cells were seeded in 12 wells plates at density 5X10
3
cells/well in 
humidified atmosphere with 37℃ and 5% CO2. After 24 hrs the cells were treated with 
different concentrations of glucose, H2O2, or mdivi-1 inhibitor and cell migration was 
monitored by time-lapse microscopy for 24hrs with images taken at 15 minute intervals. 
ImageJ (Fiji) software (MtrackJ plugin) was used to track and measure the speed of cell 























3.3.1 Effect of glucose level on the mitochondrial dynamics, metabolism, and cell 
migration: 
To evaluate the effect of mitochondrial dynamics on metabolism and cell migration, MDA-
MB-231 cells were cultured in different glucose concentrations; low glucose; 1mM, 
normal glucose; 5.5mM, and high glucose; 25mM for 48hrs then subjected to 
mitochondrial staining with MitoTracker to show changes in mitochondrial morphology, as 
shown in Figure 3.4, through measuring mitochondrial number, size, volume, and total 
mass per cell using confocal fluorescence microscopy. Results showed that the number of 
mitochondria was increased significantly to 197.4±7.4 in high glucose level compared to 
103.5±8.9 in normal glucose level (p<0.01), and 76.4±10.6 in low glucose level (p<0.001), 
while, no significant changes in the mitochondrial number was observed between normal 
glucose and low glucose levels, as seen in Figure 3.3 A. 
The size and volume of the mitochondria were also affected by the changes in glucose 
levels. Results in Figure 3.3B shows a clear trend of decreasing of the mitochondrial size 
from 6.49±0.28 µm^
2
 in low glucose to 3.56±0.15 µm^
2
 in normal glucose and 1.57±0.11 
µm^
2
 in high glucose levels (p<0.001). The changes in the mitochondrial size between 
cells cultured in normal glucose and cells cultured in high glucose was also significant 
(p<0.001). 
Similarly, the volume of mitochondria was decreased with the increases in the glucose 
levels. The results of the volume analysis shown in Figure 3.3 C revealed that mean of the 
mitochondrial volume has been decreased from 0.52±0.035µm^
3
 in low glucose to 
0.29±0.025µm^
3
 in normal glucose (p<0.01) and into 0.09±0.003µm^
3
 in high glucose 
(p<0.001). The decreases in the mitochondrial volume in high glucose compared to normal 
glucose was also significant (p<0.01). 
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We calculated total mass of mitochondria by multiplying obtained data of the 
mitochondrial volume to the number of the mitochondria. Results presented in Figure 
3.3D, revealed that the total mass of mitochondria decreased significantly from 
38.2±2.61µm^
3
 in low glucose to 14.8±0.86µm^
3
 in high glucose medium (p<0.001). No 
significant changes were detected between low glucose and normal glucose or between 


















































































































































Figure 3.3: Effect of glucose level on mitochondrial fragmentation in MDA-MB-231 cells. Cells were 
grown in different glucose levels (1, 5.5, and 25mM) for 48hrs then stained with MitoTracker probe and 
confocal microscopy was used to take mitochondrial images. (A) Quantification analysis of number of 
mitochondria, (B) Size of mitochondria, (C) Volume of mitochondria, and (D) represent quantification 
analysis of total mitochondria mass per cell. Data represent the mean ± standard error of three independent 
experiments performed in triplicate; each experiment contained at least 30 cells. One-way ANOVA and 
Tukey’s Multiple Comparison test used to compare between the mean of treatments (*, **, and ***represent 
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Figure 3.4: Micrographs showing the mitochondrial morphology. Mitochondria were stained with 
MitoTracker orange CMTMRos probe (red colour) and nucleus stained with DAPI (blue colour), for MDA-
MB-231 breast cancer cells grown in different glucose levels in DMEM medium; low glucose (1mM), 
normal glucose (5.5mM), and high glucose (25mM). Image analysis was performed by confocal microscopy. 









To confirm our results obtained by confocal microscopy we measured mtDNA copy 
number through measuring t-RNA gene of mtDNA normalized to β-actin gene as 
housekeeping gene. Results shown in Figure 3.5A revealed that the changes in mtDNA 
copy number due to increases in glucose concentrations statistically were not significant. 
However, linear regression analysis of data shows a relationship between increases in 
glucose concentration and increases in mtDNA copy number, as seen in Figure 3.5B. Then 
to verify the qPCR results and purity of amplified segments we ran qPCR products on 1% 






















C      D  
Figure 3.5: Quantification of mtDNA copy number in MDA-MB-231 cells grown in different glucose 
levels. Total DNA extracts used to measure mtDNA by (qPCR) (A) Represent quantification analysis of 
mtDNA copy number, (B) linear regression analysis of data, (C) amplification plot and Ct values of β-actin 
and t-RNA genes, and  (D) represent Agarose gel electrophoresis of β-actin (101 bp) and t-RNA gene (107 
bp). Data represent the mean ± standard error of three independent experiments performed in triplicate. One-
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To uncover the effect of glucose level on the expression of dynamin-related protein (Drp1), 
a key protein of mitochondrial fission, we measured its expression in MDA-MB-231 cells 
grown under different concentrations of glucose for 48hrs. 
The results revealed that increases in the glucose level increased the expression of Drp1 as 
shown in Figure 3.6. The expression of protein was increased significantly from 13.7±2.11 
in low glucose to 30±1.66 in normal glucose (p<0.05), and into 39.6±3.77 in high glucose 
(p< 0.01); which means the expression of protein Drp1 was increased by 118.6%, in 
normal glucose and by 188.5% in high glucose compared to low glucose. While, no 
significant changes in the expression of the Drp1 protein between normal glucose and high 

























Figure 3.6:  Western blot showing the effect of glucose levels on the Drp1 protein expression in MDA-
MB-231 cells after 48hrs. Data represent the mean ± standard error of three independent experiments 
performed in triplicate. One-way ANOVA followed by Tukey’s Multiple Comparison Test to compare mean 















To uncover the role of glucose level on metabolism, MDA-MB-231 cells were cultured for  
48hrs in medium with different concentrations of glucose and production of ATP and 
lactate were measured. 
The results of quantification ATP in Figure 3.7; show that the production of ATP by cells 
increased significantly with increasing glucose concentration in the medium. ATP 
production increased significantly from 0.75±0.013mM in low glucose to 1.11±0.016mM 
in normal glucose (p<0.01) and to 2.05±0.086mM in high glucose (p<0.001). Data also 
showed significant increases of ATP production in high glucose compared to normal 




















Figure 3.7:  Quantitation of ATP in MDA-MB-231 cells grown in different glucose levels. Lysate of 
1x10
6
 cells were used for measuring ATP level by colorimetric ATP assay kit.  Data represent the mean ± 
standard error of three independent experiments performed in triplicate. One-way ANOVA followed by 









Similarly, our results as seen in Figure 3.8 revealed that increasing glucose concentration 
increased the generation of lactate in MDA-MB-231 cells. Lactate production was 
increased significantly from 5.52±0.14mM in low glucose to 14.43±0.42mM in normal 
glucose and to 17.98±0.69mM in high glucose (p<0.001). The increases in production of 























Figure 3.8:  Lactate generation in MDA-MB-231 cells grown in different glucose levels. Cells were 
seeded in a 96-well plate at a density of 25,000 cells/well in DMEM supplemented with 10% FBS and 
different concentrations of glucose. After 48 hrs of incubation, the supernatants were assayed to determine 
generated L-Lactate level.  Data represent the mean ± standard error of four independent experiments 
performed in triplicate. One-way ANOVA followed by Tukey’s Multiple Comparison Test to compare mean 











Afterwards wound healing assay was performed to investigate the impact of glucose at 
different concentrations on the cell migration in MDA-MB-231 cells. Results showed that 
cell migration markedly increased with increasing glucose concentrations. As shown in 
Figure 3.9 and Figure 3.10, migrated cells covered 36.5±2.84% of scratched area in low 
glucose level. This ratio was increased significantly in normal glucose to 64.2±5.46% 
(p<0.01), and to 90.9±0.49% (p<0.001) in high glucose. We also found that the increased 
ratio of covered wounded area in the high glucose level was significant compared to the 





























Figure 3.9: Wound healing assay to evaluate MDA-MB-231 cell migration in different glucose levels.  
Cell cultured in different glucose concentrations for 24hrs then monolayer cells were scratched. Time-lapse 
microscopy was used to taken images every hour for 24 hrs.  The wound area was quantified using ImageJ 
Software. Data represent the mean ± standard error of three independent experiments performed in triplicate. 
One-way ANOVA followed by the Tukey’s Multiple Comparison test to compare between mean of 



























Figure 3.10:  Wound healing assay Micrographs showing the MDA-MB-231 cells under the effect of 
different glucose levels in DMEM medium. Time-lapse microscopy used to take images at 0, and 24hrs of 











To confirm the previous result of wound healing assay, cell tracking was performed to 
investigate the effect of glucose in different concentration on cell migration in MDA-MB-
231 cells.  The results revealed that cell migration increased with increasing glucose 
concentrations. As shown in Figure 3.11 cell migration was increased to 
18.1±0.54µm/hour in high glucose level compared to 15.9±0.21µm/hour in normal glucose 
(p<0.05), and 13.96±0.66µm/hour in low glucose (p<0.001). While, no significant 
differences in the cell migration was detected between the cells cultured in the normal 


































Figure 3.11: Impact of different glucose levels on cell migration in MDA-MB-231 cells. The cell 
migration was monitored by the time-lapse imaging microscopy. Images were taken every 15 minutes over 
24 hours, and ImageJ software was used for measuring single cell movement. Data represent the mean ± 
standard error of four independent experiments performed in triplicate. One-way ANOVA followed by 








To confirm whether production of reactive oxygen species (ROS) was increased with 
increasing concentration of glucose in   MDA-MB-231 cells, we measured intracellular 
ROS using a commercial assay kit. Our results revealed that production of ROS in high 
glucose was significantly increased to 20717±2029Unit compared to 12361±403.8Unit in 
low glucose level (p<0.01). While, no significant differences was found in the production 
ROS between high glucose and normal glucose or between normal glucose and low 
glucose, as seen in Figure 3.12. 
 
 
Figure 3.12: Reactive oxygen species (ROS) in MDA-MB-231 cells in different glucose levels.  Cells 
were treated with 0.2mM DCFH-DA for 60 minutes, and then incubated in different concentrations of 
glucose for 24 hrs. The intensity of fluorescence was read with a fluorometric plate reader at 485 nm/535 nm. 
Data represent the mean ± standard error of the mean of three independent experiments performed in 




































3.3.2 Effect of H2O2 on mitochondrial dynamics, metabolism, and cell migration: 
When we studied the effect of glucose on mitochondrial dynamic, we postulated that 
increased ROS will be responsible for fragmentation of the mitochondria as illustrated in 
Figure 3.1. To test this postulate we investigated the effect of exogenous hydrogen 
peroxide (H2O2) on mitochondria, as well as its effect on the metabolism and the cell 
migration. Therefore we treated MDA-MB-231 cells with different concentrations of H2O2 
(50, 100, 250, and 500µM) for 24hrs in our studies. 
To confirm that H2O2 with the concentrations that we used does not affect cell viability, we 
carried out MTT assay to MDA-MB-231 cells treated with different concentrations of 
H2O2 for 24hrs. The results shown in Figure 3.13, which are analysed using One-way 
ANOVA followed by Tukey post-test, revealed that H2O2 in all used concentrations has no 
significant effects on the cell viability compared to control as well as statistically there 
were no significant differences between treatments. 

























Figure 3.13: MTT assays showing the effect of H2O2 on the cell viability in MDA-MB-231cells.  Cells 
were seeded in a 96-well plate at a density of 10,000 cells/well in DMEM containing 10% FBS and incubated 
overnight then treated with different concentrations of H2O2 for 24hrs. After adding MTT reagent incubated 
for 4hrs at same conditions, cell viability was determined by reading plates at 570 nm with plate reader. Data 





We investigated the effect of H2O2 on the mitochondrial morphology in MDA-MB-231.  
The results in Figure 3.14A show that no significant differences in the mitochondrial 
number were found between the cells treated with H2O2 at concentrations 50, 100, and 
250µM with the control cells, except at concentration 500µM where mitochondrial number 
was increased significantly to 254.5±7.61  compared to  122.6±49.34  in the control cells 
(p<0.05). The impact of H2O2 on the size and the volume of the mitochondria were also 
studied, and results shown in Figure 3.14B revealed that H2O2 at concentrations 50, and 
100µM does not affect the mitochondrial size, while at the concentrations 250µM and 
500µM, mitochondrial size reduced to 1.72±0.078 and 1.34±0.064 µm^
2
 (p<0.01 and 
p<0.001) respectively compared to mitochondrial size 4.39±0.76 µm^
2
 in the control cells. 
The volume of the mitochondria was also affected by H2O2 as it was decreased with 
ascending concentrations of H2O2. In Figure 3.14 C, the results of the mitochondrial 
volume analysis show that mitochondrial volume was decreased significantly from 
0.41±0.079 in the control cells to 0.24±0.024µm^
3
 in the cells treated with 100µM of H2O2 
(p<0.05), and into 0.11±0.002 and 0.069±0.007µm^
3 
at concentrations 250, and 500µM of 
H2O2 respectively (p<0.001). Whereas, no significant differences were observed between 
cells treated with 50µM of H2O2 and control cells. 
The total mass of mitochondria was obtained by multiplying data of the mitochondrial 
volume to the number of the mitochondria, and results shown in Figure 3.14D, revealed 
that the total mass of mitochondria decreased significantly from 48.8±6.54µm^
3
 in the 
control to 31.7±1.26µm^
3
 at concentration 100µM (p<0.05), and into 17.8±2.44, and 
15.6±3.46µm^
3
 at concentrations 250, and 500µM respectively (p<0.001). While, no 
significant changes in the total mass of mitochondria was detected at concentration 50µM 
compared to control.  
Figure 3.15 shows the morphological changes in the mitochondria in MDA-MB-231 cells 
after treating them with different concentrations of H2O2 for 24hrs. 
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Figure 3.14: Effect of hydrogen peroxide (H2O2) on mitochondrial fragmentation in MDA-MB-231 
cells. Cells exposed to different concentrations of   H2O2 (50, 100, 250, and 500µM) for 24hrs then stained 
with MitoTracker probe and confocal microscopy used to take mitochondrial images. (A) represent 
quantification analysis of number of mitochondria, (B) Size of mitochondria, (C) Volume of mitochondria, 
and (D) which represent quantification analysis of total mitochondria mass per cell. Data represent the mean 
± standard error of three independent experiments performed in triplicate; each experiment contained at least 
30 cells. One-way ANOVA and Dunnett’s Multiple Comparison test was used to compare between the mean 




















































Figure 3.15: Micrographs showing the mitochondrial shape in MDA-MB-231 cells.  Mitochondria were 
stained with MitoTracker orange probe (red) and nucleus stained with DAPI (blue), for the cells treated with 
different concentrations of H2O2.  Scale bars on all images = 20μm 
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To confirm our results obtained through confocal microscopy, we measured mtDNA copy 
number after exposing the cells to different concentrations of H2O2 for 24hrs.  Results 
shown in Figure 3.16 revealed no changes in the mtDNA copy number at concentrations 
50, and 100µM of H2O2 compared to the control. While at concentrations 250, and 500µM 
of H2O2, mtDNA copy number was increased significantly to 1535.84±128.2 (p<0.001) 
and to 1293.45±50.83 (p<0.05) respectively compared to 822.497±106.4 in the control.     
























Figure 3.16: Quantification of mtDNA copy number in MDA-MB-231 cells treated with different 
concentrations of H2O2. Total DNA were extracted and used to determine mtDNA by quantitative real-time 
PCR. Data represent the mean ± standard error of three independent experiments performed in triplicate. 
One-way ANOVA followed by Dunnett's Multiple Comparison Test to compare mean of treatments with 












Later we studied the effect of H2O2 on the metabolism in MDA-MB-231 cells. The results 
in Figure 3.17 show that ATP production was significantly increased in the cells treated 
with 100 and 250µM of H2O2 to 1.23±0.02mM (p<0.01) and to 1.3±0.05mM (p<0.001) 
respectively compared to 1.05±0.04mM in the control cells. While, no significant changes 
was observed between the cells treated with 50, and 500µM of H2O2 with control cells. 
Also we measured the amount of the lactate produced by MDA-MB-231 cells after 24hrs 
of treating with different concentrations of H2O2. Our results in Figure 3.18 showed 
increases in lactate production in the cells treated with H2O2  at concentrations 100, and 
250µM to 16.6±0.54 and 16.96±0.34mM respectively (p<0.05) compared to 
14.42±0.42mM in control cells. Whilst, no significant differences were detected between 
cells exposed to H2O2 at concentrations 50, and 500µM and control cells.   
 






































Figure 3.17:  Effect of H2O2 on ATP generation in 
MDA-MB-231cells. Lysate of 1x10
6
 cells were used 
for measuring ATP level by colorimetric ATP assay 
kit.  Data represent the mean ± standard error of four 
independent experiments performed in triplicate. 
One-way ANOVA followed by Dunnett's Multiple 
Comparison Test to compare mean of treatments with 
control mean   (**, and *** represent P < 0.01, and 
0.001 respectively). 
Figure 3.18:  Effect of H2O2 on lactate production 
in MDA-MB-231 cells. Cells were treated with 
different concentrations of H2O2 for 24 hrs, and then 
supernatants were assayed to determine the L-Lactate 
concentrations. Data represent the mean ± standard 
error of three independent experiments performed in 
triplicate. One-way ANOVA followed by Dunnett's 
Multiple Comparison Test to compare mean of 




We have carried out the experiment to uncover the effect of H2O2 on cell migration in 
MDA-MB-231 cells. The results obtained from wound healing assay revealed that 
increasing concentrations of H2O2 have positive effect on the cell migration. As appears in 
Figure 3.19, covered wounded area by migrated cells was increased significantly from 
53.98±2.3% in the control to 81.9±4.48%, and 78.6±9.24% in cells treated with H2O2 at 
concentrations 250 and 500µM respectively (p<0.05). Whereas, no significant differences 
in the cell migration was observed in the cells treated with 50 and 100µM of H2O2 
compared to the control.  
Figure 3.20 shows the time-lapse microscope captured images at zero time and after 24hrs. 
The scratched area was covered by migrated cells treated with different concentrations of 
H2O2.  
 

























Figure 3.19: Wound healing assay of MDA-MB-231 cells treated with hydrogen peroxide (H2O2). The 
wounded monolayer was incubated with different concentrations of H2O2, and   images were captured every 
hour for 24 hrs using Time-lapse microscopy. ImageJ Software was used to measure closure area. Data 
represent the mean ± standard error of three independent experiments performed in triplicate. One-way 
ANOVA followed by the Dunnett’s Multiple Comparison test to compare mean of treatments with mean of 





























































Figure 3.20:  Wound healing assay micrographs showing the MDA-MB-231 cells treated with hydrogen 
peroxide (H2O2). Time-lapse microscopy used to take images at 0, and 24hrs of cells treated with different 





We also tracked cell movement using time-lapse microscopy to investigate the effect of 
H2O2 on the cell migration. Results in Figure 3.21 showed that the cell migration was 
increased significantly at concentrations 100, and 250µM to 18.71±0.37, and 
18.96±0.49µm/hour respectively (p<0.01) compared to 14.95±0.37µm/hour in control. 
While, no significant changes was detected at concentrations 50, and 500µM compared to 
control. 
































Figure 3.21: Effect of hydrogen peroxide (H2O2) on the cell migration in MDA-MB-231 cells. Time-
lapse microscopy used to track single cell movement; images were taken every 15 minutes during 24hrs. 
ImageJ Software used to measure cell movement. Data represent the mean ± standard error of three 
independent experiments performed in triplicate. One-way ANOVA followed by the Dunnett’s Multiple 













To find out if exposing cells to exogenous H2O2   affected intracellular levels of reactive 
oxygen species (ROS), we treated MDA-MB-231 cells with different concentrations of 
H2O2 for 24hrs. The result shown in Figure 3.22 revealed that production of ROS was 
increased significantly to 22356.7±2067, and 21635±1317Unit at concentrations 250 and 
500µM respectively (p<0.05) compared to 15855±509.8Unit in the control. While, no 
changes in ROS production were observed at lower H2O2 concentrations. 
























Figure 3.22: Effect of H2O2 on generation of reactive oxygen species (ROS) in MDA-MB-231cells.  Cells 
were treated with 0.2mM DCFH-DA for 60 minutes then treated with different concentrations of H2O2 for 24 
hours. The intensity of fluorescence was read with a fluorometric plate reader at 485 nm/535 nm. Data 














3.3.3 Effect of inhibition mitochondrial fragmentation on mitochondrial metabolism, 
and cell migration: 
We studied the effect of the glucose levels on mitochondrial dynamics and we found that 
high glucose has induced the mitochondrial fragmentation; which in turn affected the 
metabolism, and cell migration. In this section, we investigated the effect of inhibition of 
mitochondrial fission induced by high glucose level in MDA-MB-231 cells on the 
metabolism, and the cell migration. 
For this purpose we used mitochondrial division inhibitor (mdivi-1); a selective chemical 
inhibitor of mitochondrial fission protein Drp1.  It can inhibit mitochondrial fission 
through inhibiting Drp1 enzyme activity and blocking Drp1/Fis1 interaction, 
consequently   inhibiting assembly of Drp1protein around mitochondria which is essential 
for its function (Yeon et al., 2015) as presented in Figure 3.23. 
 
Figure 3.23: Mechanism of mitochondrial fragmentation inhibition by Mdivi-1 inhibitor. Graph made 




To uncover the effect of mdivi-1 inhibitor on the mitochondrial dynamics, we treated 
MDA-MB-231 cells with different concentrations 10, 30, and 50µM of mdivi-1 inhibitor 
for 24hrs in high glucose; 25mM, medium. Results in Figure 3.24A showed that no 
significant differences in the mitochondrial number have occurred in the cells treated with 
mdivi-1 inhibitor compared to control cells.  
The size of the mitochondria were measured in the treated cells with mdivi-1 inhibitor and 
the results as presented in Figure 3.24B revealed that size of the mitochondria was 
increased significantly from 1.79±0.15µm^2 in non-treated cells to 2.98±0.25, and 
3.18±0.087 µm^2 in treated cells with 30, and 50µM of mdivi-1 inhibitor respectively 
(p<0.01). Whereas, no changes were observed at concentration 10µM compared to non-
treated control cells.  
Similar results were obtained when we measured the volume of mitochondria. Figure 
3.24C shows that mitochondrial volume was increased significantly from 0.14±0.005µm^
3
 
in the control cells to 0.21±0.009µm^
3
 in the treated cells with 10µM of mdivi-1 inhibitor 
(p<0.05), and into 0.27±0.015, and 0.31±0.017µm^
3
 in the treated cells with 30, and 50µM 
of mdivi-1 inhibitor respectively (p<0.001). 
Results for measuring total mass of the mitochondria shown in Figure 3.24D, revealed  
significant changes in the cells treated with 50µM of mdivi-1 inhibitor; in which  total 
mitochondrial mass was increased significantly to 31.7±5.78µm^
3
 (p<0.05) compared to 
17.6±0.22µm^
3
 in the control cells. While, no changes were observed between cells treated 
with mdivi-1 inhibitor at concentrations (10, and 30µM) and control cells.  
Figure 3.25 shows the micrograph of mitochondrial morphology in MDA-MB-231 cells 















































































































































Figure 3.24: Effect of mdivi-1 inhibitor on the mitochondrial morphology in MDA-MB-231 cells. Cells 
cultured in high glucose medium were treated with different concentrations (10, 30, and 50µM) of mdivi-1 
inhibitor for 24hrs.  MitoTracker probe used for staining mitochondria and confocal microscopy was used to 
take images. (A) Represent quantification analysis of mitochondrial number, (B) Size of the mitochondria, 
(C) Volume of the mitochondria, and (D) Total mass of the mitochondria per cells. Data represent the mean ± 
standard error of three independent experiments performed in triplicate; each experiments with more than 30 
cells. One-way ANOVA followed by Dunnett’s Multiple Comparison test to compare between the mean of 












Figure 3.25: Micrographs showing the effect of mdivi-1 inhibitor on the mitochondrial morphology in 
MDA-MB-231 cells.  Cells treated with different concentrations Mdivi-1 inhibitor in high glucose medium. 
Mitochondria were stained with MitoTracker probe (red) and nucleus stained with DAPI (blue). Scale bars 
for all images = 10μm. 
 
 






























































To confirm obtained results by confocal microscopy for mitochondrial morphology in 
MDA-MB-231 cells treated with mdivi-1 inhibitor, we measured mtDNA copy by (qPCR). 
Results in Figure 3.26 show that no significant differences were observed in the copy 
number of mtDNA between cells treated with mdivi-1 inhibitor compared to non-treated 
control cells.   
























Figure 3.26: Quantification of mtDNA copy number in MDA-MB-231 cells treated with mdivi-1 
inhibitor. Cells were treated with different concentrations of mdivi-1 inhibitor for 24hrs in high glucose 
(25mM) medium, and then DNA extracted and used to determine mtDNA content using quantitative real-
time PCR. Data represent the mean ± standard error of three independent experiments performed in triplicate. 
One-way ANOVA followed by Dunnett's Multiple Comparison Test to compare mean of treatments with 
















Afterward we investigated the effect of mdivi-1 inhibitor on the metabolism through 
measuring the level of ATP production and lactate production. Results of quantification 
ATP production in Figure 3.27 revealed that mdivi-1 inhibitor at the concentrations 30, and 
50µM caused significant reduction in the ATP production to 1.39±0.03, and 1.11±0.02mM 
compared to 2.05±0.09mM in the control (p<0.001). Whereas, no significant differences 
were detected at concentration 10µM compared to the control.  
The levels of lactate production were also measured and results as seen in Figure 3.28 
showed significant decreases in lactate production in the cells treated with mdivi-1 
inhibitor at all used concentrations. Compared to the non-treated control cells; in which 
lactate production was 17.98±0.7mM, it has been decreased to 13.87±0.16, 12.59±0.32, 
and 11.2±0.17mM in treated cells with mdivi-1 inhibitor at concentrations 10, 30, and 
50µM respectively (p<0.001).  





































Figure3.27:  Effect of mdivi-1 inhibitor on ATP 
production in MDA-MB-231 cell. ATP levels 
were measured using colorimetric ATP assay kit at 
570nm, after treating cells with different 
concentrations of mdivi-1 inhibitor in high glucose 
medium for 24hrs.  Data represent the mean ± 
standard error of the mean of four independent 
experiments performed in triplicate. One-way 
ANOVA followed by Dunnett's Multiple 
Comparison Test to compare mean of treatments 
with the mean of control (*** represent P < 0.001).  
 
Figure 3.28: Effect of mdivi-1 inhibitor on 
lactate production in MDA-MB-231 cell.   After 
24hrs treating cells with different concentrations 
of mdivi-1 inhibitor in high glucose medium; 
supernatants were assayed using colorimetric 
glycolysis assay kit at 490nm to determine the L-
Lactate concentrations. Data represent the mean ± 
standard error of three independent experiments 
performed in triplicate. One-way ANOVA 
followed by Dunnett's Multiple Comparison Test 
to compare mean of treatments with control mean 




Later we assessed the production level of ROS in the MDA-MB-231 cells treated with 
mdivi-1 inhibitor using commercial ROS assay kit. Results in Figure 3.29 showed that the 
production of ROS was decreased significantly form 20383.7±2029Unit in the control to 
13394.3±1350Unit in the treated cells with 50µM of mdivi-1 inhibitor (p<0.05).  Whereas, 
no significant differences in ROS production was recorded between treated cells with 10 
and 30µM of mdivi-1 inhibitor with non-treated control cells.  
























Figure3.29: Effect of mdivi-1 inhibitor on the ROS production in MDA-MB-231 cells.  Cells were 
treated with 0.2mM DCFH-DA for 60 minutes then treated with different concentrations of mdivi-1 inhibitor 
in high glucose medium for 24hrs. The intensity of fluorescence was read with a fluorometric plate reader at 
485 nm/535 nm. Data represent the mean ± standard error three independent experiments performed in 











The impact of mdivi-1 inhibitor on cell migration was investigated using time-lapse 
microscopy in tracking cell movement.  Figure 3.30 shows that the cell migration was 
decreased significantly from 26.64±1.23µm/hour in the control to 19.22±0.79µm/hour in 
the treated cells with 30µM of mdivi-1 inhibitor (p<0.01), and into 15.95±1.12µm/hour in 
the treated cells with 50µM of mdivi-1 inhibitor (p<0.001). While, no significant changes 
in cell migration was observed between cells treated with 10µM of mdivi-1 inhibitor and 
the control cells. 




























Figure 3.30: Impact of mdivi-1inhibitor on the cell migration in MDA-MB-231. Cell migration was 
monitored by the time-lapse microscopy, and images were taken every 15 minutes over 24 hours. ImageJ 
software was used for measuring cell movement. Data represent the mean ± standard error of three 
independent experiments performed in triplicate. One-way ANOVA followed by Dunnett’s test used to 












3.4 Discussion  
3.4.1 Glucose levels affect mitochondrial morphology, metabolism, and cell migration. 
It was believed that reprogramming of glucose metabolism from mitochondrial oxidative 
phosphorylation to glycolysis in cancer cells, which is known as the Warburg effect, is due 
to permanent changes in mitochondria, however, there are investigations which find that 
most cancer cells depend on mitochondrial oxidative phosphorylation for generation of 
ATP and production of metabolic intermediate precursors for the synthesis of 
macromolecules such as lipids, proteins, and nucleic acids (Brault and Schulze, 2016). 
Moreover, there is evidence that cancer cells can restore mitochondrial oxidative 
phosphorylation,  this means that mitochondria are intact and oxidative phosphorylation is 
inhibited rather than being permanently altered (Zheng, 2012). 
One outcome of reprogramming glucose metabolism by cancer cells, which may be 
induced by the change in the mitochondrial dynamics, is production of lactate; the end 
product of glycolysis, which can change the pH of the tumour microenvironment towards 
acidity which may affect the motility of cells (Beckert et al., 2006, Zheng, 2012, Jiang, 
2017). 
Despite the importance of cancer cells regulating their mitochondrial morphology on the 
basis of their requirements for ATP and their need to enhance growth, proliferation and 
migration, and in response to environmental and pathologic factors including glucose 
concentration (Bordi et al., 2017), there is a gap in knowledge linking mitochondrial 
morphology, and their metabolism to cell migration. 
This chapter investigates the effect of glucose level, using three concentrations; normal 
concentration (5.5mM), low glucose (1mM), and high glucose (25mM), on mitochondrial 
dynamics and their metabolism on cell migration in MDA-MB-231 breast cancer cells. 
This study has identified that glucose concentration can affect mitochondrial morphology 
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strongly, which in turn induces changes in the mitochondrial metabolism as well as in cell 
migration.  In low glucose concentration (1mM), which mimics severe hypoglycaemia in 
humans, mitochondria appeared as elongated, network-like shapes. While in high glucose 
concentration (25mM), which mimics hyperglycaemic condition in humans, mitochondria 
were fragmented to small, circular shapes. In normal glucose (5.5mM), which represents 
normal glucose level in human blood, elongated shape mitochondria were shown (Figure 
3.4). We evaluated these changes in mitochondrial dynamics induced by glucose 
concentrations more accurately through measuring the number, size, volume, and total 
mass of mitochondria via confocal microscopy using a mitochondrial specific stain 
(MitoTracker probe). Although the mitochondria are highly dynamic organelles and the 
processes of fission and fusion can take place easily during the course of experiments, 
these challenges were solved through fixation of cells. The results confirmed our 
expectations, increasing glucose level led to increases in the number of mitochondria, 
while, mitochondrial size and volume became smaller as well as the total mass of 
mitochondria (Figure 3.3). 
Mitochondrial overlapping was one of difficulties in mitochondrial counting.  Despite that 
the confocal microscopy provides high quality 3D images of mitochondria, the large 
number of mitochondria within cells can impede mitochondrial counting especially in high 
glucose level where mitochondria were fragmented and can appear overlapped or 
aggregated.  
To confirm the results obtained by confocal microscopy, mitochondrial DNA (mtDNA) 
copy number was measured using quantitative polymerase chain reaction (qPCR). Even 
though the results suggested that increases in glucose concentrations affected mtDNA copy 
number, statistically the difference was non-significant (Figure 3.5). One explanation may 
be that the lysate buffer which used to disrupt cell membrane during isolation of DNA has 
affected the tubular network-like shape mitochondria.   
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In mammalian cells, dynamin-related protein 1 (Drp1); key mediators of mitochondrial 
fission, can be activated in response to several factors including stress induced by high 
glucose (Wang et al., 2012, Rovira-Llopis et al., 2017) and trigger mitochondrial 
fragmentation through interaction with mitochondrial fission 1 protein which is localized 
on the outer surface of mitochondrial membrane (Otera and Mihara, 2011). Our results 
from western blots confirm that increases in glucose concentrations led to increases in the 
expression of Drp1 protein (Figure 3.6). 
There are several studies suggesting that reactive oxygen species (ROS), which is mostly 
generated during mitochondrial oxidative phosphorylation (Gao et al., 2008), is responsible  
for mitochondrial fragmentation (Yu et al., 2006, Wang et al., 2012), and there are reports 
that linked high glucose level with overproduction of ROS (Trudeau et al., 2011, Yu et al., 
2011). However, studies have found that blocking ROS generation in high glucose 
concentration did not prevent mitochondrial fragmentation (Yu et al., 2006). Furthermore, 
it was reported that mitochondrial fragmentation induced by ROS leads to mitochondrial 
dysfunction (Russell et al., 2002, Georgieva et al., 2017). Which means that mitochondrial 
oxidative phosphorylation is inactivated, and this raises the question of whether the 
increased ROS is from other sources rather than mitochondria and how defective 
mitochondria can induce ROS production. In the present study, our results confirm that 
increases in the glucose concentration increased production of ROS; however, only in high 
glucose was this increase significant compared to low glucose (Figure 3.12). Despite these 
results, there will be need to further study to confirm that source of ROS is mitochondrial 
oxidative phosphorylation. There are studies that suggest the non-mitochondrial sources 
also have a role in enhancing ROS after high glucose flux into the cells (Barazzoni, 2012). 
Yu and co-workers (2006) studied the effect of hyperglycaemic conditions on cell lines 
Clone 9 and H9c2 of rat and they reported that mitochondrial fragmentation induced under 
hyperglycaemic condition contribute to overproduction of ROS and they suggest 
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prevention of mitochondrial fragmentation as a target to control ROS production, which 
means that ROS is a result of mitochondrial fragmentation not a cause to it. Other studies 
found that blocking Drp1 which triggers mitochondrial fission increases oxidative 
phosphorylation and leads to suppression of ROS production (Gan et al., 2015). Röth and 
co-workers (2014) found reduced ROS production in T cells after inhibition of Drp1. 
Many studies have documented mitochondrial dysfunction in cancer cells, this makes cells 
rely on glycolysis for generation of ATP (Phan et al., 2014), and it has been suggested  that 
mitochondrial function can be correlated strongly with changes in mitochondrial 
morphology (Wai and Langer, 2016). In the present study, ATP production as well as 
lactate production was measured to determine the effect of mitochondrial morphology 
affected by glucose concentration on the function of mitochondria and the cells. The data 
confirm a strong correlation between mitochondrial shape and function. Mitochondrial 
fragmentation induced by high glucose led to increases in ATP production (Figure 3.7), 
which has been accompanied by an increase in glycolysis (Figure 3.8). In contrast, in low 
glucose, where mitochondria have elongated network-like shapes, cells rely less on 
glycolysis and as a result generation of ATP was lower (Figure 3.8 and 3.7 respectively). 
This study supports evidence from previous observations (Aravamudan et al., 2014); they 
found that stress due to exposure to cigarette smoke induces changes in the mitochondrial 
morphology and in turn lead to mitochondrial dysfunction. Also Palorini and co-workers 
(2013) found that depletion of glucose induced cancer cells to switch from glycolysis to 
mitochondrial oxidative phosphorylation. However, they did not study its effect on 
mitochondrial morphology. 
This is might be due to  reduction in the  inner mitochondrial surface area  in fragmented 
mitochondria which can alter the normal function of mitochondria for generating ATP 
(Mannella, 2006), while, in low glucose, where mitochondria have elongated shapes the 
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inner surface area is enough to support electron transport chain enzymes to work properly, 
glycolysis is decreased compared to  normal glucose. 
The increases in generated ROS may also cause damage to mitochondrial proteins and 
enzymes that participate in oxidative phosphorylation, and this makes the cells reprogram 
their metabolism to glycolysis (Guo et al., 2013).   
Previous studies showed that cancer cells reprogram metabolism to glycolysis to support 
their rapid growth and proliferation, and as a result lactate; an end product of glycolysis 
will increase in the cells (Lunt and Vander Heiden, 2011, Liberti and Locasale, 2016). 
It is exported via monocarboxylate transporters (MCTs) into the tumor microenvironment, 
causing an extracellular acidification (Kato et al., 2013). This acidic condition activates 
protease enzymes that degrade extracellular matrix (ECM) accompanied by detachment of 
the cells, thus facilitating cell migration (Han et al., 2013, Jiang, 2017). Due to the effect of 
mitochondrial morphology on metabolism, it is expected that mitochondrial fragmentation 
increases cell migration and elongation of mitochondria decreases cell migration. Our data 
from wound healing assays (Figure 3.9) and single cell tracking by time-lapse microscopy 
(Figure 3.11) for MDA-MB-231 cells confirm our expectation.  In high glucose where 
mitochondria are fragmented cell migration is significantly increased compared to normal 
glucose where mitochondrial shape is elongated. In low glucose in which cells has 
network-like shaped mitochondria, cell migration was lower compared to normal glucose. 
Our results can be supported by findings of Wang and co-workers (2015b) where they 
found that inhibition of mitochondrial fission induced by platelet-derived growth 
factor (PDGF) in vascular smooth muscle decreases cell migration through changing 
mitochondrial function.  
The results suggest that mitochondrial function and morphology are strongly correlated to 
each other. Fragmentation of mitochondria due to high glucose leads to reduction in 
mitochondrial metabolism and this enhances cells to depend more on glycolysis which in 
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turn leads to increases in the cell migration. In contrast, shifting mitochondria to became 
more elongated and forming network-like shape, enhances cells to rely more on 
mitochondrial oxidative phosphorylation to obtain high amount of ATP as possible from 
low concentration of glucose(Palorini et al., 2013), and this leads to reduction in glycolysis  
and subsequently decreases in cell migration.  
3.4.2 Hydrogen peroxide induces mitochondria fragmentation, changes metabolism, 
and increases cell migration 
We found that high glucose induces mitochondrial fragmentation, possibly through 
increased intracellular ROS production. To investigate whether changes in mitochondrial 
morphology was due to elevated ROS, MDA-MB-231 cells were treated with hydrogen 
peroxide (H2O2) as an exogenous ROS for 24hrs to study its impact on the mitochondrial 
dynamics as well as cellular metabolism and cell migration. It has been suggested that 
H2O2 plays an important role in cancer development; however, in high levels it can induce 
apoptosis (Lopez-Lazaro, 2007, Pan et al., 2011, Xiang et al., 2016) 
Mitochondria, which are high dynamic and flexible, could adjust their morphology as a 
response to the stress induced by microenvironmental changes (Ferree and Shirihai, 2012). 
The present study showed that MDA-MB-231cells treated with H2O2 led to changes in 
mitochondria morphology. The number of mitochondria increased, and this increase was 
significant at concentration of 500µM (Figure 3.14A). We confirmed this result with 
quantitative PCR; where data showed that mtDNA copy number was increased 
significantly after treating cells with H2O2 at concentrations 250 and 500µM (Figure 3.16). 
Treating cells with H2O2 led to reduction in the size, volume, and total mass of 
mitochondria (Figure 3.4 and 3.15).  These data confirm that stress induced by elevated 
ROS is likely to be responsible for fragmentation of mitochondria. This can be supported 
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by findings of Fan and co-workers (2010), who found that H2O2 can contribute to the 
changes in the mitochondrial morphology in C2C12 mouse myoblasts. 
The extracellular pH in normal tissues is relatively basic, while, in cancer cells it is lower 
due to generation of ROS which is accompanying mitochondrial oxidative phosphorylation 
for ATP production (Gerweck and Seetharaman, 1996). Previous studies have documented 
that H2O2 can lead to  increases in the ROS level and  inhibition of oxidative 
phosphorylation in HeLa cells  (Hall and Martinus, 2013). In our study, analysis of data 
has shown that treating cells with H2O2 at low concentrations (100 and 250µM) led to 
increases in ATP generation (Figure 3.17) and lactate production (Figure 3.18). These 
results suggest that H2O2 shifts metabolism toward glycolysis which is faster in ATP 
generation. Surprisingly, at higher concentration (500µM of H2O2) the ATP generation has 
decreased which was also accompanied by decreases in the lactate production. Although it 
is difficult to explain the reason, there maybe other pathways that are affected by high 
concentration of H2O2 led to decline of glycolysis and in turn decreases in ATP production. 
Similar results were found by Molavian and co-workers (2016), who found that treating 
cells with H2O2 increases glucose uptake and leads to raising generated ROS, this in turn 
activates pentose phosphate pathway (PPP) and aerobic glycolysis for ATP production. 
The above observation opens up an expectation that treating cells with H2O2 can increase 
cell migration, and we also found previously that exessive ROS due to high glucose flux 
can increase cell migration. We found that H2O2 enhances wound closure in cultured  
MDA-MB-231 cells at concentrations  of 250 and 500µM (Figure 3.19 and 3.20). Time 
lapse microscopy for tracking single cells also showed  H2O2 enhanced cell migration at  
concentrations of 100 and 250µM (Figure 3.21), suggesting that cell migration can be 
increased with exogenous H2O2. This result is in agreement with previous reports by Pan 
and co-workers (2011), who found that treating corneal epithelial cells  with exogenous 
H2O2 enhances their cell migration.  
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Although H2O2 is one species of ROS, exogenous H2O2 can induce greater production of 
intracellular ROS through a self-amplifying mechanism (ROS-induced ROS production) 
(Park, 2016). Our data showed that intracellular ROS increased with increasing H2O2 
concentration, and it was significant at concentrations of 250 and 500µM (Figure 3.22). 
this result is in agreement with the findings of Park (2016), who found treating human 
pulmonary artery smooth muscle cells (HPASMCs) with exogenous H2O2 leads to 
increases in intracellualr ROS. He postulated that exogenous H2O2  can lead to  increases 
in ROS through generation of mitochondrial  superoxide anion (O2
•
) and depletion of 
glutathione (GSH) levels which protects cellular components from damage by ROS. 
3.4.3 Mitochondrial division-1 inhibitor decreases mitochondrial fragmentation, 
glycolysis, and cell migration. 
 It has been documented that mitochondrial division-1 (mdivi-1) inhibitor, a specific 
inhibitor for dynamin related protein1 (Drp1), can prevent mitochondrial fission through 
inhibiting assembly of Drp1 around mitochondria (Cassidy-Stone et al., 2008).  Recently, it 
was reported by Kim and colleagues (2017) that an mdivi-1 inhibitor attenuated cell death 
induced by increased intracellular and mitochondrial ROS through inhibition of 
translocation and assembly of Drp1 around the mitochondria in rat hippocampal neural 
stem cells (NSCs). In the present study, we inhibited mitochondrial fragmentation induced 
by high glucose using an mdivi-1 inhibitor to investigate its effect on cellular metabolism 
and cell migration. Our results showed that mitochondrial shape changed to become more 
elongated (Figure 3.25), and analysis of data  appeared to show that size and volume of 
mitochondria increased (Figure 3.24 B and C) especially in the cells treated with mdivi-1 
at concentrations of 30 and 40µM. Treating with the inhibitor did not affect the number of 
mitochondria. One explanation of this result is that maybe the inhibitor prevents 
fragmentation, however, because the cells are still under the effect of stress induced by 
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high glucose, the fusion process cannot be activated and mitochondria just grew and 
increased their mass (Figure 3.24 D) and became elongated in the shape without fusion of 
mitochondria which may lead to decrease in their numbers.  
We confirmed the confocal microscopy results for measuring mitochondrial number with 
qPCR for measuring mtDNA copy number, and our results showed no significant changes 
in mitochondrial number following treatment with mdivi-1 inhibitor compared with non-
treated control cells. This result is in agreement with results found by Akita and co-
workers (2014) who found that mdivi-1 inhibitor led to elongation of mitochondria and 
made them more sensitize to apoptosis induced by tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL). They also found that silencing of Drp1 gives the same results, 
confirming that the mdivi-1 inhibitor affects mitochondria through inhibition of Drp1 
protein.  Similarly, Parker (2017) found that midivi-1 inhibitor reduces mitochondrial 
fragmentation and increases apoptosis due to increases in sensitivity to radiation in A549 
lung cancer cells. 
Previously our data showed that mitochondrial fragmentation induced by high glucose led 
to reprogramming of metabolism to glycolysis. In the present study we inhibited 
mitochondrial fragmentation using mdivi-1 inhibitor to study its effect on the cellular and 
mitochondrial metabolism. Our results showed significant decreases in glycolysis (Figure 
3.28) accompanied by decreases in ATP production (Figure 3.27). This result confirms our 
previous finding which suggests correlation between mitochondrial morphology and 
function, and it is in agreement with the finding of Peiris-Pagès and co-workers (2018), 
where they found that mdivi-1 inhibitor reduces glycolysis and ATP generation in MCF7 
cells. Elongated, tubular mitochondria provide longer and wider cristae; an inner 
mitochondrial membrane, shape which will be efficient for mitochondrial oxidative 
phosphorylation (Mannella, 2006, Cogliati et al., 2013, Cogliati et al., 2016) to generate 
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ATP energy, therefore reliance on aerobic glycolysis for ATP production by the cells will 
decrease. Theoretically, in high glucose levels, metabolism reversing from aerobic 
glycolysis to oxidative phosphorylation should lead to increases in ROS generation, and 
this can induce apoptosis. Cai and co-workers (2002) have reported that high levels of 
glucose induced apoptotic cell death in cultured cardiac myoblast; they also revealed 
apoptotic cell death in myocardium tissue in diabetic mice, which is characterized by 
hyperglycaemia. However, in cancer cells, high glucose not only does not induce cell 
death, but, instead promotes proliferation, migration and invasion (Lin et al., 2015, Hou et 
al., 2017). 
We next sought to determine whether inhibition of mitochondrial fragmentation using the 
mdivi-1 inhibitor affects cell migration and ROS production in high glucose. Therefore, we 
studied measured intracellular ROS after 24hrs of treatment with inhibitor. Data showed 
decreases in ROS production at 50µM of the mdivi-1(Figure 3.29). This unexpected 
finding is quite interesting as inhibition of mitochondrial fragmentation decreased ROS 
generation. A possible explanation is that mitochondrial fragmentation may damage the 
mitochondrial antioxidant system and the mdivi-1 inhibitor removes this effect on the 
antioxidant system in mitochondria, leading to reduced ROS generation in mitochondria. It 
has been suggested to use antioxidants as therapy in neurodegenerative disease such as 
Parkinson’s disease, which are characterized with mitochondrial dysfunction, oxidative 
stress, and mitochondrial fragmentation (Jin et al., 2014, Santos et al., 2015), and it was 
reported that exercise can  increase mitochondrial mass and upregulate cellular antioxidant 
defense system (Trewin et al., 2018). This opens a possibility that the mitochondrial 
antioxidant system activity can be affected with changes in the mitochondrial morphology, 
and it would be interesting in the future to investigate the impact of mitochondrial 
fragmentation on the mitochondrial antioxidant system. 
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Previously we found that high glucose (which induces mitochondrial fragmentation, a 
switch to glycolysis and increased ROS) promotes cell migration. Therefore, it is expected 
that inhibition of mitochondrial fragmentation through using the mdivi-1 inhibitor would 
negatively affect cell migration, and as we expected, results showed decreases in cell 
migration (Figure 3.30). This result is in agreement with findings by Peiris-Pagès and co-
workers (2018), who found that the mdivi-1 inhibitor inhibit cell migration in MCF7 breast 
cancer cells. 
We have concluded that mitochondrial morphology and metabolism are strongly correlated 
with ROS generatation which can be eleveted in high glucose or via exogenous hydrogen 
peroxide, and that alteration of  oxidative phosphorylation metbolism to glycolysis induces 
cancer cell migration. However,  there is a need for  more study to know correlation 

















Chapter Four: Investigating the impact of PGC-1α on mitochondrial dynamics, 
cellular metabolism, and cell migration 
4.1 Introduction  
The peroxisome proliferator-activated receptor γ activator-1 alpha (PGC-1α)  is a powerful 
transcription factor involved in the regulation of mitochondrial biogenesis, oxidative 
metabolism, and other processes in the cells (Austin and St-Pierre, 2012). It can be 
activated in response to several factors including cold exposure, nutrient deprivation, 
exercise, chemotherapy, and oxidative stress (Tan et al., 2016).  
Cancer cells, which are characterized by high proliferation rate, require high energy 
production (Boroughs and DeBerardinis, 2015). It was reported that high demands for 
energy may activate PGC-1α. Once activated,  PGC-1α signals for expression of several 
transcription factors that lead to upregulation of proteins required for increasing the 
number and mass of the mitochondria in order to increase the production of ATP to meet 
the required energy demands (Dabrowska et al., 2015). 
Mitochondrial biogenesis which involves increases in mitochondrial mass through growth 
and division of pre-existing mitochondria is regulated by PGC-1α (Bhatti et al., 2017), and  
Dabrowska and co-workers (2015) discovered that PGC-1α can regulate mitochondrial 
dynamics, which include coordinated cycles of fission and fusion of mitochondria, through 
controlling Drp1 expression. This means that PGC-1α can regulate both mitochondrial 
biogenesis and mitochondrial dynamics through Drp1 expression. 
Balance between fission/fusion in mitochondrial dynamics can be changed in several 
pathologic disorders. There are reports mention that excessive mitochondrial fragmentation 
in some diseases such as Parkinson's disease is associated with overexpression of PGC-1α 
through increasing production of ROS; which in- turn regulates expression and 
phosphorylation of Drp1 protein (Santos et al., 2015, Peng et al., 2017).  
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It was also reported that  long term  expression of PGC1α in nerve cells exposed to 
neurotoxic lead induces neurodegeneration through changes in the mitochondrial 
morphology and alteration in the cellular metabolism(Dabrowska et al., 2015). Recently, 
studies have reported that PGC1α expression is strongly associated with the cancer 
progression through inducing alteration in mitochondrial mass and function (Jones et al., 
2012, Girnun, 2012). However, its effect on mitochondrial metabolism as well as cell 
migration, which is correlated with metabolism, is not clear. 
PGC1α also considered a powerful regulator of ROS through increasing expression of 
several ROS-detoxifying enzymes (Austin and St-Pierre, 2012). Despite that, its role 
remains unclear in cancer cells which is characterized by elevated rates of ROS due to high 
utilization of glucose (Liou and Storz, 2010). 
We hypothesize that inducing overexpression of PGC-1α coactivator (by using ZLN005 
activator) can increase mitochondrial fragmentation away from effect of ROS, which is 
detoxified by PGC-1α, and this changes metabolic pathway toward glycolysis which in 
turn affect cell migration and cancer metastasis.  
Thus this study aims the better understanding of the link between mitochondrial 
morphology, mitochondrial metabolism, and cell migration through inducing 
mitochondrial fragmentation using PGC-1α coactivator. Another aim is to know the impact 
of glucose levels and in combination with PGC-1α overexpression on mitochondrial 
morphology, mitochondrial metabolism, and cell migration. 
The specific objectives in this study include: 
 Determination the effect of ZLN005 activator on the expression of PGC-1α and 
Drp-1 proteins in different glucose concentrations; low (1mM), normal  (5.5mM), 
and high (25mM)  glucose concentrations 
 Determination the effect of ZLN005 activator on the mitochondrial morphology in 
different glucose concentrations 
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 Determination the effect of ZLN005 activator on the ATP, lactate, and ROS 
production in different glucose concentrations 
 Determination the effect of ZLN005 activator on the cancer cell migration in 
different glucose concentrations 
 
4.2 Material and Methods 
4.2.1 Cell culture 
We used MDA-MB-231 cells in our experiments and cells were continuously cultured in 
Dulbecco’s Modified Eagles Media (DMEM) with relevant glucose levels (1, 5.5, and 
25mM). ZLN005 (Sigma-Aldrich) is a potent PGC-1α transcriptional activator used to 
increase expression of PGC-1α. To prepare a stock solution of 20mM, we dissolved 10mg 
of ZLN005 in 1.997ml of DMSO. In our experiments we treated cells with three 
concentrations (10, 20, and 30µM) of ZLN005 for 24hrs in DMEM medium with different 
glucose levels as mentioned above.  
4.2.2 Mitochondrial staining and analysis 
Cells were treated with different concentrations of ZLN005 in different glucose media for 
24hrs, then mitochondria were stained with MitoTracker probe (Invitrogen, M7510), and 
DAPI was used to stain nucleus as described in section 2.2.7 Images were taken using 
confocal microscopy and analysed by  ImageJ software as explained in section 2.2.16 
4.2.3 Quantitative Real- Time PCR (qRT-PCR)  
The Quantitative real time polymerase chain reaction (qRT-PCR) was used in measuring 
mtDNA copy number (as described in section 2.2.10)  using extracted DNA  in MDA-MB-






4.2.4 Analysis of metabolism and ROS  
MDA-MB-231 cells treated with different concentrations of ZLN005 in different glucose 
levels for 24hrs, and then generated ATP was measured as described in section 2.2.14, 
lactate production was measured as described in section 2.2.13, and level of  generated 
ROS  was measured as described in section 2.2.12 
4.2.5 Western blot analysis 
Expression of Drp1 and PGC-1α proteins were measured by western blot in MDA-MB-231 
cells treated with different concentrations of ZLN005 in different glucose levels for 24hrs 
as described in section 2.2.5 
4.2.6 Cell migration  
cell migration  in MDA-MB-231 cells  treated with different concentrations of ZLN005 in 
different glucose levels     was monitored by time-lapse microscopy for 24hrs ImageJ (Fiji) 
software (MtrackJ plugin) was used to track and measure the speed of cell movement as 

















We investigated the effect of ZLN005 (PGC-1α activator) in different concentrations 10, 
20, and 30µM on the mitochondrial dynamics in MDA-MB-231 cells. Results in Figure 
4.1A showed  significant increases in the mitochondrial number in the cells treated with 
20µM of ZLN005; in which mitochondrial number was increased to 166.7± 11.41 
compared to 93.1±4.1 in non-treated control cells (p<0.05).  While, the changes were non-
significant at concentrations 10, 30µM of ZLN005 compared to the control cells.  
The effect of ZLN005 on the mitochondrial size shown in Figure 4.1B revealed a 
significant decrease in the mitochondrial size from 4.2 ±0.45μm^
2
 in the control cells to 
2.65±0.12μm^
2
 in the treated cells with 10µM of ZLN005 (p<0.01), and into 1.7±0.22, and 
1.1±0.05μm^
2
 at concentration 20, and 30µM of ZLN005 respectively (p<0.001). 
Similar changes in the mitochondrial volume were observed when the cells treated with 
ZLN005.  Results in Figure 4.1C showed that mitochondrial volume was reduced from 
0.34±0.017μm^
3
 in non-treated control cells into 0.21±0.018, 0.13±0.002, and 0.06±0.003 
μm^
3
 in the treated cells with 10, 20, and 30µM of ZLN005 respectively (p<0.001).  
Total mass of the mitochondria was also measured. Results in Figure 4.1D revealed 
significant decreases of total mitochondrial mass from 31.17±2.96μm^
3
 in non-treated 
control cells to 8.19±1.31μm^3 in treated cells with 30µM of ZLN005 (p<0.01).  Whilst, 
no significant changes were detected statistically at concentrations 10, and 20µM of 
ZLN005 compared to control.  
The Figure 4.2 shows the hyper-fragmentation of the mitochondria in MDA-MB-231 cells 









































































































































Figure 4.1: Effect of ZLN005 on the mitochondrial dynamics in MDA-MB-231 cells. Cells treated with 
different concentrations of ZLN005 (10, 20, and 20mM) for 24hrs in normal glucose (5.5mM) medium, then 
mitochondria were stained with MitoTracker probe and confocal microscopy used to take mitochondrial 
images. (A) represent quantification analysis of number of mitochondria, (B) Size of mitochondria, (C) 
Volume of mitochondria, and (D) which represent quantification analysis of total mitochondria mass per cell. 
Data represent the mean ± standard error of three independent experiments performed in triplicate; each 
experiments with more than 30 cells.. One-way ANOVA and Dunnett’s Multiple Comparison test was used 
































































Figure 4.2: Micrographs shows the changes in the mitochondrial morphology in MDA-MB-231 cells.  
After 24hrs of treating cells with different concentrations of ZLN005, mitochondria were stained with 






Then we investigated the effect of ZLN005 in low glucose medium on mitochondrial 
morphology. Therefore, we cultured MDA-MB-231 cells in 1mM of glucose in DMEM 
medium overnight, and then the cells were treated with ZLN005 in different concentrations 
10, 20 and 30µM for 24hrs.   Results in Figure 4.3A showed that treating with ZLN005 led 
to increases the number of mitochondria in the cells. This increase was significant at 
concentrations 10, and 20µM of ZLN005; in which numbers of the mitochondria was 
increased to 113.1±8.9 (p<0.05), and 146.6±7.01 (p<0.001) respectively compared to 
79.8±3.95 in non-treated control cells. While, no changes were detected between cells 
treated with 30µM of ZLN005 and to control cells.   
Treating cells with ZLN005 also affected the size and the volume of the mitochondria.  
Figure 4.3B shows that mitochondrial size was decreased significantly from 5.92±1.19 
μm^
2
 in the control cells to 2.42±0.21μm^
2
 in the treated cells with 10µM of ZLN005 
(p<0.05), and into 1.57±0.24, and 0.89±0.156μm^
2
 at concentrations 20, and 30µM of 
ZLN005 respectively (p<0.01).  
The same changes in the mitochondrial volume were observed when the cells were treated 
with ZLN005 for 24hrs in low glucose medium. Results in Figure 4.3C showed that 
mitochondrial volume was reduced from 0.59±0.14 μm^
3
 in non-treated control cells to 
0.22±0.006μm^
3
 in the treated cells with 10µM ZLN005 (p<0.05), and into 0.11±0.005, 
and 0.063±0.015 μm^
3
 at concentrations 20, and 30µM of ZLN005 respectively (p<0.01). 
Results in Figure 4.3D revealed that total mass of the mitochondria was decreased 
significantly from 46.6±8.8μm^
3
 in the control cells to 25.41±2.78μm^
3
 in the cells treated 
with 10µM of ZLN005 (p<0.05), and into 16.1±0.94μm^
3
 at concentration 20µM 
(p<0.01). As well as in the cells treated with 30µM of ZLN005, the total mitochondrial 





The Figure 4.4 shows the morphological changes in the mitochondrial dynamics in MDA-
MB-231 cells after 24hrs of treating with different concentrations of ZNL0005 in low 
glucose medium. 









































































































































Figure 4.3: Effect of ZLN005 on the mitochondrial morphology in MDA-MB-231 cells grown in low 
glucose medium. After treating the cells with different concentrations of ZLN005 in (1mM) DMEM 
medium, the mitochondria were stained with MitoTracker probe and DAPI was used to stain nucleus then z-
stack mages were taken using confocal microscopy. (A) represent quantification analysis of number of 
mitochondria, (B) Size of mitochondria, (C) Volume of mitochondria, and (D) which represent quantification 
analysis of total mitochondria mass per cell. Data represent the mean ± standard error of three independent 
experiments performed in triplicate; in each experiment more than 30cells were taken. One-way ANOVA 
followed by Dunnett’s Multiple Comparison test was used to compare between the mean of treatments with 


























































Figure 4.4: Micrographs showing mitochondrial hyper-fragmentation in MDA-MB-231 cells.  After 
24hrs of treating cells with different concentrations of ZLN005 in low glucose (1mM) DMEM medium, 







Afterward we investigated the effect of ZLN005 on the mitochondrial dynamics in high 
glucose medium. Therefore, MDA-MB-231 cells were cultured in high glucose; 25mM, 
medium overnight, then treated with ZLN005 in different concentrations 10, 20 and 30µM 
for 24hrs. Results in Figure 4.5A showed significant increases in the mitochondrial number 
in the cells treated with 20µM of ZLN005; in which mitochondrial number was increased 
to 168.6± 10.3 compared to 129.8±9.7 in non-treated control cells (p<0.05). While, no 
changes was detected at concentrations 10, and 30µM of ZLN005 compared to the control 
cells.  
Treating cells with ZLN005 also affected the size of the mitochondria.  Figure 4.5B shows 
that mitochondrial size was decreased significantly from 1.59±0.05μm^
2
 in the control 
cells to 1.24±0.06μm^
2 
in the treated cell with 20µM of ZLN005 (p<0.01), and into 
1.12±0.06 μm^
2
 at concentration 30µM of ZLN005 (p<0.001). While, no changes was 
observed between the cells treated with 10µM of ZLN005 and to control cells. 
Similar results of the mitochondrial volume were obtained when the cells treated with 
ZLN005 for 24hrs in high glucose medium. Results in Figure 4.5C showed that 
mitochondrial volume were reduced from 0.14±0.008 μm^
3
 in non-treated control cells to 
0.09±0.009 μm^
3
 in the treated cells with 20µM ZLN005 (p<0.01), and into 0.064±0.004 
μm^
3
 at concentration 30µM of ZLN005 (p<0.001).  Whilst, no changes in the 
mitochondrial volume were recorded at concentration 10µM of ZLN005 compared to 
control.  
Results in Figure 4.5D revealed significant decreases in total mitochondrial mass to 
17.64±0.72μm^
3
 in the treated cells with 30µM of ZLN005 compared to 8.47±0.75µm^
3
 in 
the control cells (p<0.001). Whereas, no significant differences was detected between cells 
treated with ZLN005 at concentrations 10, and 20µM and non-treated control cells. 
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The Figure 4.6 shows the morphological changes in the mitochondrial dynamics in MDA-
MB-231 cells after 24hrs of treating with different concentrations of ZNL0005 in high 
glucose medium. 








































































































































Figure 4.5: Effect of ZLN005 on mitochondrial dynamics in MDA-MB-231 cell grown in high glucose 
level. Cells treated with different concentrations of ZLN005 (10, 20, and 20mM) in high glucose 
(25mM)DMEME medium for 24hrs then MitoTracker probe used to stain mitochondria and z-stack images 
were taken by confocal microscopy. (A) represent quantification analysis of number of mitochondria, (B) 
Size of mitochondria, (C) Volume of mitochondria, and (D) which represent quantification analysis of total 
mitochondria mass per cell. Data represent the mean ± standard error of three independent experiments 
performed in triplicate; in each experiment more than 30cells were taken. One-way ANOVA and Dunnett’s 
Multiple Comparison test was used to compare between the mean of treatments with mean of control (*, **, 




























































Figure 4.6: Micrographs showing mitochondrial hyper-fragmentation in MDA-MB-231 cells.  After 
24hrs of treating cells with different concentrations of ZLN005 in high glucose (25mM) DMEM medium, 






We measured mtDNA copy number in MDA-MB-231 cells treated with different 
concentrations of ZLN005 in different glucose levels for 24hrs using real-time qPCR to 
confirm our results obtained by confocal microscopy for measuring the effect of ZLN005 
on mitochondrial dynamics. Results in Figure 4.7 A showed that copy number of mtDNA 
was increased significantly from 867.95±35.7 in non-treated control cells to 2353±143.5 in 
treated cells with 10µM of ZLN005 (p<0.001),  and into 2038.3±320.2 at concentration 
20µM  (p<0.01). Whilst, no changes were detected between cells treated with ZLN005 at 
concentration 30µM and control cells.  
Then we measured mtDNA copy number in MDA-MB-231 cells treated with ZLN005 in 
low glucose and high glucose medium.  Results as seen in Figure 4.7B revealed that no 
significant differences in mtDNA coy number were found between the cells cultured in 
low glucose medium and treated with ZLN005 compared to non-treated control cells. 
While, in high glucose medium results as presented  in Figure 4.7C revealed that mtDNA 
copy number was increased significantly from 1281.4±206.1 in non-treated control cells to 
2613.1±16.7 in treated cells with 10µM of ZLN005 (p<0.05),  and into 6691.2±510 in 
treated cells with 20µM of ZLN005 (p<0.001) respectively. Whereas, no significant 















































































































Figure 4.7: Quantification of mtDNA copy number in MDA-MB-231 cells treated ZLN005. Cells were 
treated with different concentrations of ZLN005 in different glucose levels for 24hrs. Extracted DNA was 
used to determine mtDNA using quantitative real-time PCR. (A) Represent quantification analysis of 
mtDNA copy number in the cells treated with different concentrations of ZLN005 in normal glucose, (B) in 
low glucose, (C) in high glucose, and (D) to compare between them. Data represent the mean ± standard 
error of three independent experiments performed in triplicate. One-way ANOVA followed by Dunnett's 
Multiple Comparison Test to compare mean of treatments with control mean (*, **, and ***represent 
P<0.05, 0.01 and 0.001 respectively).  
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Later we investigated the effect of ZLN005 on the expression of PGC-1α and Drp1 
proteins in MDA-MB-231 cells. Therefore we treated the cells with three concentrations of 
ZLN005 10, 20, and 30µM  for 24hrs in DMEM medium with different levels of glucose 
then the proteins were extracted and the expression of proteins were measured through 
western blot using β-actin as an internal loading control as shown in Figure 4.8A.  In low 
glucose, results revealed that treating cells with ZLN005 statistically did not cause 
significant changes in the expression of the protein PGC-1α. In the normal glucose, 
analyses data showed that expression of PGC-1α protein was increased significantly from 
20.09±2.4 in the control cells to 40.42±5.4 in the cells treated with 10µM of ZLN005 
(p<0.05); which means that the expression of protein PGC-1α was increased by 101.2% 
compared to the control. Whereas, no changes were detected between cells treated with 20, 
and 30µM of ZLN005 and the control cells. The results in high glucose revealed that PGC-
1α protein expression was increased significantly to 31.79± 1.9, and 33.45±1.74 in the 
cells treated with 10, and 20µM of ZLN005 respectively compared to 23.93±1.7 in non- 
treated control cells (p<0.05); these mean that expression of protein PGC-1α was increased 
by 32.85%, and 39.76% in treated cells with10, and 20µM of ZLN005 respectively 
compared to the control.  While, statistically no significant changes was observed at 30µM 
compared to control, as seen in Figure 4.8B.    
Analyses of data also show that changes in the glucose concentration affect expression of 
protein PGC-1α. The expression of protein PGC-1α was increased significantly, when cells 
treated with 10µM of ZLN005, from 27.7±5.3 in low glucose to 40.42±3.8 in normal 
glucose (p<0.05). In the cells treated with 20µM of ZLN005, expression of protein PGC-
1α was increased from 14.63±5.06 in low glucose to 26.76±3.6 in normal glucose (p<0.05) 
and into 33.45±1.23 in high glucose (p<0.001). Also it was increased from 16.8±3 in low 
glucose to 28.06±1.63 in high glucose (P<0.05) when cells treated with 30µM of ZLN005, 
as seen in Figure 4.8B. 
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The results for measuring the expression of protein Drp1 was shown in Figure 4.8C. In low 
glucose, results showed that treating the cells with 10µM of ZLN005 led to significant 
increases in the expression of the protein Drp1, it was increased to 39.53±8.39 compared to 
13.73±2.11 in control cells (p<0.05); which is mean the expression of protein Drp1 was 
increased by 187.94% compared to the control, whereas, no significant changes were 
observed between other treatments and control.  Similar results were obtained when the 
cells treated with ZLN005 in normal glucose level, in which the expression of Drp1 protein 
was increased significantly from 30.01±1.66 in the control cells to 50.57±8.89 in the cells 
treated with 10µM of ZLN005 (p<0.05); which is mean that it has been increased by 
68.53% compared to the control, whilst, no changes were observed between other 
treatments with control. In the high glucose level, treating the cells with ZLN005 
statistically did not cause significant changes in the expression of the protein Drp1. 
Changes in the glucose concentration in combination with ZLN005 also have affected 
expression of protein Drp1, as seen in Figure 4.8C. The expression of protein Drp1was 
increased markedly from13.73±2.1 in low glucose to 39.6±3.77 in high glucose (p<0.01), 
and from 26.33±4 in low glucose and 32.76±1.4 in normal glucose to 58.67±3.43 in high 



























































































































Figure 4.8:  Western blot showing the effect of ZLN005 on the PGC-1α and Drp1 proteins expression. 
MDA-MB-231 cells treated with different concentrations of ZLN005 for 24hrs in different glucose levels. 
(A) Shows PGC-1α and Drp1 bands, (B) Represent quantification analysis of protein PGC-1α expression, 
and (C) Represent quantification analysis of protein Drp1 expression. Data represent the mean ± standard 
error of three independent experiments performed in triplicate. Two-way ANOVA followed by Bonferroni 
















We investigated the impact of the ZLN005 on the cellular metabolism through measuring 
ATP production and lactate production in MDA-MB-231 cells. Therefore we treated the 
cells with different concentrations of ZLN005 for 24hrs in DMEM medium with different 
levels of glucose, then generated ATP and lactate were measured using specific 
commercial kits.  
Results of ATP production shown in Figure 4.9A revealed that treating cells with ZLN005 
led to significant increases in ATP production. It was increased from 1.11±0.016mM in the 
control cells to 1.4±0.03, 1.97±0.026, and 1.31±0.014mM in treated cells with 10, 20, and 
30µM of ZLN005 respectively (p<0.001); these mean that ATP production was increased 
by 26.37%, 78.42%, and 18.2% in treatments 10, 20, and 30µM of ZLN005 respectively 
compared to control. 
In the low glucose results show that production of ATP was increased from 
0.75±0.013mM in control to 0.93±0.034mM in treated cells with 10µM of ZLN005 
(p<0.01), and no changes were recorded at concentration 20µM of ZLN005. While, in the 
cells which treated with 30µM of ZLN005, we found that ATP production was decreased 
significantly to 0.52±0.024mM (p<0.001) compared to control. This means that ATP 
production in the cells treated with 10µM of ZLN005 was increased by 25.1% compared to 
control cells, while, when the cells treated with 30µM of ZLN005, ATP production was 
decreased by 31.01% compared to control cells. 
In high glucose level, ATP production was increased markedly when cells treated with 10 
and 20µM of ZLN005, it was increased to 3.01±0.37, and 3.74±0.43mM respectively 
compared to 2.05±0.09mM in control (p<0.001), whereas, at 30µM  of ZLN005, 
generation of ATP was declined to 1.82±0.02mM compared to control (p<0.05). This 
means that ATP production was increased by 47.3% and 82.9% in treated cells with 10µM 
and 20µM of ZLN005 respectively compared to control, while, it was decreased by 11.3% 
in cells treated with 30µM of ZLN005 compared to control. 
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Changes in the glucose concentration in combination with ZLN005 also have affected 
significantly the ATP production, as seen in Figure 4.9D. The production of ATP was 
increased markedly from 0.75±0.013 in low glucose to 1.11±0.02 in normal glucose and 
into 2.05± 0.09 in high glucose (p<0.001), the difference between normal glucose and high 
glucose was also significant (p<0.001).   
Similarly, the production of ATP in the cells treated with 10, 20, and 30µM of ZLN005, 
was increased significantly in high glucose compared to normal and low glucose as well as 
in normal compared to low glucose (p<0.001). In 10µM of ZLN005, ATP production 
increased from 0.94±0.03 in low glucose to 1.4±0.03 in normal glucose and into 3.01± 
0.04 in high glucose (p<0.001). In 20µM of ZLN005, ATP production was increased from 
0.73±0.05 in low glucose to 1.97±0.03 in normal glucose and into 3.74± 0.043 in high 
glucose (p<0.001), and in 30µM of ZLN005, ATP production increased from 0.51±0.02 in 




































































































 Figure 4.9: Effect of ZLN005 on ATP production in MDA-MB-231 cells. Lysate of 1x10
6
cells were used 
for measuring ATP level by colorimetric ATP assay kit. Cells were grown in DMEM medium with different 
glucose levels A: in normal glucose (5.5mM). B: in low glucose (1mM).C: in high glucose (25mM), and D: 
graph to compare previous data.  Data represent the mean ± standard error of four independent experiments 
performed in triplicate. One-way ANOVA followed by Dunnett's post hoc test to compare mean of 
treatments with mean of control within each glucose level in A, B, and C. While, Two-way ANOVA 
followed by Bonferroni post hoc test to compare the mean of same treatments between different glucose level 




The results of measuring lactate production in MDA-MB-231cells treated with ZLN005 in 
normal glucose presented in Figure 4.10A show that lactate production was significantly 
increased from 14.43±0.42mM in the control cells to 18.25±0.32, and 18.7±0.41mM in the 
cells treated with 10, and 20mM of ZLN005 respectively (p<0.001), and into 
17.44±0.32mM at concentration 30µM of ZLN005 (p<0.01). This means that lactate 
production was increased by 26.5%, 29.4%, and 20.9% in cells treated with 10, 20, and 
30mM of ZLN005 respectively compared to control. 
While, no significant changes in the lactate production were observed in the cells treated 
with ZLN005 in low glucose as shown in Figure 4.10B, in high glucose level, treating cells 
with ZLN005 has increased lactate production significantly from 17.98±0.69mM in the 
control cells to 20.81±0.43mM in treated cells with 20mM of ZLN005 (p<0.01), and into 
20.29±0.22mM at concentration 30µM of ZLN005 (p<0.05);  which is mean that lactate 
production was increased by 15.7%, and 12.85% in treated cells with 20, and 30µM of 
ZLN005 respectively compared to control, whereas, no changes were observed at 
concentration 10mM compared to control, as shown in Figure 4.10C. 
The changes in the glucose concentration in combination with ZLN005 have affected 
lactate production. Data analysis show significant increases in lactate production in all 
treatments (Control, 10, 20, and 30mM of ZLN005) in high glucose level compared to 
same treatments in the low glucose and normal glucose levels (p<0.001), except in the 
cells treated with 10mM of ZLN005 in normal glucose in which the difference was non-
significant. The increases in lactate production in all treatments in normal glucose was also 







































































































Figure 4.10:  Effect of ZLN005 on lactate production in MDA-MB-231 cells. Cells were seeded in a 96-
well plate at a density of 25,000 cells/well in DMEM supplemented with 10% FBS with different glucose 
level, then cells treated with different concentrations of ZLN005 for 24hrs. The supernatants were used to 
determine the generated L-Lactate. A: represent data analysis in normal glucose, B: in low glucose, C: in 
high glucose, and D: a graph to compare data between different glucose levels.  Data represent the mean ± 
standard error of three independent experiments performed in triplicate. One-way ANOVA followed by 
Dunnett's Multiple Comparison Test to compare mean of treatments with mean of control within each 
glucose level in A, B, and C. While, Two-way ANOVA followed by Bonferroni post hoc test to compare the 
mean of same treatments between different glucose level in graph D (*, ** and ***represent P< 0.05, 0.01, 




We investigated the impact of ZLN0005 on the level of ROS production in MDA-MB-231 
cells.  We treated cells with different concentrations of ZLN005 in different glucose levels 
for 24hrs, and then by using specific commercial kit the level of intracellular ROS were 
measured. Figure 4.11A that shows the result of generated ROS in the cells treated with 
ZLN005 in the normal glucose, revealed that ROS production was increased significantly 
from 15855±509.8 Unit  in control cells to 29796.7±5191 Unit in treated cells with 30µM 
of ZLN005 (p<0.05); which is mean it was increased by 87.93% compared to the control 
cells, while, statistically no significant changes were detected between the cells treated 
with 10, and 20µM of ZLN005 and control cells. 
In low glucose, no significant changes in the production of ROS were observed between 
the cells treated with ZLN005 and control cells, as shown in Figure 4.11B. In high glucose, 
significant increases in ROS production was detected only in the cells were treated with 
30µM of ZLN005. It was increased from 20383.7±2029 Unit in non-treated control cells to 
39453.3±5080 Unit in cells treated with 30µM ZLN005 (p< 0.05); which is mean it was 
increased by 93.55% compared to the control cells; whilst, no significant changes were 
recorded in other treatments, as seen in Figure 4.11C. 
Combination effects of glucose concentration and ZLN005 on the production of ROS in 
MDA-MB-231 also analysed, and results  revealed ROS production was increased in the 
cells  treated with 20µM of ZLN005 in low glucose from 15091.3±1164.2 Unit into 
27649±4855.8Unit in high glucose (p<0.05). Its production also increased significantly in 
the cells treated with 30µM of ZLN005 in low glucose from 18319.3±2747.4Unit to 
29796.7±5190Unit in normal glucose (p<0.05), and into 39453.3±5080 Unit in high 





















































































































Figure 4.11: Effect of ZLN005 on the ROS production in MDA-MB-231 cells. Cells were treated with 
different concentrations of ZNL0005 in different glucose level for 24hrs then level of intracellular ROS was 
measured using specific commercial kit. A: represent data analysis in normal glucose (5.5 mM), B: in low 
glucose (1mM), and C: in high glucose (25mM), and D: represent the graph to compare previous data. Data 
represent the mean ± standard error of three independent experiments performed in triplicate. One-way 
ANOVA followed by Dunnett's post hoc test to compare mean of treatments with mean of control within 
each glucose level in A, B, and C. While, Two-way ANOVA followed by Bonferroni post hoc test to 
compare the mean of same treatments between different glucose level in graph D (* and ***represent P< 
0.05, and 0.001 respectively). 
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To assess whether PGC-1α overexpression affects cell migration, and if glucose level have 
a role on the expression effect on cell migration, we treated MDA-MB-231 cells with 
different concentrations of ZLN005 (that induce overexpression of PGC-1α) in different 
glucose levels.   
Results in Figure 4.12A revealed that treating cells with ZLN005 led to significant 
increases in the cell migration. It was increased from 18.14±1.16µm/hour in non-treated 
control cells to 26.29±0.84µm/hour in treated cells with10µM of ZLN005 (p<0.01), and 
into 23.01±0.77µm/hour in treated cells with 20µM of ZLN005 (p<0.05). While, in the 
cells treated with 30µM of ZLN005 no significant changes in the cell migration was 
recorded.   
Similar results were obtained when the cells treated with ZLN005 in low glucose as shown 
in Figure 4.12B. Cell migration was increased significantly into 23.43±0.77µm/hour in 
treated cells with 10µM of ZLN005 (p<0.01), and into 20.67±1.23µm/hour in treated cells 
with 20µM of ZLN005 (p<0.05) compared to15.92±0.77µm/hour in non-treated control 
cells. And at concentration 30µM of ZLN005 no changes were observed compared to 
control. 
In high glucose, we have shown a significant increase in the cell migration when the cells 
treated with 10µM of ZLN005, it was increased to 31.4±1.54µm/hour compared to 
25.5±0.94µm/hour in non-treated control cells (p<0.05). In contrast, cells treated with 
30µM of ZLN005 showed marked decline in the cell migration. It was decreased to 
18.02±1.03µm/hour compared to control (p<0.05), whereas, in treatment with 20µM of 
ZLN005, no changes were detected compared to control cells. 
Combination effects of glucose concentration and ZLN005 on the cell migration in MDA-
MB-231 also analysed, and results revealed that increasing glucose concentration led to 
significant increases in cell migration into 25.5±94µm/hour in high glucose level compared 
to 18.2±1.1694µm/hour in normal glucose level and 15.9±0.77 in low glucose 
level(p<0.001). In the cells treated with 10µM of ZLN005, cell migration was increased 
significantly into 31.4±1.5µm/hour in high glucose level compared to 26.3±0.85µm/hour 
in normal glucose level (p<0.05), and compared to 23.4±0.76 in low glucose (p<0.001). 
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While, no significant differences in the cell migration were observed between treatments in 
normal glucose and treatments in low glucose, as shown in Figure 4.12D. 
Normal glucose
































































































































Figure 4.12:  Effect of ZLN005 on the cell migration in MDA-MB-231 cells.  Cells were cultured in A: 
low glucose level, B: normal glucose, and C:  high glucose.   Then cells were treated with different 
concentrations of ZLN005. The motility of cells was monitored by the time-lapse microscopy every 15 
minutes for 24 hours. The cell migration measured via tracking single cell using Image J Software.  Data 
represent the mean ± standard error of three independent experiments performed in triplicate. One-way 
ANOVA followed by Dunnett's post hoc test to compare mean of treatments with mean of control within 
each glucose level in A, B, and C. While, Two-way ANOVA followed by Bonferroni post hoc test to 
compare the mean of same treatments between different glucose level in graph D (*** and ***represent P< 
0.05, 0.01,   and 0.001 respectively). 
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4.4 Discussion  
PGC-1α, is a key regulator of energy metabolism through stimulation of mitochondrial 
biogenesis, and it promotes cells to be more oxidative rather than glycolytic (Liang and 
Ward, 2006). Peng and co-workers (2017) suggested that PGC-1α can regulate 
mitochondrial fission/fusion process through regulation of mfn2 and Drp1 protein 
expression. They also mentioned that PGC-1α can regulate the expression of Drp1 protein 
directly through binding to its promoter (Dabrowska et al., 2015). Evidences showed that 
stresses, such as prolonged fasting and exercise training, oxidative damage, and 
chemotherapy treatment can activate PGC-1α protein (Tan et al., 2016). There are reports 
that PGC-1α has been overexpressed in some neurodegenerative diseases such as 
Parkinson's disease and Alzheimer's diseases, which are characterized by mitochondrial 
hyperfragmentation due to increasing production of ROS (Santos et al., 2015, Peng et al., 
2017). It has also been found that in diabetes mellitus, which is characterized by 
hyperglycaemia, the expression of PGC-1α is increased (Lin et al., 2003). Depending on 
these reports it can be predicted that there is a link between overexpression of PGC-1α and 
mitochondrial hyperfragmentation.  
Recently, it has been demonstrated that ZLN0005, a selective transcriptional regulator of 
the PGC-1α gene, can elevate selectively the expression of PGC-1α protein, and can 
increase glucose uptake, fatty acid oxidation, and induce mitochondrial oxidative 
phosphorylation (Zhang et al., 2013). We have previously found that high glucose and 
exogenous H2O2 induce mitochondrial fragmentation and affect metabolism and cell 
migration through increasing intracellular ROS. To resolve the mystery about the source of 
ROS, we treated MDA-MB-231 breast cancer cells with ZLN005, which can increase 
expression of PGC-1α protein and its downstream mitochondrial fission protein Drp1, to 
show a link between mitochondrial morphology and metabolism, and their effect on the 
cell migration. We expected that ZLN005 will induce overexpression of PGC-1α, which in 
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turn it can increase mitochondrial fragmentation and elevate expression of Drp1 protein.  
In addition, PGC-1α can regulate and minimize the effect of mitochondrial ROS 
accompanied to oxidative phosphorylation through increasing expression of several ROS-
detoxifying enzymes (Austin and St-Pierre, 2012). Therefore, it can induce mitochondrial 
fission away from the impact of mitochondrial ROS.  Moreover, different glucose 
concentrations were used to study their effect on the expression of PGC-1α as it was 
suggested that changes in glucose concentration can induce a stress and induce PGC-1α 
activation (Herzig et al., 2001, Finck and Kelly, 2006). 
Results showed that mitochondrial morphology is markedly affected by ZLN005. In 
normal glucose ZLN005 treatment, increased the number of mitochondria, reduced their 
size and volume, indicating that mitochondria have fragmented (Figure4.1 and 4.2). 
Similar results were found after cells were treated with ZLN005 in low and high glucose. 
However, the effect was stronger in low glucose compared to normal and high glucose as 
the total mass of mitochondria significantly decreased in all treatments, whereas, in other 
glucose levels only at 30µM ZLN005 affected the total mass of mitochondria. This might 
be because in low glucose, mitochondria have elongated and network-like shape and can 
be affected easily compared to shorter and smaller mitochondria in normal and high 
glucose.  
Interestingly, data from confocal microscopy show that  mitochondrial number were 
decreased at 30µM ZLN005 after it has been increased in lower concentrations of the 
activator and this was consistent in all three glucose concentrations (Figure4.1A, 4.3A, and 
4.5A). Data obtained from qPCR shows the same results (Figure 4.7). This may be due to 
mitochondrial mitophagy; a process of removing impaired or damaged mitochondria by 
autophagy, since at this ZLN005 concentration (30µM) the cells are under strong stress of 
ROS. It has been reported by Benischke and co-workers (2017) that mitochondrial 
mitophagy lead to reduction of mitochondrial mass, production of ATP, and  mtDNA copy 
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number after increased mitochondrial fragmentation in human corneal endothelial cells 
(HCEnCs). 
The results in this investigation differ from those observed by Guo and co-workers (2015), 
who suggested that down regulation of PGC-1α in hyperglycaemic condition leads to 
increases in mitochondrial fragmentation through increasing the expression of Drp1. In 
contrast, Dabrowska co-workers (2015) reported that PGC-1α induction decreases the 
expression of Drp1 in rat mesencephalon-derived cell line 1RB3AN27, which can lead to 
increases in the level of Mfn2 transcripts, and this means that mitochondrial dynamics shift 
towards hyper fusion. However, no prior report has examined the effect of overexpression 
of PGC1α on mitochondrial morphology and fusion/fission dynamics in cancer cells. 
Western blot analysis of the effect of ZLN005 on expression of PGC-1α protein and its 
downstream protein Drp1 showed that efficiency of ZLN005 on expression of these 
proteins is limited. In low glucose it has no significant impact on PGC-1α protein 
expression; however, it significantly induced expression of PGC-1α protein at 10µM in 
normal glucose and at 10 and 20µM in high glucose (Figure4.1A). Similar results were 
observed when downstream protein Drp1 was measured. It induced expression of Drp1 
only at 10µM in both low and normal glucose (Figure4.1B). This unexpected finding is 
quite interesting as fragmentation of mitochondria was confirmed at all concentrations of 
ZLN005 used and in all glucose levels (Figure 4.2, 4.4, and 4.6).  
Although ZLN005 is considered a potent activator of PGC-1α, it has been observed to 
produce different results in different cells. For instance, in L6 myotubes it led to increasing 
expression of PGC-1α, while, in rat primary hepatocytes, it did not cause any change in the 
expression of PGC-1α (Zhang et al., 2013). Therefore, it is possible that ZLN005 induced 
fragmentation of mitochondria in low concentration (10µM) through increasing PGC-1α 
expression, while, in higher concentrations, it affect mitochondrial morphology through 
inducing expression of other unknown genes rather than PGC-1α. 
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Mitochondrial fission protein, Drp1 with mitochondrial fission 1 protein (Fis1) play an 
essential role in mitochondrial fission, therefore, it was expected that western blot analysis 
would show an increase in the expression of Drp1 protein, even if it was not affected by 
upstream protein regulator; PGC-1α, especially at 20 and 30µM ZLN005 where 
mitochondria had been fragmented markedly. However, results showed no significant 
increases of Drp1 protein at these concentrations (Figure 4.8C). This novel finding 
demonstrates that the traditional view and notion of mitochondrial fission being mediated 
by Drp1 protein may not always be the case, as other proteins also can induce 
mitochondrial fission or prevent mitochondrial fusion. Recently, mitochondrial 
fragmentation has been linked to the expression of α-synuclein, and it was suggested that 
mitochondrial fragmentation does not require Drp1 protein (Nakamura et al., 2011, Zhu et 
al., 2012, Guardia-Laguarta et al., 2014). This protein, which is localized in the  
mitochondria-associated endoplasmic reticulum (ER) membranes (MAM), is linked to 
neurodegenerative disorders and excessive accumulation of it can lead to decline a 
mitochondrial oxidative phosphorylation, changes in the mitochondrial morphology, and 
cell death (Nakamura et al., 2011, Xie and Chung, 2012, Guardia-Laguarta et al., 2014), 
and its high expression has been reported in several cancer cells (Matsuo and Kamitani, 
2010, Ye et al., 2010, Ge and Xu, 2016). It has been suggested that under conditions of 
oxidative stress, nuclear alpha-synuclein can affect mitochondrial function partially 
through reducing PGC-1α (Siddiqui et al., 2012, Ciron et al., 2015).  
Since mitochondrial fusion-fission process is highly dynamic process and mitochondrial 
fragmentation is reversible process, treating cells with high concentrations of ZLN005 may 
induce mitochondrial fragmentation in a short time, then protein PGC-1α and Drp1 will 
degrad. Therefore,  effects at longer time points will be missed. It was reported by Din and 
co-workers (2013) that half life time of Drp1 is 16hrs. Therefore, future study on 
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mitochondria fragmentation using PGC-1α should be conducted over different periods of 
time. 
There are many studies that suggest that PGC-1α protein plays a regulatory role in 
mitochondrial oxidative phosphorylation and protect cells against oxidative stress via 
induction of several ROS detoxifying enzymes including superoxide dismutase and 
glutathione in cancer cells (Sano and Fukuda, 2008, Dabrowska et al., 2015). In the study 
by Liang and Ward (2006) they found that PGC-1α enhanced mitochondrial oxidative 
phosphorylation in skeletal muscle through remodeling skeletal muscle fibers type IIb, 
which exhibit relatively fewer mitochondrial numbers and is more glycolytic, to the more 
oxidative type I and type IIa fibres. In another study by LeBleu and co-workers (2014) they 
reported that PGC-1α suppression in cancer cells leads to downregulation of mitochondrial 
oxidative phosphorylation, while, overexpression of it leads to mixed metabolic response. 
However, the effect of overexpression of PGC-1α, which led to mitochondrial 
hyperfragmentation, on mitochondrial metabolism remains unclear.  
Production of ATP and lactate were measured in MDA-MB-231 cells after treating these 
cells with ZLN005, to understand the link between mitochondrial fragmentation induced 
by ZLN005 and cell metabolism. In normal glucose, our data revealed that treating cells 
with ZLN005 led to a significant increase in the generation of ATP (Figure 4.9A) and this 
increase was due to the increase in the lactate production which represents glycolysis 
(Figure 4.10A). This result was expected as fragmented mitochondria drive the cells to 
reprogram their metabolism and rely more on glycolysis rather than oxidative 
phosphorylation due to reducing mitochondrial inner surface where electron transport 
chain enzymes located (Mannella, 2006, Cogliati et al., 2013). However, we cannot 
confirm that increasing ATP generation is restricted to glycolysis, because, increased PGC-
1α expression (Figure 4.8B) can elevate mitochondrial metabolism through control of 
generated ROS (Figure 4.12A) through increasing detoxification enzymes; therefore, it is 
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possible that mitochondrial metabolism has been also increased and contributed to 
increased ATP. This finding was also reported by LeBleu and co-workers (2014) that 
overexpression of PGC-1α can enhance mixed metabolism. Also it has been demonstrated 
by Chen and co-workers (2014) that increasing expression of PGC-1α can prevent cell 
death induced by P53 through maintaining a balance between oxidative phosphorylation 
and glycolysis. Our data also show that despite generated ATP being increased 
significantly at 30µM ZLN005 treatment compared to control in low glucose, it was 
decreased by 20µM treatment. This suggests that fragmented mitochondria are intact in the 
cells treated with low concentrations of ZLN005 and participate partially in ATP 
production through oxidative phosphorylation, while, in higher ZLN005 concentration 
(30µM), where mitochondria are defective and a number of them were removed via 
mitophagy, ATP energy is generated mainly through aerobic glycolysis. 
In low glucose, where no differences in glycolysis were observed (Figure 4.10B), 
increasing ATP production in the cells treated with 10µM of ZLN005 (Figure 4.9B) 
suggests that mitochondrial metabolism is enhanced by excessive expression of ZLN005. 
While, at higher concentrations ATP production declined for the same reason mentioned 
for normal glucose above.  
In high glucose, increasing ATP production (Figure 4.9 C) without changes in glycolysis in 
10µM treatment (Figure 4.10 C) indicates increases in mitochondrial metabolism enhanced 
by excessive expression of ZLN005 (Figure 4.8B). While, at 20µM, where production of 
ATP and lactate were significantly increased, results suggest that aerobic glycolysis 
partially contributed to ATP production. In similar manner to low and normal glucose, at 
30µM where ATP production was decreased despite increases in the aerobic glycolysis 
suggests defect in the mitochondrial oxidative phosphorylation. High fragmentation of 
mitochondria by ZLN005 at 30µM leads to reduction of mitochondria inner surface 
(Mannella, 2006), which is essential in ATP generation via oxidative phosphorylation, 
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causing defect of oxidative phosphorylation. This result suggests that mitochondrial 
oxidative phosphorylation contributes to total ATP production and increasing glycolysis is 
not enough for supply cancer cells with required ATP. 
In regards to the impact of ZLN005 on cellular and mitochondrial metabolism, Iacovelli 
and co-workers (2016), revealed that overexpression of PGC-1 α in human Retinal 
Pigmented Epithelial cell lines leads to increases in the expression of mitochondrial 
oxidative phosphorylation and fatty-acid β-oxidation genes, they also found it induces a 
number of antioxidants to reduce ROS. Whereas, Chen and co-workers (2014) reported 
that suppression of PGC-1α leads to defects in the mitochondrial oxidative phosphorylation 
in the receptor-interacting protein 1 (RIP1) gene knockdown.  
Mitochondrial fragmentation has been linked with elevated ROS production in several cell 
lines (Picard et al., 2013, Martin-Guerrero et al., 2017, Ježek et al., 2018). Therefore, it is 
expected that production of ROS has been increased with increasing concentration of 
ZLN005 as it promotes mitochondrial fragmentation as mentioned above. However, it is 
well documented that PGC-1α plays an important role in removing and detoxifying ROS 
(Austin and St-Pierre, 2012). To find out the effect of overexpression of PGC-1α induced 
by ZLN005 on the ROS production in MDA-MB-231 cells; we measured total intracellular 
ROS in these cells after 24hrs of treating with different concentrations of ZLN005. Our 
data show that in low glucose level, no significant differences in the generation of ROS 
were observed between cells treated with ZLN005 compared to non-treated control cells 
(Figure 4.11B). This result was expected as increasing PGC-1α expression can increase the 
expression of antioxidant enzymes which remove the excessive generated ROS. Similarly, 
in normal and high glucose levels, the cells were treated with 10 and 20µM of ZLN005 
(Figure 4.11A and C) did not show significant changes in the production of ROS compared 
to non-treated control cells, and this suggests that despite the fragmentation, mitochondria 
are active and participate in the detoxification of generated ROS through enzymes such as 
155 
 
Manganese superoxide dismutase (MnSOD) which is located in the mitochondrial matrix 
(Li and Zhou, 2011, Miriyala et al., 2012). The production of ROS was significantly 
increased at 30µM, despite defects of mitochondrial oxidative phosphorylation; a main 
source of generated ROS. One explanation of this result might be defects of detoxifying 
enzymes system of which is located in mitochondria due to mitochondrial fragmentation. 
However, chronic mitochondrial fission may be another potential cause of increasing ROS 
level (Knott et al., 2008). 
In regards to the PGC-1α effect on ROS level, Baldelli and co-workers (2014) reported that 
downregulation of PGC-1α leads to increases of ROS levels due to decreases in the 
antioxidant enzymes in the murine skeletal muscle cell line C2C12. Similar result was 
reported by Iacovelli and co-workers (2016) who found that expression of several 
antioxidant genes induced by PGC-1α overexpression can limit the increase of ROS due to 
increased mitochondrial oxidative phosphorylation. 
These findings suggest that ROS generation accompanying a mitochondrial oxidative 
phosphorylation have no role in inducing mitochondrial fragmentation. When 
mitochondria are active in ATP generation via mitochondria oxidative phosphorylation, 
detoxifying enzymes will also be active in removing generated ROS, while, in 
hyperfragmented mitochondria, where antioxidant enzymes are defective, mitochondria 
oxidative phosphorylation is also impaired and does not contribute in ROS production. 
The present study also attempts to investigate the effect of ZLN005, which induces 
mitochondrial fragmentation, on cancer cell migration. Upon detailed analysis of cell 
migration monitored by time-lapse microscopy of MDA-MB-231 cells treated with 
ZLN005 during 24hrs revealed that cell migration was increased in low concentration of 
ZLN005 (10µM) in all glucose levels (Figure 4.12). Then in higher concentration (20µM); 
cell migration was decreased. However, it was still significant compared to control in low 
and normal glucose levels, whereas, at 30µM it was decreased more and in high glucose 
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level this decrease in the cell migration was significant compared to the control. This novel 
finding is quite interesting since cell migration decreased when the cells were treated with 
high concentration of ZLN005 despite increasing mitochondrial fragmentation and 
increasing aerobic glycolysis. These results suggest that cell migration is related to 
mitochondrial oxidative phosphorylation more than glycolysis, because, it was postulated 
that cell migration being increased at 30µM in all glucose levels due to significant 
mitochondrial fragmentation which has led to decreases in the mitochondrial oxidative 
phosphorylation and increases in the glycolysis, whilst, in contrast to the expectation, cell 
migration has been decreased. Moreover, at 20µM in normal and high glucose levels where 
production of ATP was increased significantly due to increases in glycolysis, cell 
migration also was decreased. This is the first time that ZLN005 used in studying cancer 
cell migration. 
PGC-1α regulates several genes involved in energy metabolism and mitochondrial 
biogenesis (Jornayvaz and Shulman, 2010) , and it was predicted that ZLN005 induce 
overexpression of PGC-1α  leading to hyperfragmentation of mitochondria. However, non-
significant effect of ZLN005 on PGC-1α gene expression as well as Drp1gene expression 
despite fragmentation of mitochondria when used at high concentrations (20 and 30µM) 
suggests that the ZLN005 effect is not related to PGC-1α. It may be ZLN005 induce 
changes through expression of unknown proteins and pathways, as it has several nuclear 
receptors and can regulate several metabolic processes(Lin et al., 2005). Moreover, 
increasing ATP and lactate production in the cells treated with ZLN005 activator 
especially at 20µM may be related to mitochondrial morphologic changes more than the 
effect of PGC-1α which did not show significant changes at this ZLN005 concentration.   
Our result in agreement to results obtained by Zhu and co-workers (2009) reported that 
overexpression of  PGC-1α induced either by stimulation with palmitic acid or infection 
with adenovirus can lead to reduces in the  vascular smooth muscle cell proliferation and 
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migration induced by high glucose level. Whereas, LeBleu and co-workers (2014) 
suggested that silencing of PGC-1α in cancer cells leads to reduction in cell migration and 
invasion of cells.  
Taken together, these findings provide that PGC-1α plays an important role in inducing 
cell migration through enhancing mitochondrial metabolism, while, overexpression of 
PGC-1α leads to mitochondria hyperfragmentation and defects a mitochondrial metabolism 
and this can reduce cell migration. These effects are magnified with increases in glucose 
concentration.  
Data presented in this chapter have demonstrated that treating MDA-MB-231 cells with 
ZLN005 induced mitochondrial fragmentation and promoted metabolic reprogramming to 
glycolysis. However, the novel finding here is despite these changes, cancer cell migration 
was decreased. In order to increase cell migration, increases in both mitochondrial 
oxidative phosphorylation and aerobic glycolysis are required by cancer cells (Jose et al., 
2011). Mitochondria ROS have no role in inducing and activation of mitochondrial fission 
protein Drp1and fragmentation of mitochondria.  
Despite that ZLN005 activator is a selective transcriptional regulator of the PGC-1α gene, 
It should be remembered that it may have, like many drugs, a direct or indirect effects on 
other factors which can involve in mitochondrial fragmentation and cellular metabolism, 
therefore, it is possible that its effect is not due to direct effect of expression of PGC-1α or 








Chapter Five: Investigating the effect of metabolism on mitochondrial 
dynamics and cell migration 
5.1 Introduction  
Since the discovery of metabolic reprogramming  hallmark of cancer, many studies have 
been performed to targeting metabolism for cancer treatments (Podo et al., 2017, Luengo et 
al., 2017). At present, several inhibitors and drugs that target metabolic enzymes and 
pathways have been developed (Zhao et al., 2013b, Sborov et al., 2015). However,  
undesirable toxicity and side effects remain a big challenge in developing drugs, because 
all cells relay on oxidative phosphorylation  and/or glycolysis in generation of ATP (Zhang 
et al., 2015). Moreover, there is evidence that targeting cell metabolism will induce 
significant increase in oxidative stress, which can lead to mitochondrial fragmentation and 
cell death (Le et al., 2010, Cao et al., 2017). 
In the previous chapter the result showed that changes in the mitochondrial dynamic will 
affect cellular metabolism and cell migration. However, it is not clear if changes in cellular 
metabolism also affect the mitochondrial dynamics as well as cell migration. To 
understand the links between them, in this chapter we investigated the impact of the 
cellular metabolism, through targeting oxidative phosphorylation  with Antimycin A, and 
glycolysis and 3-bromopyruvic acid, on the mitochondrial dynamics and cell migration in 
MDA-MB-231 cells. 
5.1.1 Targeting glycolysis with 3-bromopyruvate  
3-Bromopyruvate (3BrPA), a potent alkylating agent, can induce cell death through 
alkylating agents and through inhibition of aerobic glycolysis and oxidative 
phosphorylation (Jardim-Messeder and Moreira-Pacheco, 2016). It was reported that 
3BrPA targets hexokinase II (HKII), which catalyses the first step of glycolysis (Zhang et 
al., 2014, Lis et al., 2016, Ho et al., 2016). Further studies show that 3BrPA causes cancer 
cell death via pyruvylation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The 
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pyruvylation triggers loss of enzymatic activity of GAPDH resulting in the anti-glycolytic 
effects (Ganapathy-Kanniappan et al., 2009).  It has been observed that 3BrPA treatment 
induces cell death through increasing level of ROS and total cellular stress (Kim et al., 
2008), and it is well known that ROS can induce mitochondrial fragmentation. However, it 
is not clear if targeting cellular metabolism with 3BrPA affects mitochondrial dynamics 
and cell migration or not. To understand this relation, we targeted MDA-MB-231 cell 
metabolism with different concentrations of 3BrPA for 24hrs to study its effect on the 
mitochondria morphology, and cell migration.  
5.1.2 Targeting oxidative phosphorylation with Antimycin A  
Antimycin A (AMA), is a specific inhibitor which targets cytochrome c oxidoreductase 
complex (complex III) of electron transport chain (ETC) in mitochondria, it can generate 
ROS and induce apoptosis (Wang et al., 2015a). In the study published by Rakhmatullina 
and co-workers (2016), they concluded that treating Tritium aestivum roots with AMA, 
which led to increase in the production of ROS, changed mitochondrial morphology 
(Rakhmatullina et al., 2016), and other studies suggested that AMA can inhibit growth of 
HeLa cells and A549 cells through increasing ROS levels (Park et al., 2007, Han et al., 
2008).  However, no attempt was made to study the effect of oxidative phosphorylation 
inhibited by AMA on mitochondrial morphology, as well as cell migration in the cancer 
cells. For this purpose, we targeted MDA-MB-231 cells with AMA in different 
concentrations for 24hrs. 
5.2 Material and methods 
5.2.1 Cell culture 
MDA-MB-231 cells were used in our experiments.  They were continuously cultured in 
Dulbecco’s Modified Eagles Media (DMEM) supplemented with 10% FBS, 1% L-
glutamine, 100 Unit/ml of penicillin and 100 µg/ml of streptomycin (Gibco), at 37°C in a 
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humidified atmosphere containing 5% CO2. However, antibiotic free medium was used 
when the cells treated with AMA (Sigma) or 3BrPA (Sigma) during experiments. 
5.2.2 Mitochondrial staining and analysis 
Cells were treated with different concentrations of AMA (12.5, 25, 50, and 100µM) or 
3BrPA (25, 50, 100, 250µM) for 24hrs, then mitochondria were stained with MitoTracker 
probe (Invitrogen, M7510), and nucleus stained with DAPI as described in section 2.2.7 
Images were taken using confocal microscopy and analysed by ImageJ software as 
explained in section 2.2.16 
5.2.3 Quantitative Real- Time PCR (qRT-PCR)  
The Quantitative real time polymerase chain reaction (qRT-PCR) was used in measuring 
mtDNA copy number, as described in section 2.2.10,  using extracted DNA  in MDA-MB-
231 cells after 24hrs treating with either AMA or 3BrPA. 
5.2.4 Analysis of metabolism and ROS  
MDA-MB-231 cells treated with different concentrations of either AMA or 3BrPA for 
24hrs, then generated ATP was measured as described in section 2.2.14, lactate production 
was measured as described in section 2.2.13, and level of generated ROS was measured as 
described in section 2.2.12. 
5.2.5 Cell migration  
Cell migration in MDA-MB-231 cells treated with different concentrations of AMA or 
3BrPA was monitored by time-lapse microscopy for 24hrs ImageJ (Fiji) software (MtrackJ 









We investigated the effect of 3-bromopyruvic acid (3BrPA); which targets glycolysis, and 
Antimycin A (AMA); which targets oxidative phosphorylation, on the cellular metabolism, 
mitochondrial dynamics, and cell migration.  Therefore, we treated MDA-MB-231 cells 
with 3BrPA in different concentrations 25, 50, 100, 250µM and different concentrations of 
AMA; 12.5, 25, 50,100µM for 24hrs. 
To determine whether treating cells with 3BrPA and AMA could affect cell viability, we 
performed MTT assay. The results shown in Figure 5.1A revealed that 3BrPA does not 
affect cell viability after 24hrs of treatment. Whereas, when we treated the cells with 
AMA, we found that AMA at concentration (200µM) strongly affected cell viability 
compared to non- treated control cells (p<0.001), while, at lower concentrations no 
significant differences were observed with control, as seen in Figure 5.1B. 
Depending on these results we treated cells in our next experiments with 3BrPA in 
concentrations 25, 50, 100, 250µM, and with AMA in concentrations 12.5, 25, 50,100µM. 
















































Figure 5.1: MTT assays showing the cell viability after 24hrs treating cells with 3BrPA or AMA. MDA-
MB-231 cells were treated with different concentrations of (A) 3BrPA or (B) AMA, for 24hrs. Cell viability 
determined by reading plates at 570 nm with plate reader. Data represent the mean ± standard error of three 







To uncover the impact of treating MDA-MB-231 cells with 3BrPA and AMA on the 
generation of the intracellular ROS; we incubated cells with 0.2mM DCFH-DA for 60 
minutes before treating them with different concentrations (25, 50, 100, 250µM) of 3BrPA 
and different concentrations (12.5, 25, 50,100µM) of AMA. After 24hrs of treating cells, 
the fluorescence intensity of DCF which was oxidized by ROS was read with a 
fluorometric plate reader at 485nm/535nm, the fluorescence intensity is proportional to the 
intracellular ROS levels generated by the cells. Results of 3BrPA treatments in Figure 5.2A 
showed that intracellular ROS level was increased markedly from 18578±1823Unit in non-
treated cells to 27315±2442Unit in the treated cells with 25µM of 3BrPA (p<0.05), and 
into 32546.5±2566, 38436±1571, and 45514.3±1843Unit in the treated cells with 50, 100, 
and 250µM of 3BrPA respectively (p<0.001); these mean that ROS production was 
increased by 47.03%, 75.19%, 106.89%, and 144.99% in the cells treated with 25, 50, 100, 
250µM of 3BrPA respectively compared to control cells. Similar results were obtained 
when cells treated with AMA. As shown in Figure 5.2B, level of ROS was increased 
significantly from 16143.3±306Unit in non-treated cells to 17355.7±287Unit in the treated 
cells with 12.5µM of AMA (p<0.05), and into 19208±180.8, 28368.3±192.9, and 
24953.3±360.9Unit in the treated cells with 25, 500, and 100µM of AMA respectively 
(p<0.001); these mean that treating with AMA induced increases in the ROS production by 
7.51%, 18.98%, 75.73%, and 54.57% at concentrations 12.5, 25, 50,100µM of AMA 
























































Figure 5.2: Effect of 3-BrPA and AMA on the ROS production in MDA-MB-231cells.  Cells were 
incubated with 0.2mM DCFH-DA for 60 minutes treated either with (A): different concentrations of 3-BrPA 
or with (B): different concentrations of AMA for 24 hours. The intensity of fluorescence was read with a 
fluorometric plate reader at 485nm/535nm. Data represent the mean ± standard error of three independent 
experiments performed in triplicate. One-way ANOVA followed by Dunnett's Multiple Comparison Test to 
compare the mean of treatments with the mean of control. (*, and *** represent P < 0.05, and 0.001 

















Afterwards we investigated the effect of 3BrPA on the mitochondrial dynamics through 
measuring mitochondrial number, size, volume, and total volume of mitochondrial mass in 
the cell. For this purpose, we treated cells with 3BrPA for 24hrs then z-stack images were 
taken using confocal microscopy, and ImageJ was used for analysis data.  The results are 
presented in Figure 5.3 and 5.4. 
Results in Figure 5.3 A show that treating cells with 3BrPA changed  the number of 
mitochondria  significantly at  concentration 250µM and it was increased from 150.18±5.7 
in non-treated control cells to 207.6±10.6 in mentioned concentration (p<0.001), while, in 
other concentrations, no significant changes were detected compared to control.  
Treating cells with 3BrPA reduced the volume of the mitochondria significantly. As 
presented in Figure 5.3B, the volume of mitochondria has been decreased from 
0.46±0.038µm^
3
 in control cells to 0.36±0.018µm^
3
 in treated cells with 25mM of 3BrPA 
(p<0.05), and into 0.29±0.02, 0.18±0.012, and 0.11±0.009µm^
3
 in treated cells with 50, 
100, and 250mM of 3BrPA respectively (p<0.001). 
When we measured the size of the mitochondria, we found it was decreased significantly. 
It was decreased from 5.29±0.46µm^
2
 in control cells to 3.69±0.2, 2.88±0.18, and 
2.1±0.2µm^
2
 in treated cells with 50, 100, and 250mM of 3BrPA respectively (p<0.001), 
while, no significant changes in the mitochondrial size were detected in treated cells with 
25mM of 3BrPA compared to the control cells, as shown in Figure 5.3C.   
Total mass of the mitochondria was calculated by multiplying volume of mitochondria 
with the number of the mitochondria, and the results as shown in Figure 5.3D revealed it 
was decreased significantly from 67.24±3.73µm^
3
 in control cells to 47.6±2.9µm^
3
 in 
treated cells with 50µM of 3BrPA (p<0.05), and into 31.94±2.33, and 23.35±1.94µm^
3 
at 
concentrations 100, and 250µM of 3BrPA  respectively (p<0.001), while, in cells treated 
with 25µM, no significant changes were observed compared to control cells.  
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These dynamic changes in mitochondria in the cells treated with 3BrPA were presented in 
Figure 5.4. 










































































































































Figure 5.3: Effect of 3-BrPA on the mitochondrial morphology in MDA-MB-231 cells. Cells treated with 
3-BrPA for 24hrs then mitochondria were stained with MitoTracker probe and DAPI was used to stain 
nucleus. Z- Stack images were taken by confocal microscopy used to take mitochondrial images. (A) 
Represent quantification analysis of number of mitochondria, (B) Volume of mitochondria, (C) Size of 
mitochondria, and (D) represent quantification analysis of total mitochondria mass per cell. Data represent 
the mean ± standard error of three independent experiments performed in triplicate; each experiment 
contained at least 30 cells. One-way ANOVA followed by Dunnett’s Multiple Comparison test to compare 


























































Figure 5.4: Micrographs showing the mitochondrial morphology in MDA-MB-231 cells treated with 
3BrPA. Mitochondria were stained with MitoTracker orange CMTMRos probe (red colour) and nucleus 
stained with DAPI (blue colour), for MDA-MB-231 cells treated with different concentrations of 3-BrPA. 
Images were taken by confocal microscopy. Scale bar = 20 μm. 
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To discover the effect of AMA on the mitochondrial dynamics, we treated MDA-MB-231 
cells with different concentrations 12.5, 25, 50, and 100µM of AMA for 24hrs, and then 
changes in mitochondrial morphology were measured as shown in Figure 5.5 and 5.6.   
The effect of AMA on the mitochondrial numbers was analysed as shown in Figure 5.5A, 
and it was revealed that AMA statistically did not induce significant changes in the 
mitochondrial numbers. 
Figure 5.5B shows the effect of AMA on the size of the mitochondria. The results found 
that mitochondrial size was decreased significantly from 4.78±1.05µm^
2
 in non-treated 
control cells to 1.59±0.11, and 1.5±0.09µm^
2
 in treatments 50, and 100µM (p<0.05), 
while, no significant changes were recorded between cells treated with 12.5, and 25µM of 
AMA and control cells.  
Similar results were obtained when we measured the volume of the mitochondria in treated 
cells with AMA as shown in Figure 5.5C. Treating cells with 50, and 100µM led to 
decreases in the mitochondrial volume markedly, it was decreased from 0.38±0.11µm^
3
 in 
control cells to 0.11±0.011, and 0.09±0.007µm^
3
 respectively (p<0.05), whereas, no 
significant changes were found between treatments 12.5, and 25µM compared to the non-
treated control cells. 
At the end, total mass of the mitochondria per cell was calculated, and the results in Figure 
5.5D, revealed that AMA reduced on it. It declined significantly from 31.84±8.94µm^
3
 in 
control cells to 9.11±1.96µm^
3
 in cells treated with 100µM of AMA (p<0.05), while, one 









































































































































Figure 5.5: Effect of AMA on mitochondrial morphology in MDA-MB-231 cells. Cells treated with 
AMA for 24hrs then mitochondria stained with MitoTracker probe and confocal microscopy used to take z-
stack images. (A) Represent quantification analysis of number of mitochondria, (B) Size of mitochondria, (C) 
Volume of mitochondria, and (D) represent quantification analysis of total mass of mitochondria per cell. 
Data represent the mean ± standard error of three independent experiments performed in triplicate; each 
experiment contained at least 30 cells. One-way ANOVA and Dunnett’s Multiple Comparison test used to 

































































Figure 5.6: Micrographs showing the mitochondrial morphology in MDA-MB-231 cells treated with 
AMA. Mitochondria were stained with MitoTracker probe (red colour) and nucleus stained with DAPI (blue 
colour), for MDA-MB-231 cells treated with different concentrations of AMA. Images were taken by 
confocal microscopy. Scale bar = 20 μm. 
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To confirm our results of mitochondrial morphology obtained by confocal microscopy in 
MDA-MB-231 cells treated with 3-BrPA, and AMA, we measured mtDNA copy number 
after treating cells with 3BrPA or AMA for 24hrs.  
Figure 5.7A show the results of mtDNA copy number in MDA-MB-231cells treated with 
different concentrations of 3BrPA, and it was revealed that mtDNA copy number was 
increased significantly from 822.5±106.4 in non-treated control cells to 1863.6±111.7 in 
treatment 50µM (p<0.05), and into 2993.6±129.7, and 7270.3±440.9 in treatments 100, 
and 250µM respectively (p<0.001), whilst, no differences in mtDNA copy number were 
detected between the cells treated with 25µM and control.    
The results presented in Figure 5.7B, show the mtDNA copy number in MDA-MB-
231cells treated with different concentrations of AMA. It appears that treating cells with 
AMA at concentration 50µM induced significant increases in the mtDNA copy number, it 
was increased form 822.5±106.4 in control cells to 1466.8±236 (p<0.05), while, no  
significant changes  in the mtDNA copy number were recorded between other treatments 
compared to control. 
























































Figure 5.7: Impact of 3-BrPA and AMA on the mtDNA copy number in MDA-MB-231 cells. Cells were 
treated with 3-BrPA or AMA for 24hrs, and then DNA extracted and used to determine mtDNA using 
quantitative real-time PCR. (A) Represent quantification analysis of mtDNA copy number in cells treated 
with 3-BrPA, (B) Represent quantification analysis of mtDNA copy number in cells treated with AMA. Data 
represent the mean ± standard error of three independent experiments performed in triplicate. One-way 
ANOVA followed by Dunnett's Multiple Comparison Test to compare mean of the treatments with mean of 




To find out the extent of the impact of 3BrPA and AMA on cellular metabolism, we 
measured generated ATP and lactate after 24hrs of treated MDA-MB-231cells with 
different concentrations of 3BrPA and AMA using specific commercial kits. 
Figure 5.8A shows the results of ATP production in the cells treated with 3BrPA. It was 
revealed that ATP production was decreased significantly from 0.41±0.08mM in control to 
0.14±0.05mM in treated cells with 100µM (p<0.05), and into 0.05±0.02mM in treatment 
250µM (p<0.01); which is mean that ATP production was decreased by 66.25%, and 
86.85% in treated cells with 100 and 250µM of 3BrPA compared to control, whereas, no 
differences were detected between treatments 25, and 50µM and control. On the contrary, 
treating cells with AMA led to increases in ATP production as seen in Figure 5.8B. It was 
increased markedly from 0.41±0.08mM in control to 0.801±0.06mM in treated cells with 
25µM of AMA (p<0.01), and into 1.09±0.07mM in treatment 50µM (p<0.001); these 
mean ATP production was increased by 93.97%, and 163.03% in treated cells with 25 and 
50µM of AMA compared to control, whereas, no significant differences were recorded 
between treatments 12.5, and 100µM and control. What is interesting to note is that after 
increasing ATP production at concentrations 25, and 50µM of AMA, we found decline of 
ATP production again at concentration 100µM. 

































Figure 5.8: Quantification of ATP in MDA-MB-231 cells treated with 3-BrPA or AMA. After treating 
cells with different concentrations of 3-BrPA or AMA for 24hrs, lysate of 1x10
6
 cells were used for 
measuring ATP level by colorimetric ATP assay kit. Graphs represent quantification analysis of ATP 
production in the cells treated with (A) 3-BrPA, and (B) with AMA. Data represent the mean ± standard error 
of four independent experiments performed in triplicate. One-way ANOVA followed by Dunnett’s Multiple 
Comparison Test to compare mean of treatments with mean of control (*, ** and ***represent P < 0.05, 0.01 
and 0.001 respectively) 
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When we measured lactate production in MDA-MB-231 cells treated with 3BrPA, results 
as shown in Figure 5.9A revealed that lactate production was decreased sharply from 
0.42±0.01mM in control to 0.35±0.009, and 0.27±0.005mM in treated cells with 100, and 
250µM of 3BrPA respectively (p<0.001); which is mean lactate production was decreased 
by 17.1%, and 35.5% in treated cells with 100 and 250µM of 3BrPA compared to control, 
whilst, no significant differences in lactate production were found between cells treated 
with 25, and 50µM of 3BrPA and control cells.  On the contrary to 3BrPA, we found 
treating cells with AMA increased lactate production. As seen in Figure 5.9B, lactate 
production was increased strongly from 0.33±0.007mM in control cells to 0.46±0.004, 
0.48±0.005, 0.53±0.005, and 0.38±0.008mM in treated cells with 12.5, 25, 50, and 100µM 
respectively (p<0.001); these mean that lactate production was increased by 37.7%, 
45.02%, 59.95%, and 15.06% in treated cells with 12.5, 25, 50 and 100µM of AMA 
compared to control. 








































Figure 5.9:  Effect of 3-BrPA and AMA on lactate production in MDA-MB-231 cells. After 24 hours of 
treating cells with 3-BrPA or AMA, supernatants were assayed to determine the L-Lactate concentrations. 
(A) Represent quantification analysis of L-Lactate production in the cells treated with 3-BrPA, and (B) with 
AMA.  Data represent the mean ± standard error of four independent experiments performed in triplicate. 
One-way ANOVA followed by Dunnett's Multiple Comparison Test to compare mean of treatments with 





After we found that 3BrPA and AMA induced changes in mitochondrial dynamics and 
metabolism, we investigated their effects on the cell migration using time-lapse to track 
cell movements during 24hrs.  
Effect of 3BrPA on the cell migration presented in Figure 5.10A revealed that speed of cell 
migration was decreased significantly at concentrations 100, and 250µM compared to 
control. It was decreased from 31.1±0.9µm/h in control to 19.9±1.6, and 16.1±0.4µm/h in 
mentioned concentrations respectively (p<0.001), while, no significant changes were 
recorded between treatments 25, and 50µM and control.  
In the Figure 5.10B, results showed that treating cells with AMA increased the cell 
migration significantly. It was increased from 19.4=±0.75µm/h in control to 23.9±0.67, 
and 24.1±1.13µm/h in the cells treated with 12.5, and 25µM of AMA respectively 
(p<0.05), and into 26.27±1.15, and 24.87±0.8µm/h in cells treated with 50, and 100µM of 
AMA respectively (p<0.01). 






























































Figure 5.10:  Effect of 3-BrPA and AMA on the cell migration in MDA-MB-231 cells. Cell migration 
was monitored by the time-lapse microscopy. Images were taken every 15 minutes over 24 hours, and ImageJ 
software was used for tracking individual cell. A: represent quantification analysis of speed of cell migration 
in cells treated with 3BrPA, and B:  with AMA. Data represent the mean ± standard error of three 
independent experiments performed in triplicate. One-way ANOVA followed by Dunnett test to compare 







There is evidence that confirms a relationship between mitochondrial morphology and 
function (Picard et al., 2013, Nadova et al., 2016). In previous chapters we found that 
changes in the mitochondrial morphology induced by high ROS can affect cellular 
metabolism, here we targeted cellular and mitochondrial metabolism with pharmacological 
treatments to understand the impact of mitochondrial metabolism on mitochondrial 
morphology and cell migration. Therefore, we used 3-bromopyruvate (3BrPA), which 
targets glycolysis, and Antimycin A (AMA), which targets oxidative phosphorylation, in 
sub-lethal concentrations in MDA-MB-231 breast cancer cells. First we measured cell 
viability after exposing these cells to both 3BrPA and AMA for 24hrs to find sub-lethal 
concentrations. Our data show that 3BrPA did not affect cell viability with the 
concentrations used (Figure 5.1A), whereas, AMA led to significant decrease in cell 
viability at 200µM. In lower concentrations no significant effect on cell viability was 
observed (Figure 5.1B). These results were confirmed with time-lapse microscopy results 
for cell migration (Figure 5.10) which showed that treating cells with 250µM 3BrPA and 
100µM AMA did not induce apoptosis.  
Induction of ROS has been demonstrated as one of the side effects of many cancer 
treatments on non-cancerous normal cells (Yokoyama et al., 2017), and it has been 
suggested that anticancer drugs exert their cytotoxic effect on cancer cells through 
generation of ROS to lethal levels that can kill cancer cells through inducing apoptosis 
(Conklin, 2004, K. Maiti, 2012, Kasiappan and Safe, 2016). To know whether 3BrPA and 
AMA induce generation of ROS, we measured intracellular ROS using Dichloro-dihydro 
fluorescin diacetate (DCFH2-DA) as the ROS sensitive probe, and results showed both 
3BrPA and AMA can induce production of ROS significantly in all used concentrations 
(Figure5.2A and 5.2B for 3BrPA and AMA respectively). This result is in agreement with 
findings by Lin and co-workers (2016) who found that 3BrPA enhances apoptosis through 
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inducing ROS production after myeloid cell leukemia-1 (MCL-1) knockdown in MDA-
MB-231 cells. Similarly, Zou and co-workers (2015) found that 3BrPA induces non-
apoptotic necroptosis by generation of ROS in nasopharyngeal carcinoma. It was reported 
that 3BrPA in multiple myeloma cells can contribute to the generation of ROS via marked 
decreases in the glutathione (GSH) concentration (Lis et al., 2016). Whereas, previous 
observations by Park and co-workers (2007) support the impact of AMA in inducing ROS, 
they found that in HeLa cells AMA induces apoptosis through significant increases in the 
production of ROS and depletion of glutathione. It was suggested that AMA induces 
production of ROS in high rates through binding to the Qi site and blocks the oxidation of 
cytochrome b heme, which in turn limits oxidation of semiquinone in the Qo site and this 
promotes reduction of oxygen molecule to generate superoxide (Quinlan et al., 2011).  
Previously we found that increased production of ROS can induce mitochondrial fission 
through activation of Drp1 protein.  To know whether targeting metabolism with 3BrPA 
and AMA (in different concentrations), which have induced ROS production, affected 
mitochondrial morphology; we measured number, size, volume and total mass of 
mitochondria through confocal microscopy of MDA-MB-231 cells stained with 
MitoTracker probe. Markedly reducing of mitochondrial size, volume, and total mass 
(Figure 5.3 and 5.4) suggest that 3BrPA induces mitochondrial fragmentation. Despite that, 
mitochondrial number has increased significantly only when the cells treated with highest 
concentration of 3BrPA (Figure 5.3A), the data obtained from qPCR show significant 
increases of mtDNA copy number after treating the cells with 3BrPA at 50µM and higher 
concentrations (Figure 5.7), and this confirms mitochondrial fragmentation in the MDA-
MB-231 breast cancer cells treated with 3BrPA. One challenge  of counting mitochondrial 
number using confocal microscopy was mitochondrial overlapping, that is maybe the 
reason of that data obtained from confocal microscopy of the cells treated with 3BrPA did 
not show significant differences only at highest concentration. 
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. Similar results were observed with AMA as data showed that mitochondrial size, volume, 
and total mass were reduced, whereas, mitochondrial number was not affected (Figure 5.5 
and 5.6). This result suggests that AMA has also induced mitochondria fragmentation, 
which is mainly due to generating high rate of ROS.   
In the previous chapter we found a correlation between mitochondrial fragmentation and 
glycolytic reprogramming, and it was supposed that targeting glycolysis through using 
3BrPA would decrease mitochondrial fragmentation. However, due to increased oxidative 
stress induced by ROS, mitochondrial fragmentation has increased. It was predicted that 
treating with AMA would induce mitochondrial fragmentation, because inhibition of 
oxidative phosphorylation by AMA promotes the cancer cells to reprogram their 
metabolism to glycolysis to obtain required ATP energy. This is in addition to high rate of 
ROS generation which increases the impact of AMA on mitochondrial morphology, which 
in turn induces metabolism reprogramming to glycolysis. Pletjushkina and co-workers 
(2006) report similar results when they inhibited the respiratory chain in HeLa cells and 
epithelial CV-1 cells, they found that inhibition of complex I and III stimulated generation 
of ROS which has led to mitochondrial fragmentation.  
3BrPA has several targets in cancer cells (Marrache and Dhar, 2015). It can target 
hexokinase II (HK II), which catalyzes the initial step in glycolysis pathway (Chen et al., 
2009), as well as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Baghdadi, 2017); 
which converts glyceraldehyde 3-phosphate to D glycerate 1, 3-bisphosphate in the 
glycolysis pathway (Krasnov et al., 2013) leading to decrease in the level of ATP 
production (Sun et al., 2015). Our data show that 3BrPA has a potential effect on ATP 
production as increased concentration of 3BrPA has increased the decline of ATP 
production (Figure 5.8A), and this decrease in ATP level was due to the effect of 3BrPA 
on the glycolysis, as shown in Figure 5.9A, L-lactate production; the end product of 
glycolysis was markedly decreased with increased concentration of 3BrPA. This result 
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confirms our previous finding about the role of glycolysis in raising ATP level in MDA-
MB-231 cells. The result also confirms that mitochondrial fragmentation leads to increase 
of ATP via glycolysis, because targeting glycolysis minimized ATP production despite 
mitochondrial fragmentation. Our results are in agreement with findings by Ihrlund and co-
workers (2008), who found that 3BrPA led to loss of ATP by 65% and 90% at 
concentrations 50 and 100µM in HCT116 colon carcinoma cells. Similarly, Zou and co-
workers (2015) found decreases in ATP production in HNEI and CNE-2Z cell strains of 
NPC (Nasopharyngeal carcinoma) cells after 5hrs of treating with 3BrPA.  
Despite the fact that many cancer cells rely mainly on glycolysis for ATP production, 
mitochondrial oxidative phosphorylation in cancer cells is still intact and contributes to 
ATP production (Zheng, 2012). Targeting the glycolysis pathway leads to reduction of 
ATP levels as both glycolysis and oxidative phosphorylation will be affected, whilst, 
targeting oxidative phosphorylation does not affect glycolysis. Therefore, it is expected 
that targeting oxidative phosphorylation such as by using AMA can induce the cancer cells 
to reprogram their metabolism to rely more on glycolysis to obtain required ATP for their 
activity, and because glycolysis generates lower amount of energy compared to oxidative 
phosphorylation, cancer cells rise glucose uptake to generate higher amount of ATP via 
acceleration of glycolysis. Obtained data agree with our expectation and showed that 
treating cells with AMA,  which targets complex III in the electron transport chain in 
mitochondria, led to increase in ATP production (Figure 5.8B) as well as increase in the 
lactate production (Figure 5.9B).  These results suggest that metabolism was altered toward 
glycolysis for production of ATP due to a defect in mitochondrial metabolism induced by 
AMA. Kale (2016) found that treating rat L6 cells with AMA did not induce increases in 
the ATP generation; however, he treated cells with low concentrations of AMA (5, 10, and 
25µM) and for 48hrs. 
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The link between cell migration and metabolism is well documented.  Since migration of 
cells requires high amount of ATP energy, most cancer cells alter their metabolism from 
oxidative phosphorylation to aerobic glycolysis which known as Warburg effect (Han et 
al., 2013), however, this does not mean that oxidative phosphorylation does not have a role 
in generating ATP, as most cancer cells still rely on it by 30-50% (Zheng, 2012). 
Therefore, targeting metabolism may affect cell migration strongly. In our study, we found 
that targeting glycolysis with 3BrPA reduced cell migration in MDA-MB-231 cells 
(Figure5.10 A). Another explanation of reducing cell migration by 3BrPA is that inhibition 
of glycolysis leads to decrease of lactate; the end product of glycolysis, which has an 
important role in the acidification of the tumor microenvironment and in cell migration 
(Annibaldi and Widmann, 2010, Beckert et al., 2006). Our results agree with finding by 
Tomizawa and co-workers (2016), who reported that 3BrPA, can suppress cell migration in 
hepatocellular carcinoma (HCC) cells at 100µM. It was reported also that 3BrPA can 
potentiate the effect of photodynamic therapy (PDT) of cell migration inhibition in MDA-
MB-31 cells (Feng et al., 2015).  
In contrast to the effect of 3BrPA, treating cells with AMA promoted cell migration 
markedly (Figure 5.10B). This change in cell migration may be due to the effect of AMA 
on reprogramming metabolism toward glycolysis in addition to its effect on rising ROS 
generation that increases mitochondrial fragmentation, which in turn increase glycolysis. 
Hung and co-workers (2012) results confirm our finding; they found that treating human 
gastric cancer SC-M1 cells with AMA induced cell migration due to mitochondrial 
dysfunction. While Kouvroukoglou and co-workers (1998) suggest that AMA has no effect 
on cell migration in MatLu cell line; a variant of the Dunning R-3327 rat prostate 
adenocarcinoma model. This novel finding suggests that targeting mitochondrial oxidative 
phosphorylation with the anticancer agent AMA in sub-lethal concentration can increase 
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cancer metastasis, while, fragmentation of mitochondria mediated by AMA can increase 


























Chapter Six:  Role of p66shc and TRAP1 proteins in cancer cell 
migration.  
6.1 Introduction: 
Protein p66shc is one of three shc isoforms and  plays an important role in the cellular 
response to oxidative stress through inducing apoptosis (Pacini et al., 2004). Like the other 
two shc isoforms, p52shc and p46shc, p66shc has a tyrosine activation site which activates 
after growth factor receptor activation.  However, it has no effect on Ras signaling pathway 
(Bonfini et al., 1996, Migliaccio et al., 1997, Trinei et al., 2002). 
Oxidative stress which is the result of over accumulation of ROS in the cell is due to an 
imbalance between ROS production and cellular antioxidant system, and it is responsible 
for cell damage, necrosis, and apoptosis through oxidation and degradation of several 
macromolecules including lipids, proteins, and DNA (Elahi et al., 2009, De Marchi et al., 
2013).  
Protein p66shc is localized in different subcellular compartments and can be activated in 
response to oxidative stress induced by UV radiation, H2O2 treatment, and high glucose 
(hyperglycaemia) (Migliaccio et al., 1999, Sun et al., 2010, Lebiedzinska-Arciszewska et 
al., 2015). It is activated through phosphorylation at ser36 residue by PKC-β, which 
facilitates its translocation to the intermembrane space (IMS) of mitochondria via 
TIM/TOM mitochondrial import machinery. In IMS, p66shc oxidizes cytochrome c and 
catalyzes the reduction of O2 to generating H2O2, which leads to elevating mitochondrial 
ROS level. This ROS can cause opening of mitochondrial permeability transition pore 
(PTP), which increases permeability of mitochondrial membrane to ions. This leads to 
swelling and disruption of the outer mitochondrial membrane (OMM) and release of 
cytochrome c; a pro-apoptotic factor which lead to formation of the apoptosome and 
activation of caspase proteins triggering cell death (Galimov, 2010, Lebiedzinska-
Arciszewska et al., 2015), as illustrated in Figure 6.1. 
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In  normal cells high level of glucose causes oxidative stress and in turn triggers p66shc 
activation and apoptosis (Pagnin et al., 2005, Xi et al., 2010, Hung et al., 2014), while, 
several types of cancer cells exhibit high expression of  p66shc without inducing apoptosis 
(Lebiedzinska-Arciszewska et al., 2015). On the contrary, high expression of p66shc 
enhances cell proliferation, migration and invasion (Zhu et al., 2013, Takatani-Nakase et 
al., 2014). 
 
Figure 6.1: Impact of glucose on mitochondrial dynamics. Oxidative stress due to high glucose activates 
protein kinase C-β isoform activate p66Shc via phosphorylation of Ser36, allowing transfer of it from the 
cytosol to the mitochondrion through TIM-TOM import system. In the mitochondrion, p66Shc can oxidizes 
cytochrome C and catalyzes the reduction of O2 to H2O2, which induces opening of the mitochondrial 
permeability transition pore (PTP). This increase permeability of mitochondrial membrane to ions, solutes 
and water, swelling and disruption of the organelle, and consequent release of pro-apoptotic factors into the 
cytosol. 
p66Shc also plays important role in metabolism, in the study by  Soliman and co-workers 
(2014), they concluded that p66Shc has a suppressive effect on cancer cell metabolism 
through dampening growth factor signalling(Lebiedzinska-Arciszewska et al., 2015).  
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Although, until now it is not clear how activation of p66shc affects metabolism. However, 
may be  that activated p66shc affects metabolism through disrupting electron transport 
chain through oxidizing cytochrome c; the small haemoprotein component of the electron 
transport chain in mitochondria, in which heme group accepts electrons from complex III 
and transfers electrons to the complex IV. 
Recently it was revealed that Tumor Necrosis Factor (TNF) receptor-associated protein 1 
(TRAP1); a mitochondrial chaperone protein highly expressed during cellular stress (Liu et 
al., 2010), especially in cancer cells (Ghosh et al., 2010, Leav et al., 2010), protects cells 
from apoptosis induced by oxidative stress (Matassa et al., 2011). It was suggested that 
TRAP1 chaperone protects cells through binding and inhibiting cyclophin D; a peptidyl-
prolyl cis-trans isomerase enzyme which is located in the mitochondrial matrix and it 
catalyses protein folding. Mitochondrial oxidative stress can induce  cyclophin D to  
interact with the permeability transition pore (PTP) complex, forming and opening  non-
selective pores in the mitochondrial inner membrane allowing the release of cytochrome c; 
a first step in triggering apoptosis (Xiang et al., 2010, Matassa et al., 2011, Su et al., 2013) 
Besides the protective effect of TRAP1, it has been suggested that it can promote growth 
of cancer cells through inhibiting succinate dehydrogenase, complex II of the respiratory 
chain and switching metabolism to aerobic glycolysis which is important for cancer cell 
growth (Sciacovelli et al., 2013). However, the mechanism remains unclear. 
Despite upregulation of cytoprotective TRAP1 expression in several cancer cells, its 
relation to p66shc, which is overexpressed under oxidative stress remains unclear, as well 





We suggest that cancer cells upon exposure to oxidative stress, upregulate expression of 
TRAP1 to prevent apoptosis which can be induced by activated p66shc. While, generated 
mitochondrial ROS can inhibit oxidative phosphorylation and thus promote glycolysis that 
increase cancer cell migration.    
 
Figure 6.2: Mitochondrial electron transport chain. Electrons were passing through complexes I, II, and 
III, then transferred from cytochrome C to complex IV. Flow of electron is accompanied by proton transfer 
across the membrane, producing both a chemical gradient (pH) and an electrical gradient ().protons can 
reenter the matrix via complex V or ATP synthase providing the energy for ATP synthesis. Translocated 
activated p66shc oxidize cytochrome c, this rise ROS that induce cyclophin D to bind and open PTP 
consequently release of cytochrome C and trigger apoptosis. TRAP1 that also induced by high ROS can 
avoid binding cyclophin D and prevent apoptosis.     
In this chapter we aimed to study the impact of silencing p66shc and TRAP1 on the cancer 
cell migration and metabolism through measuring generated ATP and lactate in three cell 





6.2 Materials and Methods 
6.2.1 Materials 
 On-TARGET plus Human TRAP1 siRNA-Smart pool with following targets were 
obtained from Dharmacon GE Company.  
Target sequence 1 GAGAUGUGGUAACGAAGUA 
Target sequence 2 UAACCAGCCUCUCAGAAUA 
Target sequence 3 GCUCCAGCGUUGCACUGUA 
Target sequence 4 GAUUGCUGCUGGACUUGUU 
 On-TARGET plus Non-target TRAP1 siRNA from Dharmacon GE Company with 
following target sequence 
Target sequence  UGGUUUACAUGUCGACUAA 
 DharmaFECT 1 Transfection Reagent and DharmaFECT 4 Transfection Reagent 
were obtained from Thermo Scientific, UK.  
 5X siRNA Buffer, 100ml obtained from Dharmacon GE Company. 
 P66shc siRNA were designed depending on instruction by Sigma-Aldrich, UK. 
With the following targets. 
Target sequence 1 UGAGUCUCUGUCAUCGCUG 
Target sequence 2 AUAGUCCCACUACCCUGUG 
Target sequence 3 AGCAACCUGAGGCUGGCCA 
6.2.2 Cell culture 
In the present study, we used three cell lines; MDA-MB-231 breast adenocarcinoma cell 
line, HT1080 fibrosarcoma cells line, and HeLa cells line. MDA-MB-231 cells were 
continuously cultured in Dulbecco’s Modified Eagles Media (DMEM) with relevant 
glucose levels (5.5, and 25mM) supplemented with 10% FBS, 1% L-glutamine, 100 
Unit/ml of penicillin and 100 μg/ml of streptomycin (Gibco), at 37°C in a humidified 
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atmosphere containing 5% CO2. HT1080 and HeLa cells were cultured in Eagle's 
Minimum Essential Medium (EMEM) instead of DMEM.  
Cells were grown in T-75 (75 cm
2
) culture flasks and during experiments cells were grown 
in T-75 (75 cm
2
) culture flasks for western blot,  in twelve wells plate for time-lapse 
microscope imaging or immunostaining, or in 96 well plates for measuring ROS, ATP, and 
lactate production.   
6.2.3 siRNA Transfection 
Small interfering RNA (siRNA) transfection is considered a potent gene silencing method, 
in which a double-stranded RNA, of short length (21-23 base pairs), is used to inhibit gene 
expression. The mechanism of siRNA action can explain in brief, the double-strand RNA 
(dsRNA) is delivered into cultured cells by transfection reagents. We used DharmaFECT 
reagent from Dharmacon, DharmaFECT 1 for HeLa cells, and DharmaFECT 4 for MDA-
MB-231, and HT1080 cells, depending on the manufacturer instructions. The dsRNA is 
complexed with reagent making packaging particles called liposomes that can be uptake 
easily by the cells. Once entered into the cell, dsRNA will be processed to siRNA by the 
RNase III enzyme Dicer. Then the siRNA binds to the RNA inducing silencing complex 
(RISC), which dissociates and degrades the sense strand.  While, the other strand 
(antisense strand) remains with the RISC complex, and assists in the identification of target 
mRNA sequence that is complementary to this single stranded siRNA. Upon recognition of 
the target, it will cleave mRNA by activated RISC, and then it will be degraded by cellular 
machinery, resulting in of downregulation of gene expression.  
We performed a silencing of TRAPI and p66shc genes using a commercial available 
TRAP1 siRNA and our designed p66shc siRNA.  Cells were transfected with 25 nM of 
either TRAP1 siRNA, p66shc siRNA, combination of TRAP1& p66shc siRNA, or with 
scrambled siRNA. Oligonucleotide stock solutions of 20µM were prepared depending to 
the manufacturer’s instructions. 
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Prior to transfection, cells were seeded at density mentioned in Table 6.1 and incubated 
overnight under normal growth conditions for cancer cells. In the day of transfection, 
depending on Dharmacon protocol for siRNA transfection two sets of 4 tubes were 
prepared. In the first set, oligonucleotides were diluted to the desired concentration 
(25nM) in antibiotic and serum free high glucose medium. In the second set, transfection 
reagent was diluted in antibiotic and serum free high glucose medium; DharmaFECT 
reagent type 1 was diluted to final concentration (1µL / ml), while, DharmaFECT reagent 
type 4  was diluted to final concentration (0.5µL / ml). Next, all tubes were incubated for 5 
minutes in room temperature (RT), then content of  each tube in set 2 were mixed with 
same tube in set1 and incubated for 20 minutes in RT allowing complexes to form. Later, 
the volume of each tube was completed to the final used volume using complete medium 
(without antibiotic), then used for treating cells. After 12 hrs of incubation, transfection 
medium was replaced with complete medium to reduce cytotoxic effects of the transfection 
reagent, and then cells were incubated again to complete total 48hrs.  
6.2.4 Immunostaining  
Immunostaining was performed using specific primary anti-p66Shc antibody (Cell 
Signaling Technology) to measure activated p66shc after 48hrs of gene silencing as 
described in section 2.2.8. However, mitochondria were also stained with MitoTracker 
probe prior to fixation step. Images were taken using confocal microscopy and analysed by 
ImageJ software as explained in section 2.2.16. 
6.2.5 Quantitative Real- Time PCR (qRT-PCR)  
The Quantitative real time polymerase chain reaction (qRT-PCR) was used to measure 
mtDNA copy number as described in section 2.2.10.  DNA was extracted after 48hrs of 
gene knockdown.  Primers for the t-RNA gene (for mitochondrial) and the β-actin gene 




Table 6.1: The cell numbers used in the experiments 
Experiment Plates (surface area) Seeding Density 


























6.2.6 Analysis of metabolism and ROS  
ATP, lactate, and ROS production were measured using specific commercial kits as 
described in sections 2.2.14, 2.2.13, and 2.2.12 respectively, after 48hrs of gene 
knockdown.   
6.2.7 Western Blot 
Western blot was used to evaluate protein expression.  The total protein was isolated using 
RIPA lysis buffer containing a cocktail of protease inhibitors (PI), as described in section 
2.2.3. Expression of total p66Shc and TRAP1 were assessed, using anti-p66Shc, anti-
TRAP1 respectively. 
6.2.8 Apoptosis  
Time-lapse microscopy was used for monitoring cell death after 24hrs of silencing p66shc 
and TRAP1 genes. NIS-Elements, Nikon’s imaging software were used to take a series of 
images every 15minutes for 24hrs, and ImageJ software was used for data analysis through 
the cell counter plugin as described in chapter two in section 2.2.18 in page 66.  
6.2.9 Cell migration  
Time-lapse microscopy was used to track single cell migration after 24hrs of silencing 
genes and for duration of 24hrs, and 24hrs ImageJ (Fiji) software (MtrackJ plugin) was 





6.3.1 TRAP1 and p66shc gene silencing efficiency  
To evaluate  the efficiency  of silencing p66shc and TRAP1 genes  on the expression  of 





 flask in high glucose (25mM) DMEM medium (except 
normal glucose control) overnight under humidified condition at 37℃ and 5% CO2. Then 
cells were transfected with (25nM) of smart pool of p66shc siRNA and /or TRAP1 siRNA 
using Dharmacon transfection reagent. Western blot analysis was then performed to 
measure protein p66shc and TRAP1expression.  
We normalized our data to the high glucose control, as we used high glucose to induce 
expression of proteins p66shc and TRAP1. Normal glucose control was used to confirm 
that high glucose induced the expression of these proteins. 
Normalized results showed in Figure 6.3A, revealed that expression of protein p66shc in 
MDA-MB-231 cells was decreased significantly after knockdown of p66shc and 
TRAP1genes alone and in combination together. Compared to scrambled treatment in 
which the expression of p66shc was 94.4%±14.9, it was decreased to 46.4%±1.76 in 
p66shc siRNA treatment (p<0.05). Also we found that TRAP1gene knockdown as well as 
combination of TRAP1 and p66shc gene knockdown were affected the  expression of the 
protein p66shc which decreased to 33.2%±10.4 and 28.1%±4.9 respectively compared to 
p66shc protein expression in scrambled treatment (p<0.01).  
Then we measured the expression of the protein TRAP1 in MDA-MB-231 cells after 
silencing p66shc gene and TRAP1 gene alone and in combination together. Normalized 
results in Figure 6.3B, revealed that expression of protein TRAP1 was reduced markedly 
from 81.7%±3.5 in scrambled treatment to  46.5%±8.9, 43.8%±10.7, and 44.8%±7.4 in 
p66shcsiRNA, TRAP1siRNA, and combination of p66siRNA and TRAP1siRNA 
treatments respectively (p<0.05).  
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The Figures also showed that in the normal glucose control, expression of p66shc and 
TRAP1 proteins was lower than in high glucose control, with 63.3%±6.83 and 49.3%±8.5 
for p66shc and TRAP1 respectively in normal glucose compared to them in high glucose at 








































































































































































Figure 6.3:  Western blot of p66shc and/or TRAP1 proteins in MDA-MB-231 cells after 48hrs of 
silencing p66shc and TRAP1 genes. Cells cultured in high glucose medium overnight then transfected with 
25nM of p66shc siRNA and/or TRAP1 siRNA. (A) Western blot analysis of expression of p66shc protein, 
and (B) Western blots analysis of expression of TRAP1 protein. Data represents the mean ± standard error of 
three independent experiments performed in triplicate. One-way ANOVA followed by Dunnett’s Multiple 
Comparison Test to compare mean of treatments with mean of scrambled siRNA. (*, and **represent 
P<0.05, and 0.01 respectively). 
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When we measured the expression of the protein p66shc and TRAP1 in HT1080 cells to 
know the efficiency of silencing p66shc and TRAP1 genes, we found significant decreases 
in the expression of p66shc from 92.85%±5.37 in non-target siRNA treatment to 
54.95%8.2, and 52.5%±11.46 in p66shcsiRNA, and TRAP1siRNA treatments (p<0.05), 
whereas, statistically no significant differences were observed between the treatment where 
both genes silenced and non-target siRNA treatment, as seen in Figure 6.4A. 
Figure 6.4B shows the results of the expression of protein TRAP1 in HT1080 cells after 
silencing of p66shc and TRAP1 genes, and we found that expression of this protein was 
reduced significantly. It was reduced from 106.4%±5.48 in scrambled siRNA treatment to 
74.65%±9.89, 74.4%±7.96, and 72.87%±4.61 in p66shc siRNA, TRAP1 siRNA, and 
combination of both genes knockdown treatments respectively (p<0.05). 
The results also shows the increases in the expression of both proteins in high glucose 
control compared to normal glucose control.  The expression of p66shc protein was 
52.3%±7.5 (p< 0.01) and protein TRAP1 was 72.7%±5.65 (p<0.05) in normal glucose 

























































































































































































Figure 6.4:  Western blot of p66shc and/or TRAP1 proteins in HT1080 cells after 48hrs of silencing 
p66shc and TRAP1 genes. Cells cultured in high glucose medium overnight then transfected with 25nM of 
p66shc siRNA and/or TRAP1 siRNA. (A) Western blot analysis of expression of p66shc protein, and (B) 
Western blots analysis of expression of TRAP1 protein. Data represents the mean ± standard error of three 
independent experiments performed in triplicate. One-way ANOVA followed by Dunnett’s Multiple 
Comparison Test to compare mean of treatments with mean of scrambled siRNA.  (*, and **represent P < 
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Afterward the efficiency of silencing p66shc and TRAP1 genes in HeLa cells on the 
expression of their protein was measured via western blot. Results in Figure 6.5A, show 
that p66shc expression was reduced from 88.4%±3.57 in scrambled siRNA treatment  to 
51.4%±7.6, 49.3%±8.9, and 58.9%±6.68 in p66shc siRNA, TRAP1siRNA, and both gene 
knockdown treatments respectively (p<0.05). Figure 6.5A also shows that high glucose 
induced significant increases in the expression of this protein, and its expression in normal 
glucose was 50.95%±15.2 of it in high glucose (p<0.01). 
In Figure 6.5B, results showed that silencing the TRAP1 gene was efficient in reducing 
expression of protein TRAP1, it was reduced to 59.8%±6.65 compared to 95.9%±2.76 in 
scrambled siRNA treatment (p<0.05), while, in other treatments statistically no significant 
differences were recorded compared to scrambled siRNA treatment. The results also 
confirm that high glucose enhanced expression of TRAP1 protein, with its expression of 




























































































































































































Figure 6.5:  Western blot of p66shc and/or TRAP1 proteins in HeLa cells after 48hrs of p66shc and 
TRAP1 genes knockdown. Cells cultured in high glucose medium overnight then transfected with 25nM of 
p66shc siRNA and/or TRAP1 siRNA. (A) Represent western blot analysis of expression of p66shc protein, 
and (B) Western blots analysis of expression of TRAP1 protein. Data represents the mean ± standard error of 
three independent experiments performed in triplicate. One-way ANOVA followed by Dunnett’s Multiple 
Comparison Test to compare mean of treatments with mean of scrambled siRNA.  (*, **, and ***represent P 
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6.3.2 Effect of silencing p66shc and/or TRAP1 genes on the activation of p66shc in 
MDA-MB-231 cells.  
To evaluate the effect of silencing p66shc and TRAP1 on the activated p66shc, MDA-MB-
231 cells were grown in high glucose medium (except normal glucose control) overnight. 
Cells were then transfected with p66shc siRNA and /or TRAP1siRNA for 48hrs. Next cells 
were subjected to staining with a mitochondrial probe, and the immunofluorescence 
analysis with anti-p66shc antibody. Images were taken using confocal microscopy and 
ImageJ software was used to measure activated p66shc in treated cells compared to 
scrambled siRNA. Figure 6.6 and micrographs in Figure 6.7 show that silencing of p66shc 
and TRAP1 genes alone and together led to significant decline of activated p66shc 
compared to scrambled siRNA. The mean of activated p66shc was decreased to 140.6±4.2, 
102.3±9.9, and 142.7±7.5 in p66shc siRNA, TRAP1 siRNA, and combination p66shc & 
TRAP1 siRNA treatments respectively compared to 204.5±2.6 in scrambled siRNA 
treatment (p<0.001).  
Analysis of data also found that the mean of activated p66shc was increased from 
93.3±20.7 in normal glucose control to 220.2±14.6 in high glucose control (p<0.001), 
whereas, no significant differences in the mean of activated p66shc was detected between 





























































Figure 6.6:  Effect of silencing p66shc and TRAP1 on the activation of protein p66shc in MDA-MB-231 
cells. After transfection cells with p66shc siRNA and/or TRAP1 siRNA, cells subjected to 
immunofluorescence analysis using anti-p66shc (green) antibody and mitochondrial probe (red). Data 
represents the mean ± standard error of three independent experiments performed in triplicate. One-way 
ANOVA followed by Dunnett’s Multiple Comparison Test to compare mean of treatments with mean of 
scrambled siRNA.  (***represent P < 0.001). 
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Figure 6.7: Microscopic images shows activated p66shc in MDA-MB-231 cells after 48hrs of silencing 
p66shc or/and TRAP1 genes. Green fluorescence represents activated p66shc, and red fluorescence 





6.3.3 Effect of silencing p66shc and/or TRAP1 genes on apoptosis in MDA-MB-231 
cells. 
TRAP1 prevents opening of mitochondrial permeability transition pores and consequently 
prevents apoptosis. To investigate its silencing effect on the apoptosis, we grew MDA-
MB-231 cells in high glucose (25mM) DMEM medium (except normal glucose control) 
overnight.  Then cells were transfected with (25nM) of smart pool of p66shc siRNA and/or 
TRAP1 siRNA after 24hrs from transfection, plate transferred to time-lapse microscope for 
monitoring cell death during next 24hrs. Our results revealed that silencing TRAP1 
significantly induced cell death compared to scrambled siRNA; it was increased from 
6.1%±0.26 in the scrambled siRNA treatment to 18.1%±1.98 in silencing TRAP1 
treatment, while, statistically no significant differences were found in cell death between 
silencing p66shc alone or together with TRAP1 compared to scrambled siRNA, as shown 









































































Figure 6.8:  Effect of Silencing p66shc and TRAP1 genes on cell death in MDA-MB-231 cells. Cells 
were transfected with 25nM of p66shc siRNA and/or TRAP1 siRNA for 48hrs after have been cultured in 
high glucose medium overnight. Scrambled siRNA treated with 25nM of non-target siRNA, whereas, N.G 
and H.G controls were treated only with DharmaFECT reagent. Cell death was measured by time-lapse 
microscopy for 24hrs (during transfection time). Data represents the mean ± standard error of three 
independent experiments performed in triplicate. One-way ANOVA followed by Dunnett’s Multiple 
Comparison Test used to compare mean of treatments with mean of scrambled siRNA  (**represent P 
<0.01). Dharma-FECT 1 
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6.3.4 Effect of silencing p66shc and/or TRAP1 genes on the intracellular ROS 
production.  
To uncover the effect of silencing p66shc and TRAP1 genes alone and together on the 
ROS production, specific commercial ROS assay kit was used to measuring generated 
intracellular ROS by cells.  The genes, p66shc and TRAP1 were silenced in three cell lines, 
MDA-MB-231, HT1080, and HeLa cells, and after 48hrs of silencing genes, the intensity 
of fluorescence DCF which equivalent to generated ROS has been read with fluorometric 
plate reader at 485nm/535nm. The result in Figure 6.9A shows that in MDA-MB-231 cells 
silencing of p66shc alone or with TRAP1 led to decreases in the ROS production, it was 
decreased markedly from a mean of 32142.3±2085 in scrambled siRNA treatment to a 
mean of 18237.8±2427 in p66shc siRNA treatment (p<0.01), and into a mean of 
20381.8±2867 in combination of p66shc siRNA and TRAP1 siRNA treatment (p<0.05); 
this mean that ROS production was decreased by 43.3%, and 36.6% in p66shc siRNA 
treatment and in combination of p66shc siRNA and TRAP1 siRNA treatment respectively. 
No significant differences in the ROS production were observed when the TRAP1 gene 
silenced alone.   
Results for HT1080 cells revealed that silencing of p66shc gene reduced the generation of 
ROS significantly, while, other treatments did not cause significant differences. As seen in 
Figure 6.9B, ROS production was decreased to 17764±2650 in p66shc siRNA treatment 
compared to 32966.3±4926 in scrambled siRNA treatment (p<0.05); which is mean it was 
decreased by 85.6%. 
We found that silencing of p66shc and TRAP1 genes alone and together, statistically did 
not induce significant changes in the ROS production, as shown in Figure 6.9C. 
The results also confirmed that high glucose has induced raised ROS production compared 
to normal glucose in all cell lines, it was increased significantly from 17186.3±3470 in 
normal glucose control to 35115.6±2816 in high glucose (p<0.001) inMDA-MB-231; 
which is mean it was increased by 104.4%, in HT1080 cells it was increased from 
16063±1860  to  34301.5±4456 (p<0.01); which is mean it was increased by 113.6%, and 
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in HeLa cells it was increased from 15915±2676 to 29664.3±3726 (p< 0.05); which is 




































































































































































































































































































































Figure 6.9: Effect of silencing p66shc or/and TRAP1 genes on the ROS production. Intracellular ROS 
production was measured after 48hrs of transfection the cells with p66shc and/or TRAP1 siRNA. A: 
Represents analysed data of MDA-MB-231 cells, B: data of HT1080 cells, C: data of HeLa cells, and D: 
graph shows data of all cell lines together. Data represents the mean ± standard error of four independent 
experiments performed in triplicate. One-way ANOVA followed by Dunnett's Multiple Comparison Test to 




6.3.5 Effect of silencing p66shc and/or TRAP1 genes on cellular metabolism  
Activation and translocating of p66shc to mitochondria leads to a rise of ROS level; this 
can change the mitochondrial microenvironment and affect mitochondrial oxidative 
phosphorylation enzymes. To investigate the effect of silencing p66shc and TRAP1 genes 
alone and together on the cellular metabolism, we measured generated ATP and lactate 
after 48hrs of silencing p66shc and TRAP1 in MDA-MB-231, HT1080, and HeLa cells. 
The Colorimetric ATP Assay Kit was used to quantify generated ATP in cells, while, The 
Glycolysis Cell-Based Assay Kit was used to quantify generated L-lactate.  
Results of ATP production in MDA-MB-231 cells are shown in Figure 6.10A, and it was 
revealed that silencing of p66shc and/or TRAP1 genes decreased ATP production 
significantly. Its production was decreased from 1.12±0.15mM in scrambled siRNA 
treatment to 0.63±0.098, and 0.59±0.12mM in p66shcsiRNA and TRAP1siRNA treatments 
respectively (p<0.05), and into 0.55±0.08mM in treatment of both silenced genes. These 
mean that ATP production was decreased by 43.2%, 46.5%, and 50.6% in p66shcsiRNA, 
TRAP1siRNA, and combination of p66shcsiRNA and TRAP1siRNA treatments 
respectively. 
In the HT1080 cells, silencing of p66shc and TRAP1 genes alone or in combination did not 
cause a significant change in ATP production, as seen in Figure 6.10B. 
While, in HeLa cells, ATP production was strongly affected with silencing mentioned 
genes. Compared to scrambled siRNA treatment, which ATP level was 1.09±0.09mM, it 
was decreased sharply to 0.46±0.05 and 0.43±0.06 in p66shcsiRNA treatment and in 
combination of p66shc siRNA and TRAP1siRNA treatments respectively (p<0.001), and 
into 0.54±0.02mM in TRAP1siRNA treatment (p<0.01); which is mean it was decreased 
by 57.2%, 60.9%, and 50.6% in p66shc siRNA, TRAP1siRNA, and combination of p66shc 
siRNA and TRAP1 siRNA treatments respectively, as shown in Figure 6.10C. 
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Figure 6.10 also shows that high glucose increased ATP production compared to normal 
glucose. In MDA-MB-231 cells ATP production was increased from 0.42±0.08mM in 
normal glucose control to 1.29±0.14mM in high glucose control (p<0.001); which is mean 
it was increased by 213.07% in high glucose control, in HT1080 it was increased from 
1.03±0.2mM to 2±0.22mM (p<0.05); which is mean it was increased by 95.3% in high 
glucose control, and in HeLa cells it was increased from 0.56±0.09mM to 1.02±0.12mM 
(p<0.05); which means it was increased by 82.8% in high glucose control compared to 
















































































































































































































































































Figure 6.10:  Effect of silencing p66shc and/or TRAP1 genes on the ATP production. ATP production 
was measured after 48hrs of transfection the cells with p66shc and/or TRAP1 siRNA using colorimetric ATP 
assay kit. A: Represents analysed data of MDA-MB-231 cells, B: data of HT1080 cells, C: data of HeLa 
cells, and D: a graph shows data of all cell lines together.  Data represents the mean ± standard error of four 
independent experiments performed in triplicate. One-way ANOVA followed by Dunnett's post hoc test to 
compare mean of treatments with the mean of scrambled siRNA treatment (*, ** and ***represent P<0.05, 
0.01, and 0.001 respectively). 
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The results of lactate production presented in Figure 6.11 revealed that silencing p66shc 
and TRAP1 genes alone and together have a strong effect on the production of lactate. In 
MDA-MB-231 cells, it was decreased from 0.31±0.0055mM in scrambled siRNA 
treatment to 0.25±0.004, 0.21±0.003, and 0.27±0.004mM in p66shcsiRNA, TRAP1 
siRNA, and in combination of p66shcsiRNA and TRAP1siRNA treatments respectively 
(p<0.001); which means it decreased by 19.4%, 32.9%, and 13.9% respectively, as seen in 
Figure 6.11A. Similar results were found when we measured lactate production in HT1080 
cells, as shown in Figure 6.11B. It was reduced from 0.46±0.007 mM in scrambled siRNA 
treatment to 0.42±0.005, and 0.42±0.006mM in p66shc siRNA, and combination of p66shc 
siRNA and TRAP1siRNA treatments respectively (p<0.01), and into 0.35±0.007mM in 
TRAP1siRNA treatment respectively (p<0.001); which is mean it was decreased by 
10.2%, 23.7%, and 8.9% in p66shc siRNA, TRAP1 siRNA, and combination of p66shc 
siRNA and TRAP1siRNA treatments respectively. 
In HeLa cells, results shown in Figure 6.11C confirm that silencing of mentioned genes led 
to decrease in lactate production. Compared to scrambled siRNA treatment, in which 
lactate level was 0.27±0.004mM, it decreased to 0.2±0.003, 0.16±0.002, and 0.17±0.002 
mM in p66shcsiRNA, TRAP1siRNA, and combination of p66shcsiRNA and TRAP1 
siRNA treatments respectively (p<0.001); this means it decreased by 27.3%, 39.9%, and 
38% in p66shc siRNA, TRAP1 siRNA, and combination of p66shcsiRNA and TRAP1 
siRNA treatments respectively. 
The results also showed that lactate production was higher in high glucose compared with 
normal glucose in all three cell lines. In MDA-MB-231 cells it was increased from 
0.28±0.03mM in normal glucose control to 0.33±0.006mM in high glucose control 
(p<0.001); which means it increased by 20.85%, in HT1080 it was increased from 
0.42±0.007mM to 0.47±0.005mM (p<0.01); which means it increased by 9.8%, and in 
HeLa cells it was increased from 0.21±0.003mM to 0.29±0.004mM (p<0.001); which 














































































































































































































































































Figure 6.11: Effect of silencing p66shc and/or TRAP1 genes on lactate production. Lactate production 
was measured after 48hrs of transfection the cells with p66shc and/or TRAP1 siRNA using colorimetric 
lactate assay kit. A: Represents analysed data of MDA-MB-231 cells, B: data of HT1080 cells, C: data of 
HeLa cells, and D: a graph shows data of all cell lines together.  Data represents the mean ± standard error of 
three independent experiments performed in triplicate. One-way ANOVA followed by Dunnett's post hoc test 
to compare mean of treatments with the mean of scrambled siRNA treatment (*, ** and ***represent P<0.05, 




6.3.6 Effect of silencing p66shc and/or TRAP1 genes on the cancer cell migration.  
From time-lapse microscopy, cell migration was tracked during 24hrs of MDA-MB-231, 
HT1080, and HeLa cells on aplastic surface and ImageJ software was used to measure 
speed of cell movement. Cells were grown in high glucose medium (except normal glucose 
control) overnight, and then cells were transfected with p66shc siRNA and/or TRAP1 
siRNA.  24hrs post transfection; we started imaging of cell migration. 
The analysed data in Figure 6.12A shows that silencing p66shc and TRAP1 alone or in 
combination, led to decreases in cell migration significantly in MDA-MB-231 cells. It was 
decreased from 23.6±0.79µm/hour in scrambled siRNA treatment to 10.8±1.33, 12.1±1.35, 
and 14.1±0.74µm/hour in p66shcsiRNA, TRAP1siRNA, and combination of p66shc 
siRNA and TRAP1siRNA treatments respectively (p<0.001). Similar results were found 
for HT1080 cells, as shown in Figure 6.12B. It was decreased from 26.98±1.65µm/hour in 
scrambled siRNA treatment to 15.78±0.22, 15.47±0.89, and 16.29±1.1µm/hour in p66shc 
siRNA, TRAP1 siRNA, and combination of p66shc siRNA and TRAP1 siRNA treatments 
respectively (p<0.001). 
Whereas, in HeLa cells, only silencing p66shc gene led to significant decreases in the cell 
migration. It was decreased from 12.6±0.44 µm/hour in scrambled siRNA treatment to 
8.1±0.34µm/hour in p66shc siRNA treatment (p<0.001), while, statistically no significant 
differences were detected between other treatments with scrambled siRNA treatment, as 
shown in Figure 6.12C 
Data also show that high glucose induced cell migration compared to normal glucose in all 
three cell lines. It was increased from16.4±1.39µm/hour in normal glucose to 
29.85±0.33µm/hour in high glucose (p<0.001) in MDA-MB-231 cells, from 13.66±1.3µm/hour to 
28.24±0.6µm/hour in HT1080 (p<0.001), and from 5.9±0.24µm/hour to 12.49±1.2µm/hour in 









































































































































































































































Figure 6.12: Effect of silencing p66shc and/or TRAP1 genes on the cell migration. Time-lapse 
microscopy was used to monitor cell migration for 24 hrs after 24hrs of transfection cells with p66shc and 
TRAP1 siRNA alone and together. A: Represents analysed data of MDA-MB-231 cells, B: data of HT1080 
cells, C: data of HeLa cells, and D: a graph shows data of all cell lines together.  Data represents the mean ± 
standard error of three independent experiments performed in triplicate. One-way ANOVA followed by 
Dunnett test to compare mean of treatments with the mean of scrambled siRNA treatment (*, **and *** 









6.4 Discussion   
There are several studies that report increasing p66shc expression in high metastatic cancer 
(Rajendran et al., 2010, Ma et al., 2007, Bhat et al., 2014, Jackson et al., 2000). In normal 
cells p66shc, which is recognized as a pro-apoptotic protein, can be activated in response 
to oxidative stress induced by different pro-apoptotic stimuli such as H2O2, UV exposure 
(Migliaccio et al., 1999, Straface et al., 2015), and hyperglycaemia (Fadini et al., 2010, 
Minami et al., 2018). Upon activation, p66shc translocate from  cytoplasm to mitochondria 
through TOM/TIM complex where it oxidizes cytochrome c and transfers electrons from 
reduced cytochrome c to oxygen (Galimov, 2010, Giorgio et al., 2005) leading to  
generation of  H2O2 which can induce apoptosis (Giorgio et al., 2005, Galimov, 2010). In 
contrast, cancer cells can avoid apoptosis induced by activated p66shc; however, the 
mechanism is still unclear.  
Interestingly, TRAP1, which is present in very small amounts or nearly absent in normal 
cells is highly expressed and activated in various cancer cells under oxidative stress (Kang 
et al., 2007, Pak et al., 2017). It can minimize the apoptotic effect mediated by ROS 
through inhibition of oxidative phosphorylation (Sciacovelli et al., 2013), and inducing 
glycolysis (Yoshida et al., 2013). It can protect cells also through binding to cyclophin D 
(CypD) to prevents formation and opening of mitochondrial permeability transition pore 
(mPTP) and therefore apoptosis (Matassa et al., 2011). However, the link between p66shc 
and TRAP1 in cancer cells has not been investigated. 
Previously our data showed that oxidative stress induced by high glucose, H2O2, and anti-
cancer agents trigger several changes in MDA-MB-231 cells including fragmentation of 
mitochondria and reprogramming metabolism from oxidative phosphorylation to 
glycolysis which promoted cell migration. This chapter investigated the role of p66shc, 
which can be activated under oxidative stress, on cell migration and cellular metabolism as 
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well as its relationship with TRAP1 in preventing apoptosis in MDA-MB-231, HT1080, 
and HeLa cells, grown under high glucose level that can induce oxidative stress.  
It was found that silencing p66shc and TRAP1genes reduced the expression of their 
proteins; p66shc and TRAP1 in MDA-MB-231 (Figure 6.3), HT1080 (Figure 6.4), and 
HeLa cells (Figure 6.5). However, there was an unexpected decrease in the expression of 
protein p66shc after silencing TRAP1 gene in all three cell lines (Figures 6.3A, 6.4A, and 
6.5A), as well as decreases in the expression of protein TRAP1 after silencing p66shc gene 
in both MDA-MB-231 and HT1080 cell lines (Figures 6.3B, and 6.5B). This finding 
suggests a strong correlation between the function of p66shc and TRAP1 proteins under 
oxidative stresses. The data from the cells that both p66shc and TRAP1 genes were 
silenced, showed significant decreases in the expression of p66shc protein in MDA-MB-
231(Figure 6.3A) and HeLa cells (Figure 6.5A) and the expression of TRAP1 in MDA-
MB-231(Figure 6.3B) and HT1080 (Figure 6.4B) without inducing apoptosis (Figure 6.8). 
This is because silencing p66shc gene will reduce generated ROS which is critical for 
activation TRAP1 that protect cells from its apoptotic effect. Thus, silencing TRAP1 gene 
in combination with p66shc gene confirms this strong relation between the function of 
p66shc and TRAP1 proteins. The data obtained from confocal microscopy that show 
reducing activated p66shc protein after silencing TRAP1 separately and in combination 
with p66shc (Figure 6.6) also confirm the relation between the p66shc and TRAP1 
proteins. 
The mechanism by which silencing p66shc leads to decreasing TRAP1 expression maybe 
due to reducing production of ROS by activated p66shc which promotes expression of 
TRAP1. While the mechanism by which silencing TRAP1 leads to decreasing p66shc 
expression remains unknown. This is the first time that a link between the expression of 
p66shc and TRAP1 has been reported.  
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Increasing expression of p66shc protein in all cell lines under high glucose level (25mM) 
(Figures 6.3A, 6.4A, and 6.5A), along with increased activation (Figure 6.6) were 
predicted as high glucose can induce oxidative stress which leads to increasing ROS 
generation (Figure 6.9).  This study supports evidence from previous observations (Xi et 
al., 2010, Camici et al., 2007, Pagnin et al., 2005, Song et al., 2014) which reported that 
increasing p66shc expression is promoted by hyperglycaemia and diabetes mellitus (which 
is characterized by high glucose conditions) leads to increasing production of ROS and 
apoptosis. Declining levels of intracellular ROS production after silencing p66shc gene 
(Figure 6.9) confirms the important role of p66shc protein in enhancing ROS production. 
This result is in agreement with findings by Migliaccio and co-workers (1999) who found 
that treating mutant mice lacking the p66shc gene with hydrogen peroxide or irradiation 
with UV light did not induce a stress response and their life span was increased by 30% 
compared with wild-type mouse expressing the p66shc gene. Similarly, Galimov and co-
workers (2011) reported that knockout of p66shc gene using lentiviral vector pLSLP in 
RKO cell line (colon cancer cell line) decreased response to oxidative stress induced by 
hydrogen peroxide or serum starvation.  
Surprisingly, despite the strong relationship between TRAP1 and p66shc expression 
(Figure6.3), silencing TRAP1 did not lead to decreases in the intracellular ROS in any of 
the three cell lines (Figure 6.9). One explanation of this finding is that ROS production 
may not be restricted to mitochondria, other organelles such as peroxisomes and 
endoplasmic reticulum also have role in generation of ROS (Brown and Borutaite, 2012, 
Yoboue et al., 2018).   
In agreement with previous studies, our data suggest that TRAP1 plays an essential role in 
prevention of apoptosis induced by high generated ROS by activating p66shc.Whereas, 
silencing of TRAP1 induced apoptosis (Figure 6.8), silencing of p66shc gene separately 
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and in combination with TRAP1gene did not induce apoptosis. One explanation of this 
finding is that TRAP1 protein in mitochondria suppresses pro-apoptotic activity of CypD, 
which is activated in response to ROS induced by p66shc, and prevents opening of mPTP 
and apoptosis. Therefore, silencing of TRAP1 leads to increasing apoptosis, whilst, 
silencing p66shc did not affect apoptosis as a result of decreasing ROS production. 
Moreover, increased generation of ROS in all three cell lines (Figure 6.9) with silenced 
TRAP1 may be an additional factor that enhanced cell apoptosis. These results reflect 
those of Basit and co-workers (2017) who also found that overexpression of TRAP1 led to 
inhibition of the opening of mPTP and therefore of apoptosis in melanoma cell line 
through lowering ROS levels. It was demonstrated that TRAP1 minimizes ROS via 
inhibition of succinate dehydrogenase (SDH) activity and avoiding mPTP opening and 
apoptosis (Sciacovelli et al., 2013, Guzzo et al., 2014). Accordingly, targeting TRAP1 in 
cancer cells in order to induce apoptosis can represent a valuable strategy for cancer 
therapy. 
The present study revealed that in response to oxidative stress induced by high glucose 
levels, p66shc will be activated leading to generation of H2O2. It was documented that 
oxidation of cytochrome c by p66shc, which leads to H2O2 generation, inhibits ATP 
production via oxidative phosphorylation (Hüttemann et al., 2011). Moreover, there is 
evidence that TRAP1, whose expression increases in response to the oxidative stress,  
inhibits succinate dehydrogenase; respiratory complex II in ETC (Guzzo et al., 2014), and 
triggers reprogramming of metabolism from oxidative phosphorylation to 
glycolysis(Yoshida et al., 2013). Indeed, previously our data provided evidence that high 
glucose levels alter metabolism from oxidative phosphorylation towards glycolysis. 
Therefore, it was very interesting to know whether silencing of p66shc and TRAP1 alone 
and in combination affects cellular metabolism and ATP production or not. This is because 
metabolism and ATP production may determine cancer cell migration. 
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Results revealed that high glucose levels led to increasing ATP production (Figure 6.10) 
due to increases in aerobic glycolysis (Figure 6.11) in all three cell lines. Silencing of 
p66shc and TRAP1 alone and together lead to decline of ATP production and slowing 
down of glycolysis in MDA-MB-231 cells (Figure6.10A and 6.11A) and in HeLa cells 
(Figure6.10C and 6.11C). This result suggests that activation of p66shc as well as TRAP1 
plays important roles in rising glycolysis pathway in order to increase ATP production. 
Despite activated p66shc in mitochondria oxidizing cytochrome c as well as TRAP1 
inhibiting SDH (Cosentino et al., 2008, Guzzo et al., 2014), there is evidence that the 
mitochondrial defect in many cancer cells is not permanent and oxidative phosphorylation 
function can be recovered with removing inhibitory factors (Smolková et al., 2011, Lu et 
al., 2015).  Therefore, silencing of p66shc and/or TRAP1 can enhance cells to reverse 
metabolism from glycolysis to oxidative phosphorylation for compensation of required 
ATP. 
 Surprisingly, the results show that despite decreasing glycolysis in HT1080 due to 
knockdown of p66shc, TRAP1, and the combination of them, the decreases in the ATP 
production was nonsignificant (Figure6.10B and 6.11B). One possibility is maybe due to 
high metastatic ability of this cell, and as documented that high metastatic cells are more 
dependent on the glycolysis (Zheng, 2012, Simões et al., 2015), therefore, it may be 
despite decreases of p66shc and TRAP1 expression, cancer cells still rely on glycolysis for 
generating ATP, however, our data cannot confirm this hypothesis as there is a need to 
measure oxidative phosphorylation activity. 
This finding supports the work of other studies in this area linking dysfunction of 
mitochondria with expression of p66shc. Hagopain and co-workers (2016) reported 
decreases in glycolysis in Shc knockout mice, while, β-oxidation enzyme activities were 
increased, which means oxidative phosphorylation is active to generate ATP. They also 
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found that skeletal muscle with low levels of shc proteins have decreased glycolysis 
activities (Hagopian et al., 2015, Hagopian et al., 2016). Similarly, Edwards and co-
workers (2016) reported that increasing expression of p66shc level alters metabolism in 
cultured embryos, they found that ATP production decreased due to defects in oxidative 
phosphorylation as a result of increased superoxide production. While, this finding is 
contrary to previous study by Soliman and co-workers (2014) which have suggested that 
depletion of p66shc in murine embryonic fibroblasts enhanced glycolysis and restoring its 
expression inhibited glycolytic metabolism. They related the effect of p66shc partially to 
inhibition of the mammalian target of rapamycin (mTOR) signaling in response to insulin. 
However, it was shown that Ras/MAPK signaling which has been activated by insulin, 
growth factors, cytokines, and hormones and upstream of mTOR (Carriere et al., 2011, 
Posada et al., 2017), was not affected by p66shc protein (Bonfini et al., 1996, Migliaccio et 
al., 1997, Trinei et al., 2002), and that it is possible that other isoforms of shc1 protein have 
the effect activated by insulin.  
In regard to the effect of silencing TRAP1 on ATP production and glycolysis metabolism, 
a similar result was reported in murine fibroblast TRAP1 knockout cells. It has been found 
that overexpression of TRAP1 negatively regulates mitochondrial oxidative 
phosphorylation and reducing its expression will deregulate mitochondrial respiration 
(Yoshida et al., 2013, Lisanti et al., 2014). The same result was also documented in 
glioblastoma cell line by Chae and co-workers (2012). They suggested that TRAP1 
silencing leads to a variety of metabolic changes including declining glycolysis and 
reduced secretion of lactic acid. Whereas, Guzzo and co-workers (2014) provide more 
detail about TRAP1 function. They suggest that TRAP1 affects respiration through 
inhibition of SDH which leads to reduced ROS generation and protection of cancer cells 
from apoptosis.  The results suggest that overproduction of TRAP1 under oxidative stress 
induced by activated and translocated p66shc protect cancer cells by reducing ROS 
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generated via oxidation of cytochrome c and by inhibiting SDH and the activation of 
CypD, which prevents opening of the mPTP. 
Cell migration is strongly affected by changes in the metabolism (Marelli-Berg and 
Jangani, 2018), and because expression of p66shc and TRAP1induced reprogramming  
metabolism to glycolysis, it was interesting to investigate the  role of them on cell 
migration. As expected, silencing of p66shc and TRAP1 alone and in combination reduced 
cell migration (Figure 6.12) in MDA-MB-231 and HT1080 cell lines, whereas, in HeLa 
cells, only silencing p66shc led to decreasing cell migration. The reason may be due to 
generated ROS and glycolytic metabolism, and as we mentioned above that high metastatic 
cancer cells are more glycolytic (Simões et al., 2015), therefore, silencing of these genes in 
high metastatic cancer cells will markedly affect cell migration. In accordance with the 
present result, a previous study by Jackson and co-workers (2000) demonstrated that 
increased p66shc expression in response to EGF led to increasing metastasis. Ou and co-
workers (2014) found that expression of TRAP1 protein in oesophageal squamous cell 
cancer (ESCC) promoted cell migration, and silencing of it reduced ability of migration. 
This finding is contrary to a previous study by Agliarulo and co-workers (2015) which 
suggested that knockdown of TRAP1 enhanced cell migration in human colorectal tumours 
through modulation of the expression of genes involved in cell migration. It should be 
mentioned here that despite of silencing TRAP1 led to increase in apoptosis (Figure 6.8); 








Chapter Seven:  Investigation role of mitochondria in 3D migration using Collagen 




It has been well documented that the tumor microenvironment (TME) plays a vital role in 
the initiation, progression, and metastasis of cancer cells via interactions between cells and 
its microenvironment (Weber and Kuo, 2012, Kamińska et al., 2015). TME includes 
stromal cells, signaling molecules, immune cells, extracellular matrix (ECM), and blood 
vessels that surround cancer cells and supply them with nutrients and oxygen and remove 
waste. It can affect the cancer cells through deregulation of ECM, activation of 
proliferative signalling, inhibition of cell death, inducing invasion and metastasis, 
deregulation of cell metabolism, and deactivation of immune systems (Spano and Zollo, 
2012, Kamińska et al., 2015). Cancer cells in turn can affect their microenvironment 
through secreting factors that remodel ECM which leads to alteration in their 
microenvironment making it more suitable for their growth, progression, migration and 
colonization at distant organs (Lu et al., 2012, Xiong and Xu, 2016). Moreover, stromal 
cells and stroma can promote cancer cell migration through reprogramming metabolism. It 
was reported that secretion of H2O2 by metastatic cancer cells induces neighbouring 
stromal cell to initiate aerobic glycolysis and efflux by-products such as L-lactate to the 
microenvironment which is taken and used by cancer cells (Sotgia et al., 2012, Xing et al., 
2015). These links and interactions which exist between cancer cells and their micro-
environment pose a challenge in cancer cell studies in the artificial micro-environments. 
For several decades two-dimensional (2D) cell culture techniques served as an essential 
tool in cell and molecular biology studies. In this technique, monolayers of cells adhere to 
a thin flat surface such as glass, and polystyrene plastic, which provides easier 
environmental control, observation of the cells, and measurement and treatment of the cells 
(Lee et al., 2008, Edmondson et al., 2014, Antoni et al., 2015). However, it cannot mimic 
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the true microenvironment that is present in vivo, where cell-cell and cell-extracellular 
matrix (ECM) interaction occurs which is important in the cell survival, growth, and 
migration (Aljitawi et al., 2014, Edmondson et al., 2014). 
3D cell culture models allow the cells to grow and interact with surrounding artificial 
microenvironment that resembles to some extent human tissues and tumors (Vinci et al., 
2012). Despite that 3D cell culture lacks the vascular systems which are essential to 
support tissues with oxygen, nutrients, and to remove waste as in vivo when compared to 
2D cell culture, it is much more effective in studying several biological mechanisms such 
as; cell viability, morphology, drug resistance, cytotoxicity,  gene expression and protein 
synthesis, immune system evasion, migration and invasion of cancer cells into surrounding 
tissues, cell metabolism and apoptosis (Edmondson et al., 2014, Antoni et al., 2015, Ravi 
et al., 2015). 
In the previous chapters, we investigated the impact of the mitochondrial dynamics on cell 
migration. However, there are many studies that found that cells in 3D environments 
exhibit different characteristics, at both morphological and molecular levels that can induce 
cell growth and migration, from monolayer cells in 2D environment (Even-Ram and 
Yamada, 2005, Fried and Gilmour, 2009, Song et al., 2015). Therefore, it was important to 
investigate the impact of mitochondria in 3D environments (Collagen, Alvetex, and 
Decellularised lung tissue) on cell migration. 
7.1.1 Collagen I gel as 3D cell culture: 
In tissues, cells exist in 3D - extracellular matrix which is rich in collagen especially type I. 
In vitro, cells can be cultured in/on 3D collagen matrices that reflect 3D microenvironment 
in vivo, it provides simple and fast method to study and analysis cell migration, cell 
proliferation, and apoptosis (Wolf et al., 2009, Edmondson et al., 2014). It was found that 
cell migration in 3D matrices is different from that on a 2D surface (Fraley et al., 2010), 
because cells grown on collagen rich 3D matrix form a dendritic protrusion instead of 
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lamellipodia and filopodia which display on 2D surface (Giri et al., 2013). As well as cell 
migration in 3D collagen matrix depending  on the expression of matrix metalloproteinases 
(MMPs) enzyme  which initiates the breakdown of matrix and release of  the back of the 
cell (trailing edge)  that in turn  allows the front of the  cell to move forward (Bloom et al., 
2008).  
7.1.2 Alvetex scaffold as 3D cell culture: 
Alvetex is a highly porous, cross-linked polystyrene scaffold that allows invasion and 
proliferation of cells. It is designated as a thin disc that can be located at the bottom of 
wells or suspended in it, with a thickness of 200 μm that allow diffusion of medium and 
removal of waste products, as shown in Figure 7.1. It provides a suitable niche 
environment for proliferation, and migration of cancer cells and allows the cells to 
maintain their 3D shape and interactions with adjacent cells, and can be used to study cells 
in both short and long time experiments (Reinnervatecom, 2017). 
 
 
Mitochondria are highly dynamic organelles; their shape and size are changed upon 
exposure of the cells to stresses.  It has been well known that microenvironment plays an 
important role in cell response to the stresses, in the study by Bai and co-workers (2015); 
they found that cell response to the external stress induced by radiation or chemotherapy 
agents, is influenced by cell culture system. They concluded that expression of genes and 
proteins that participate in regulation of ECM, cell proliferation, cell adhesion, cell 
Figure 7.1:  Alvetex Scaffold. 
Electron Microscope image of 
alvetex scaffold viewing its highly 
porous structure with a thick of 




signaling, and apoptosis in 3D cell culture is different significantly compared to 2D cell 
culture. However, impact of 3D microenvironment on changes in the mitochondrial 
dynamics as a response to stress is not well studied. 
7.1.3 Decellularised lung tissue as 3D cell culture 
The ECM matrix composition is complex and different from one tissue to another. Mixing 
specific single ECM molecules, for example collagen obtained from rat tail, to make 3D 
cell culture in vitro cannot recreate the same ECM composition in vivo exactly. Recently, 
several studies have suggested using decellularised tissue that is used in organ engineering 
and cancer cell studies (O'Neill et al., 2013, Mazza et al., 2015, Xiang et al., 2016). Tissue 
of interest can be taken in vivo and decellularised to be used as an in vitro ECM matrix 
(Gilbert et al., 2006, Hoshiba et al., 2010). Different tissues can be used for this purpose 
such as lung (Mishra et al., 2012) , liver (Mazza et al., 2015), kidney (Bonandrini et al., 
2014), brain (De Waele et al., 2015) and pancreatic tissue (Goh et al., 2013). 
Decellularised lung tissue has been used for studying several cancer cells especially lung 
cancers and breast cancer cells (Mishra et al., 2012, Lu et al., 2014), due to the relevance 
of these decellularised tissues to cancer cell tissues. Xiong and co-workers (2016) used 
decellularised lung tissue for studying invasion and colonization of MDA-MB-231 breast 
cancer cells and 4T1 mouse mammary carcinoma cells (which mimic human breast cancer 
cells). Also, Mishra and co-workers (2012) studied the formation of perfusable tumor 
nodules by A549, H460, and H1299 lung cancer cells on decellularised lung tissue. 
However, until today there is no study on   the mitochondria in 3D decellularised tissue.  
7.2 Aim  
In this chapter we aimed to study the effect of mitochondrial dynamics on cell migration in 





7.3 Material and methods: 
7.3.1 3D collagen I gel cell culture  
 Coating with collagen I gel 
Collagen type 1 was obtained from Merck Millipore at 3.9mg/ml. It was stored at 4℃ and 
kept on ice during preparation. For preparing collagen gels, 1:10 volume of 10X DMEM 
with phenol red (Gibco, Fisher Scientific) was mixed with collagen stock solution, then pH 
neutralized with 1 M sodium hydroxide solution to reach pH  7.4, and completing the 
volume with 1X DMEM to final required volume. Each step was conducted on ice to avoid 
collagen polymerization.  The final collagen concentration was 2mg/ml; 400µL of 
prepared solution was spread into 10 cm
2 
well (6-well plates) to make a thin film. For 
immunostaining, clean coverslips were placed in each well and 100µL of prepared solution 
spread over them to make a thin film.  Collagen was polymerized by incubating plates for 
30 minutes at 37℃ and wells rinsed with PBS and allowed to dry before use.  
 Culture of cells on collagen I gel 
MDA-MB-231 cells that are grown in different glucose concentrations for more than one 
week on 2D plastic surface were trypsinized with 0.05% Trypsin and 0.02 % EDTA and   
2.5X10
4 
cells were seeded in DMEM medium with different glucose concentrations (1, 5.5, 
and 25mM) on 3D collagen gel for 48hrs, then subjected to live imaging with Nikon time-
lapse microscope for tracking cell migration as explained in section 2.2.17, staining with 
MitoTracker probe for staining mitochondria as described in section 2.2.7. For studying 
mtDNA copy number through real-time PCR technique, we seeded 5X10
5
 cells on 3D 
collagen gel in each well for 48hrs,   then total cell DNA was extracted as described in 






7.3.2 3D Alvetex cell culture  
 Preparation of Alvetex scaffolds for cell seeding 
Alvetex 12-well plates (AVP002) were obtained from AMS Biotechnology.  The sterile 
Alvetex scaffold discs were kept in transwell and placed in 12-well plates, before seeding 
of cells.  Scaffolds were treated with 70% ethanol for 15 minutes to allow wetting of 
polymer followed by three washings in sterile PBS. MDA-MB-231 cells were grown in 
DMEM medium with different glucose concentrations were trypsinized with 0.05% 
Trypsin and 0.02 % EDTA then each scaffold was seeded with 100 μl of medium 
containing 2X10
5 
cells. The cells were allowed to settle down for 1 hour in the incubator 
then 4ml of DMEM medium with different glucose concentrations added to each well. The 
culture plates were incubated at 37˚C and 5% CO2, medium was changed every 2-3 days 
for 10 days to allow the cells to penetrate and proliferate into maximum cell number. Then 
cells were processed for mitochondrial staining and DNA extraction for real-time PCR as 
described in section 2.2.7 and 2.2.10 respectively. 
Staining and Sectioning of Alvetex scaffolds 
The 3D alvetex scaffolds were washed twice with PBS after removal of medium, then 2mL 
of pre-warmed serum and antibiotic free growth medium that contains reduced Mito-
Tracker® Orange probe with a final concentration 300 nM was placed into each well. The 
plates were incubated at 37 ℃ and 5% CO2 for 20-30minutes, then medium was removed 
and alvetex scaffolds washed twice with PBS and fixed with 3ml of 4% (w/v) 
Paraformaldehyde (PFA) for 30 minutes in the incubator at 37℃. After three washings in 
PBS, alvetex scaffold disc were cut to small pieces of 15mm length and 5mm width then 
embedded in OCT (Fisher) to make blocks.  The OCT blocks were sectioned at 10-14μm 
thickness using a Cryostat (Bright Model OTF) and sections were transferred to glass 




7.3.3 Decellularised lung tissue as 3D cell culture 
 Decellularization of rat lung  
Decellularised lung (dLung) was prepared based on the protocol (Tris-Trypsin-Triton) 
described by Lu and colleagues for modeling of 3D tumor microenvironments (Lu et al., 
2014). We obtained lungs from 12 week old Sprague Dawley rats.  Prepared decellularised 
rat lung was used as 3D microenvironment tissue for seeding cells after testing it with 
confocal microscope to confirm tissue is free from the cells, as shown in Figure 7.2. 
  
 
 Culture of cells on dLung  
Decellularised rat lung tissue was prepared for use as a 3D culture matrix. It was cut into 
small sizes and placed in 35mm tissue culture dishes under a UV lamp for at least 15-20 
minutes for UV sterilisation. Sterile PBS was added and dLung /PBS placed into a tissue 
culture incubator at 37℃ and 5% CO2 for 24hrs. Then PBS was carefully removed and 
replaced with DMEM culture medium; the tissue was re-incubated for at least 2 days 
before adding the cells. After removing the medium, 2X10
5
 cells were suspended in 100µL 
of DMEM medium with different glucose concentrations and added to the tissue surface 
and incubated for 3hrs to allow the cells to attach to the matrix before flooding the wells 
with a further 3ml of medium. The plates were incubated for 10 days with changes of 
Figure 7.2: Decellularised rat lung 
tissue. Cells removed from lung 





medium every 2-3 days, this allowed the cells to penetrate the dLung tissue and grow to 
the maximum cell numbers that will be enough for generation of required high yields. 
 Fixing and staining colonized decellularised tissue 
The colonized decellularised tissue (cells and decellularised tissue) were washed twice 
with pre-warmed PBS after the removal of medium, then 3mL of pre-warmed serum-
antibiotic free growth medium containing reduced Mito-Tracker® Orange probe with a 
final concentration of 300 nM was added into each well. The plates were incubated at 37℃ 
and 5% CO2 for 20-30minutes, the medium then was removed and colonized decellularised 
tissue washed twice with pre-warmed PBS and fixed with 3ml of 4% PFA for 30 minutes 
in incubator at 37℃.  After one washing with PBS, colonized decellularised tissue was 
permeabilized and blocked with 1% Triton X100/PBS / 10% Goat Serum (Fisher 
Scientific) overnight. Later the colonized decellularised tissue was placed in solution of 
DAPI (Sigma)/PBS for staining nucleus for 1hrs, and then washed twice with PBS buffer 
to remove excess stain on it.  
 Embedding and sectioning colonized decellularised tissue  
Colonized decellularised tissue was soaked in sucrose solution (5% overnight at 4℃, then 
15% and 30% for 2hrs each at room temperature) then embedded in OCT (Fisher). OCT 
blocks were sectioned in thick between 10-14μm using a Cryostat (Bright Model OTF), 
then sections were transferred to clean glass slide.  
 Confocal microscopy  
Nikon A1 confocal microscope was used to take a series of images (Z-stack) captured 
every 0.250 μm of the focal plane. Then obtained 3D series images, as shown in Figure 





Figure 7.3: Micrographs showing 3D image of MDA-MB-231 cells cultured in decellularised lung 
tissue. Mitochondria stained with MitoTracker probe (Red), and nucleus Stained with DAPI.Z-stack 
images were taken by confocal microscope and ImageJ was used for analysing it.  
 
 Extraction of total DNA  
Total DNA (genomic and mitochondrial DNA) was extracted using DNeasy Blood & 
Tissue Kit (QIAGEN) according to the protocol for purification of total DNA from animal 





















7.4.1 Impact of the glucose levels on the mitochondrial number in 3D cell culture 
Unlike 2D surfaces, measuring the changes in the mitochondrial dynamics especially 
mitochondrial number was not accurate in 3D environment. Therefore, we measured 
mtDNA copy number in MDA-MB-231 cells via real-time PCR to investigate the effect of 
the glucose on the mitochondrial number in different 3D cell cultures. In this study, MDA-
MB-231 cells were cultured on collagen coated surfaces for 48hrs, and for 10 days in 
dLung tissue and alvetex scaffolds. Next, total DNA was extracted for measuring of 
mtDNA copy number. Results revealed that increasing glucose concentrations has a 
positive effect on the mtDNA copy number. Figure 7.4A that shows the mtDNA copy 
number in cells cultured on collagen and in different glucose levels was increased to 
2531.9±121.8  in high glucose compared to 1884.98±46.8, and 1637.1±53.6  in normal 
glucose (p<0.01) and in low glucose (p<0.001) respectively. Whereas, no significant 
changes in mtDNA copy number were found between normal and low glucose treatments.  
Similar results were found when we measured mtDNA copy number in the cells cultured in 
Alvetex scaffolds. The mean of the copy number of mtDNA in cells grown in high glucose 
was 2348.4±106.5, and it was significantly higher than it in the normal glucose and in low 
glucose which was 1912.3±54.3 (p<0.05) and 1650.9±77.8 (p<0.01) respectively, and no 
significant differences were recorded between normal and low glucose treatments, as 
shown in Figure 7.4B.  
Figure 7.4C that shows the mtDNA copy number in cells cultured in decellularised lung 
tissue, revealed that mtDNA copy number in cells grown in high glucose was markedly 
higher than in low glucose, the mean of it was 2530.7±171.8 in high glucose treatment 
compared to 1744.1±52.01 in low glucose treatment (p<0.01). Statistically no significant 
differences were observed between high glucose and normal glucose or between normal 
















































































Figure 7.4: Quantification of mtDNA copy number in MDA-MB-231 cells cultured in different glucose 
levels and in different 3D cell cultures. Cells seeded in decellularised lung tissue and Alvetex scaffold for 
10 days and for 48hrs on collagen I gel  in DMEM medium with different glucose concentrations (1, 5.5, and 
25 mM).  Then total cell DNA extracted, mtDNA copy number was determined using quantitative real-time 
PCR. A: Represents data from Collagen I gel, B: from Alvetex, C: from Decellularised lung tissue.  Data 
represent the mean ± standard error of three independent experiments performed in triplicate. One-way 
ANOVA followed by Tukey’s Multiple Comparison Test to compare mean of treatments.  (*, **, and 









7.4.2 Impact of the glucose level on the mitochondrial dynamics in 3D cell culture 
Although the changes in the mitochondrial morphology can be noticed using confocal 
microscopy, however, if we do not say it is impossible to measure these changes, it is 
certainly not easy and not accurate.  In the previous experiment we revealed that mtDNA 
copy number in MDA-MB-231 cells has been affected with different glucose levels in 3D 
cell cultures. To show these changes in the mitochondrial morphology, cells were grown 
on the coverslip coated with the collagen, and in the Alvetex scaffolds, and in the dLung 
tissue. After the incubation period, mitochondria were stained with MitoTracker probe and 
the nucleus with DAPI.  
The micrograph images show that in low glucose levels, mitochondria in the cells appear 
in elongated shape that forms tubular network-like structures throughout the cell. In the 
normal glucose, cells possess mitochondria which have an elongated shape and resemble to 
some extent the mitochondrial morphology of cells grown in the low glucose medium. 
While, the mitochondria in the cells cultured in high glucose have been fragmented to 
small size shape, as they can be seen in Figure 7.5 for cells cultured on collagen gel  , 
Figure 7.6 for cells cultured in Alvetex, and 7.7 for cells cultured in dLung tissue in 








































Figure 7.5: Micrographs showing mitochondria in MDA-MB-231 cells cultured in different glucose levels 
on collagen gel. In low glucose (1mM), mitochondria have an elongated, network like shape.  In normal 
glucose (5.5mM), mitochondria showing elongated shape. In high glucose (25mM), mitochondria appear as 
small fragmented shape. Cells were cultured for 48hrs on 2mg/ml collagen gel. Mitochondria stained with 







































Figure 7.6:  Micrographs showing mitochondria in MDA-MB-231 cells cultured in different glucose levels 
in Alvetex scaffold. In low glucose (1mM), mitochondria have an elongated, network like shape.  In normal 
glucose (5.5mM), mitochondria showing elongated shape. In high glucose (25mM), mitochondria appear as 
small fragmented shape. Cells were cultured for 10 days in Alvetex scaffolds. Mitochondria stained with 
MitoTracker probe (Red), and nucleus Stained with DAPI. Scale bar=10µm 







































Figure 7.7: Micrographs showing mitochondria in MDA-MB-231 cells cultured in different glucose level in 
decellularised lung tissue. In low glucose (1mM), mitochondria have an elongated, network like shape.  In 
normal glucose (5.5mM), mitochondria showing elongated shape. In high glucose (25mM), mitochondria 
appear as small fragmented shape. Cells were cultured for 10 days in decellularised lung tissue. Mitochondria 








7.4.3 Impact of mitochondrial dynamics on 3D cell migration in MDA-MB-231  
In previous experiments as well as in section 3.3.1, we found that increasing the glucose 
level in the medium increased mitochondrial fragmentation, and we also found it led to 
increase in cell migration in 2D plastic surfaces. To know the effects of the mitochondrial 
shape on the cell migration in 3D cell culture, we cultured MDA-MB-231 cells on collagen 
coated surfaces for 48hrs, and different concentrations of glucose were used to induce 
changes in mitochondrial shape. Then through time-lapse microscopy cell movement have 
been tracked for 24hrs. Cell movement was measured using ImageJ-MtrackJ plugin.  
The analysed data showed that cell migration significantly increased with increasing 
glucose level. As shown in Figure7.8, mean of cell movement was increased from 
25.4±0.6µm/h in low glucose to 31±1.06µm/h in normal glucose (p<0.01), and into 
34.4±0.68µm/h in high glucose (p<0.001), whilst, no significant differences were detected 
in the cell movements between cells cultured in the normal glucose and cells cultured in 



































Figure 7.8:  Effect of glucose level on 3D cell migration. Cells were seeded in different glucose 
concentrations on pre-coated collagen surface for 48hrs.  Then cell movement was monitored using time-
lapse microscopy, and ImageJ software used for tracking cell movement every 15 minutes over 24 hours. 
Data represent the mean ± standard error of three independent experiments performed in triplicate. One-way 





7.4.4 Impact of the mitochondrial division inhibitor on 3D cell migration  
The previous results suggested that mitochondrial fission increased with increasing glucose 
level, may be linked with cell migration. We also found in section 3.3.3 that inhibiting 
mitochondrial fission affected cell migration on 2D plastic surface negatively. To uncover 
the effect of inhibiting mitochondrial fission on 3D cell migration, we treated pre-cultured 
cells on the collagen coated surfaces in high glucose medium with different concentrations 
10, 30, 50µM of mitochondrial division-1(mdivi-1) inhibitor for 24hrs. Then, for 24hrs cell 
migration was monitored using time-lapse microscopy and ImageJ-MtrackJ plugin used for 
measuring cell movement. 
The analysed data showed that cell migration declined significantly after inhibition of 
mitochondrial division with mdivi-1 inhibitor. It was decreased sharply from 
34.38±0.68µm/h in non-treated control cells to 23.52±0.34, 18.6±1.2, and 13.76±0.57µm/h 
in treated cells with 10, 30, and 50µM of mdivi-1 inhibitor respectively (p<0.001), as 
shown in Figure 7.9. 































Figure 7.9: Effect of mdivi-1 inhibitor on 3D cell migration. MDA-MB-231 cells were grown in high 
glucose medium on pre-coated collagen surface before treated with mdivi-1 inhibitor for 24hrs.  Then 
through time-lapse microscopy, cell migration was monitored and images were taken every 15 minutes over 
24 hours. The cell movement was measured using ImageJ software. Data represent the mean ± standard error 
of three independent experiments performed in triplicate. One-way ANOVA followed by Dunnett’s test to 




7.5 Discussion  
Since the tumour microenvironment (TME) plays an important role in cancer cell 
migration and metastasis (Quail and Joyce, 2013, Wang et al., 2017a) we investigated the 
impact of mitochondrial dynamics under different glucose levels on cell migration in 
various 3D environments. Collagen has been used in cancer research for a long time (Di 
Lullo et al., 2002, Song et al., 2015, Gu et al., 2016), while, using alvetex scaffolds and 
decellularised lung tissue as 3D culture matrix environments are more recent developments 
(Kramer et al., 2013, Mazza et al., 2015, Ravi et al., 2015). Herein, for the first time they 
were used in mitochondrial study.   
In the present study, MDA-MB-231 cells were seeded on collagen, in Alvetex scaffold, 
and in decellularised tissue, in different glucose levels to quantify mitochondrial DNA 
copy number (mtDNA) through qPCR as an indicator of changes in the mitochondrial 
number. Our data showed that mtDNA increased significantly in high glucose compared to 
low glucose in all three environments as well as compared to normal glucose level in 
collagen and in alvetex scaffold, whereas, no significant changes were observed between 
normal and low glucose levels in all three environments( Figure 7.4). These results suggest 
that increasing glucose level increases fragmentation of the mitochondria, and they are in 
agreement with our previous finding on 2D plastic surface. Mitochondria are highly 
sensitive to oxidative stress such as when induced by high glucose as a result of generated 
ROS which promotes their fragmentation through activation of mitochondrial fission 
protein; Drp1, and inhibition of mitochondrial fusion (Wu et al., 2011, Trudeau et al., 
2011).  
In an attempt to give further insight on mitochondrial morphology under the effect of 
different glucose levels in various 3D environments, a series of images were taken by 
confocal microscope using MitoTracker to stain mitochondria. Results show that 
mitochondria appear as an elongated shape in low glucose and normal glucose, whereas, in 
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high glucose, it has small fragmented shape (Figure 7.5 on collagen, 7.6 in Alvetex, and 
7.7 in decellularised lung tissue), suggesting that the changes in the mitochondrial 
morphology has been induced by increasing glucose level. This result confirm real-time 
qPCR finding as well as support our previous results on 2D plastic surface.                  
These findings in 3D environments may help to understand better the changes in the 
mitochondria in response to stress induced by high glucose, as these environments mimic 
to natural scaffold in vivo (Lu et al., 2014). However, they were more complex than 2D 
culture systems to measure the number, size, and volume of mitochondria due to their 
background which prevented accuracy of these measurements by microscopy.  
Cell migration in 3D environments differ from their 2D counterparts as the cell often 
display a high dendritic pseudopodial protrusions for their migration instead of 
lamellipodia and filopodia, which are displayed in 2D migration (Wu et al., 2014). It has 
been reported that production of matrix metalloproteinases (MMPs); matrix degrading 
enzymes, which play a fundamental role in cancer cell migration and metastasis, increased 
in acidic TME (Kato et al., 2005, Amaral et al., 2018). Previously, we demonstrated that 
mitochondrial fragmentation induces metabolic reprogramming to glycolysis, which leads 
to increases in production of lactic acid, and it is well known that lactic acid contributes to 
acidification of microenvironment (Romero-Garcia et al., 2016, Jiang, 2017). In the present 
study we investigated whether changes in mitochondrial morphology induced by different 
glucose levels can affect cell migration in 3D environments or not. Contrary to 
expectations, this study did not find a significant difference in cell migration between cells 
cultured in high glucose and  normal glucose levels (Figure 7.8), despite of significant 
fragmentation of mitochondria in high glucose compared to normal glucose (Figure 7.4A, 
and 7.5). However, there was increased cell migration in high glucose and normal glucose 
compared to low glucose (Figure 7.8) confirming that changes in mitochondrial morphology 
affect cell migration. 
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This result is in agreement with those obtained by Zanotelli and co-workers (2017), who 
documented that generation of ATP in cancer cells seeded in three-dimensional collagen 
environments   is correlated with speed of cell migration. 
Motility of cells depend on the production of ATP (Campello et al., 2007, Zanotelli et al., 
2017), which can be affected by mitochondrial morphology (Anesti and Scorrano, 2006). In 
low glucose level where mitochondria appear in elongated network-like shape, cells generate 
ATP via oxidative phosphorylation (Li et al., 2017), whereas, fragmentation of mitochondria 
such as when induced by high glucose,  reduces its function for ATP production  (Mannella, 
2006), and this forces the cells to alter metabolism to aerobic glycolysis for production of ATP 
energy(Jiang, 2017). The end product of aerobic glycolysis, lactate, which is released into 
extracellular microenvironment, changes the pH to acidity(Zheng, 2012). In low pH, activated 
matrix metalloproteinase enzymes can enhance cell migration through degradation of matrix 
and non-matrix proteins(Nagase et al., 2006). 
To confirm whether mitochondrial fragmentation leads to increases in cell migration, we 
targeted mitochondrial fission through inhibition of Drp1 protein which mediates 
mitochondrial division with different concentrations of mdivi-1 inhibitor in MDA-MB-231 
cells grown in high glucose level on collagen. Previously we have demonstrated that the 
mdivi-1 inhibitor prevents fragmentation of mitochondria leading to decreases in 
glycolysis as well as ATP generation. Herein, as expected, the result showed significant 
decreases in cell migration in all concentrations of the mdivi-1 inhibitor (Figure 7.9). This 
outcome has supported above results as well as our previously finding in 2D plastic 
surfaces related to the role of mitochondrial dynamic in regulation of cell migration. 
Altogether, these results in 3D environment agree with our previous finding in 2D plastic 
surface that mitochondrial morphology affects cell migration. Alvetex and decellularised 
lung tissue were used for the first time in mitochondrial studies revealed that stress induced 
by high glucose led to fragmentation of mitochondria, whereas, low glucose enhanced 
elongation of mitochondria.    
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we are more confident about our results obtained on 2D surface since it were in agreement 
with obtained results on 3D environment, which are mimic to  human tissues and tumors. 
This mean that the mitochondrial changes and their effect on the cancer cells observed in 



















Chapter Eight:  General Discussion  
Mitochondria play a central role in many cellular pathways including ATP generation, 
lipid metabolism, calcium homeostasis, aging, and apoptosis, as well as being a main 
source for ROS production (Giorgi et al., 2012, Osellame et al., 2012, Payne and Chinnery, 
2015, Sas et al., 2018).  It has been documented that  mitochondria contribute in many 
disorders and diseases such as diabetes mellitus (Kwak et al., 2010), cardiovascular disease 
(Marzetti et al., 2013), neurodegenerative diseases such as Alzheimer and Parkinson 
diseases (Keogh and Chinnery, 2015), autism (Rose et al., 2014), and cancer (Singleterry et 
al., 2014). They are highly dynamic organelles (Yin and Cadenas, 2015, Mishra and Chan, 
2016) and continuously undergo fission and fusion processes in response to different 
cellular signals (Suárez-Rivero et al., 2017). The balance between these two events is 
critical for maintaining mitochondrial function and efficiency (Yin and Cadenas, 2015, 
Mishra and Chan, 2016).  Many factors such as hyperglycaemia, hypoxemia, heat, H2O2, 
U.V., and chemotherapy can disrupt this balance and shift mitochondria toward 
fragmentation (Yu et al., 2006, Yu et al., 2011, Van Beersel et al., 2013, Aung et al., 2017, 
Fan et al., 2010).   
The relationship between mitochondrial morphology and function has been well studied 
(Picard et al., 2013), and there are reports that mitochondrial fragmentation can lead to 
mitochondrial dysfunction (Anesti and Scorrano, 2006, Giedt et al., 2016, Wai and Langer, 
2016). Cell migration, which is a fundamental characteristic of metastasis, can be affected 
by changes in mitochondrial function (Han et al., 2013, Ma et al., 2013). However, the link 
between mitochondrial morphology and their metabolism with cell migration is not yet 
clear. 
Our aim in this study was to determine the link between mitochondrial morphology and 
their metabolism with cell migration through investigating the effect of different glucose 
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levels, H2O2, ZLN005 activator (PGC-1α coactivator), and anti-cancer drugs on 
mitochondrial morphology, mitochondrial metabolism, and cell migration as well as 
studying the role of p66shc and TRAP1, which activated by oxidative stress, alone and in 
combination, on metabolism reprograming and cell migration. 
To investigate the impact of mitochondrial morphologic changes on the cellular 
metabolism and cell migration, we seeded MDA-MB-231 cells in different glucose 
concentrations (1, 5.5, and 25mM). These concentrations were chosen depending on 
reports that related hyperglycaemia with progression of several mitochondria associated 
diseases including cancer initiation (Saha et al., 2017, Chang and Yang, 2016) Indeed, 
there is increasing evidence confirming progression of several types of cancer among 
obesity, and diabetic patients, which are characterized by high glucose rate in the blood, 
albeit the exact reason is not known (Gristina et al., 2015, Wang et al., 2015c). While, in 
low glucose level, down regulation of Drp1 has been reported which leads to mitochondria 
elongation (Rambold et al., 2011) 
Our findings demonstrated that increasing glucose levels led to fragmentation of 
mitochondria, and induced the cells to reprogram their metabolism to be more glycolytic 
and generate higher amount of ATP, which has promoted speed of cell migration.    
Mitochondrial morphology has been affected significantly with increasing oxidative stress 
induced by high glucose, leading to significant fragmentation of mitochondria. This change 
reduced mitochondrial outer membrane and mitochondrial inner membrane, which can 
increase apoptotic resistance and change cell metabolism.   
Despite that changes in mitochondrial morphology depend on the oxidative stress which 
can be induced by several factors, durartion of exposure consider another factor that can 
determine the changes in mitochondrial morphology, since it is not stable and it can be 
reversed as oxidative stress decreased by time. Therefore, it is possible that real 
236 
 
fragmentation rates of mitochondria induced for example by high glucose concentration or 
elongation of mitochondria induced by low glucose concentration, could be higher than 
obtained data. Moreover, mitochondrial overlapping that can occur may impede correct 
counting of mitochondrial number, however, we measured mitochondrial number via real 
time PCR as confirmation test. 
Metabolism reprogramming in high glucose level was expected, because, reduced inner 
membrane surface in small fragmented mitochondria cannot support ETC enzyme function 
to generate ATP (Mannella, 2006). Therefore, cells reprogram their metabolism to aerobic 
glycolysis. In contrary, in low glucose level due to decreases in mitochondrial division 
protein; Drp1, mitochondria elongate with sufficient inner membrane surface for 
production of ATP via ETC. Despite generated ATP /molecule of glucose through 
oxidative phosphorylation is higher compared to generated ATP via aerobic glycolysis, 
however, it is much slower by 10-100 times(Lunt and Vander Heiden, 2011, Liberti and 
Locasale, 2016). Therefore, total generated ATP is lower.   
It was important to measure O2 consumption since it can show changes in oxidative 
phosphorylation rates. However, unavailability of suitable commercial kit and Seahorse XF 
Analyzer, limits the measurment of O2 consumption as an important indicator for 
metabolic reprogrsmmimg in cancer cells. 
Data for cell migration was obtained from two techniques; wound healing assay and 
tracking cell during 24hrs, confirm that speed of cell migration increases significantly with 
increasing concentrations of glucose. This finding shows the importance of glucose in 
controlling cell migration and thereby spreading of tumours. Cancer cells rely on glucose 
not only for generating ATP, but also for cell migration through the end product of 
glycolysis; lactate, which changes acidity of tumour microenvironment and induce 
enzymes for degradation ECM (Rofstad et al., 2006, Kato et al., 2013). 
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This finding of this study may explain the reason for progression of several types of cancer 
among obesity and diabetic patients, which characterised by excessive glucose level in 
their blood hyperglycaemia (Ryu et al., 2014, Martyn et al., 2008, Ozougwu, 2013).  
In diabetes mellitus, glucose concentration in the blood  increases significantly either due 
to an insufficient amount of insulin in the body or due to insulin resistance by body cells 
(Hu et al., 2017). Persistent hyperglycaemic condition causes several complications 
including tissue necrosis, retinopathy (vision loss), neuropathy (peripheral nerve injury), 
and nephropathy (kidney damage) , cancer progression and metastasis (Yagihashi et al., 
2011, Levigne et al., 2013, Kang et al., 2015, Sayin et al., 2015, Volpe et al., 2018). 
Obesity, which is a metabolic disease and can be defined as a massive accumulation of 
adipose tissue, is strongly implicated with progression of several types of cancers (Iyengar 
et al., 2015, De Marchi et al., 2013). Adipose tissue can secrete several adipokines, 
including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), resistin, adipsin, and 
adiponectin that can change the metabolic, immunologic, and endocrine state and promote 
insulin resistance (John et al., 2006), and hyperglycaemia associated with type-2 diabetes 
(Martyn et al., 2008). It also secretes growth factors such as insulin-like growth factor-
1(IGF-1), chemokines, and vascular endothelial growth factor (VEGF), which is seen to 
increase in metastatic cancer (Silha et al., 2005). It was reported that obesity can induce 
systemic oxidative stress as a result of high accumulation of fat and increasing glucose 
level in the circulatory bloods (De Marchi et al., 2013).  
Oxidative stress induced due to high glucose level can regulate development and 
progression of several cancers including liver, pancreatic, lung, breast, colon, prostate, 
ovary, and brain cancers (Saha et al., 2017, Duan et al., 2014) through modification and 
mutation in mtDNA, gnomic DNA, and several proteins and signaling pathways (Al-Kafaji 
and Golbahar, 2013, Lee and Chan, 2015), including tumor suppressor protein, p53, which 
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plays a crucial role in the regulation of the cell cycle and programmed cell death (Bates 
and Vousden, 1999), This protein controls expression of glucose transporter 1 and 4 
(GLU1 and GLU4) through suppression of the promoter activity of GLUT1 and GLUT4 
genes, thereby controls glucose uptake by the cells (Matsuura et al., 2016). Moreover, p53 
inhibits metabolism reprogramming through downregulating the gene expression of 
hexokinase-2 (HK II), first enzyme in glycolysis pathway that converts glucose to glucose-
6-phosphate, and high  expressed and  required for tumor initiation (Patra et al., 2013, 
Matsuura et al., 2016), as well as through regulation of cytochrome c oxidase (COX) 
complex in ETC (Puzio-Kuter, 2011). 
Hyperglycaemia can make a major challenge during cancer treatment. Moreover, 
corticosteroids, which are usually used with chemotherapy to lesson nausea, can increase 
glucose levels in the blood dramatically (Hwangbo and Lee, 2017, Clore and Thurby-Hay, 
2009). Using anti-diabetes drugs such as metformin and insulin, which are usually used in 
treatment for type-2 and type-1 diabetes respectively, in combination with chemotherapy, 
can solve hyperglycaemic conditions through decreasing glucose level in the blood, mainly 
through increasing glucose uptake.  However, using these drugs continuously and for long 
time, can increase glucose flux to the cells more than they tolerate (Sonksen and Sonksen, 
2000) inducing intracellular oxidative stress similar to metabolic stress (Ben Sahra et al., 
2008, Ben Sahra et al., 2010, Giacco and Brownlee, 2010) that can induce fragmentation of 
mitochondria (Lefevre et al., 2012), and  impairing mitochondrial oxidative 
phosphorylation(Suárez-Rivero et al., 2017), which can lead to apoptosis autophagy, and 
cell cycle arrest (Brooks and Dong, 2007). 
Our results in regards to treating MDA-MB-231 cells with H2O2 as an exogenous ROS 
source, which led to fragmentation of mitochondria, reprogramming metabolism to 
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glycolysis, and increases in cell migration, confirmed that the effect of high glucose on the 
cells was likely due to increased oxidative stress. 
Inhibition of mitochondrial fragmentation using mitochondrial division inhibitor1, which 
targets Drp1 protein in MDA-MB-231 cells, show significant decreases in glycolysis and 
cell migration. Fission and fusion are important for biogenesis, mitophagy, and 
mitochondria dynamics and it appears that targeting mitochondrial fission may be effective 
in reducing cancer cell progression and metastasis. Moreover, prevention of mitochondrial 
fragmentation can decrease resistance to apoptosis. Therefore, using mitochondrial 
division inhibitor in cancer treatment in combination with other anti-cancer therapy could 
increase effectiveness of anti-cancer treatments significantly as it increases cancer cell 
sensitivity to apoptosis.  
The missing point in previous studies on cancer progression among diabetes mellitus and 
obesity patients were p66shc and TRAP1 proteins. Protein  p66shc activated and 
translocated from cytoplasm to mitochondria in response to oxidative stress such as that 
exerted by high glucose, U.V , and exogenous H2O2 (Migliaccio et al., 1999, Sun et al., 
2010, Lebiedzinska-Arciszewska et al., 2015) and contributes to increasing mitochondrial 
ROS through oxidizing of cytochrome c (Giorgio et al., 2005). Its expression has been  
linked to defects in mitochondrial metabolism (Soliman et al., 2014) and apoptosis 
(Galimov, 2010). It was shown that oxidative stress induced in obesity and diabetes can 
lead to phosphorylation of p66Shc and triggers mitochondrial apoptosis (De Marchi et al., 
2013). 
Cancer cells can avoid apoptosis induced by p66shc through raising expression of 
cytoprotective protein TRAP1, which is located in the mitochondria and its expression 
increased in response to oxidative stress, can protect the cells from apoptosis through 
inhibition of Cyp D, which is essential in the formation of mPTP channel for release of 
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cytochrome c (Sinha and D'Silva, 2014). It also can inhibit oxidative phosphorylation 
through binding to and inhibiting SDH (Sciacovelli et al., 2013). It appears that cancer 
cells under oxidative stress can avoid themselves from apoptosis as one hallmark through 
increasing expression of TRAP1 and fragmentation of mitochondria. Therefore, preventing 
and inhibition of them can be a key for therapy of several types of cancer.  
A novel finding in our study is that the strong correlation between p66shc and TRAP1 
function may explain how they contribute in cell transformation to cancerous cells in 
diabetic and obesity patients, which characterized by hyperglycaemic and high oxidative 
stress state, through increasing cell resistance to apoptosis and to reprogram mitochondrial 
metabolism to aerobic glycolysis, which is important for initiation, proliferation, and 
success cancer metastasis.  
Despite that p66shc can  play a protective role from the consequences of the damaged 
oxidative stress on the normal cells by  inducing apoptosis,  targeting p66shc as well as 
TRAP1 separately can be effective for treatment of several types of cancers. Targeting  
p66shc protects oxidative phosphorylation and inhibits its reprogramming to glycolysis, 
which is crucial for cancer cell proliferation and increasing cell migration  (Galimov, 
2010). While, targeting TRAP1, which is expressed in very small amounts or nearly absent 
(Kang et al., 2007, Pak et al., 2017), will decline apoptotic resistance significantly, as well 
as maintain oxidative phosphorylation and prevent reprogramming metabolism. Therefore, 
targeting TRAP1 with specific inhibitor in cancer therapy can be in a great value especially 
if combined with other anti-cancer agents that induce apoptosis.  
PGC-1α is a powerful transcription factor involved in the regulation of mitochondrial 
biogenesis, oxidative metabolism (Austin and St-Pierre, 2012), and mitochondrial 
fission/fusion through controlling Drp1 expression (Dabrowska et al., 2015). It is also 
considered a powerful regulator of ROS removal through increasing expression of several 
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ROS-detoxifying enzymes (Austin and St-Pierre, 2012). ZLN005 has been designed as 
selective transcriptional regulator of PGC-1a (Zhang et al., 2013).We were inspired to 
investigate the possibility that overexpression of PGC-1a can induce mitochondrial fission 
independent from oxidative stress, therefore, we treated MDA-MB-231cells with ZLN005. 
The results revealed that ZLN005 can induce mitochondrial fragmentation. However, 
western blotting analysis revealed that increases in expression of PGC-1α and its 
downstream protein Drp1 were limited (only at 10µM of ZLN005).  This finding is quite 
interesting, since, it was supposed that expression of mitochondrial division protein Drp1 
will be increased even if it is not affected by upstream protein regulator; PGC-1α, as 
mitochondria has fragmented significantly in all used concentrations of ZLN005. This 
result can suggest that ZLN005 may be interacting with other unknown proteins and 
pathways that induce fragmentation of mitochondria.  
To further investigate the relationship between mitochondrial morphology and their 
metabolism with cell migration, we targeted glycolysis with 3BrPA inhibitor, which 
inhibits glycolysis through inhibiton of HKII and GAPDH (Ganapathy-Kanniappan et al., 
2009, Ho et al., 2016), and oxidative phosphorylation was targeted with  AMA, which 
inhibit cytochrome c oxidoreductase complex (complex III) in ETC (Ma et al., 2011). The 
findings show that treating MDA-MB-231 cells with both 3BrPA and AMA led to 
fragmentation of mitochondria, with significant increases in ROS production. Our  results 
show that targeting cells with AMA induce reprogramming metabolism to glycolysis, with  
increases in speed of cell migration. Whereas, treating the cells with 3BrPA inhibitor led to 
declining   glycolysis with slowdown of cell migration speed 
These novel finding demonstrates that using AMA in cancer therapy can promote cancer 
cell migration and metastasis as it inhibits oxidative phosphorylation and promotes 
redirection of metabolism to aerobic glycolysis, whereas, fragmentation of mitochondria 
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mediated by AMA can increase resistance to apoptosis. In contrast,  using 3BrPA inhibitor 
for targeting cancer cells may reduce cancer progression and metastasis significantly. 
However, cytotoxic effect of 3BrPA inhibitor on the normal cells can limit its usage as 
anti-cancer therapy in vivo. Since normal cells also rely on glycolysis for generating either 
ATP as in muscle and cardiac cells (Conley et al., 2001, Doenst et al., 2013) or acetyl Co-
A, which enters TCA cycle in mitochondria in most body cells (DeBerardinis and Chandel, 
2016). Recently, it has been reported that metabolic profiles of both T lymphocytes and 
cancer cells are similar, and this increases the risk of targeting cancer cell metabolism with 
3BrPA inhibitor on immune system (Allison et al., 2017).  
Moreover, elevated levels of generated ROS accompanied to 3BrPA inhibitor treatment 
lead to hyperfragmentation of mitochondria, which can increase resistance of cancer cells 
to treatments including 3BrPA inhibitor itself (Renault et al., 2015, Han et al., 2018), as 
well as it can affect and interact with several other pathways, proteins, and enzymes 
(Görlach et al., 2015; Liou and Storz, 2010; Nicco and Batteux, 2017).  Although it has 
been suggested a fragmentation of mitochondria as an initial step of apoptosis (Parone and 
Martinou, 2006), many studies suggested that mitochondrial fragmentation have no role in 
apoptosis (Parone et al., 2006, Suen et al., 2008). Furthermore, there are reports found that 
in some conditions mitochondrial fragmentation can inhibit apoptosis (Arnoult, 2007, 
Renault et al., 2015).Therefore; targeting glycolysis using 3BrPA for cancer treatment 
would not be a good choice to recommend.  
Although targeting metabolism as strategy for cancer treatment has been developed for 
long time (Tran et al., 2016), depending on our result, AMA and 3BrPA are not 
recommended to be used as anti-cancer therapy. However, targeting glucose transporter 
(GLUTs), lactate dehydrogenase A (LDHA), which catalyzes the conversion of pyruvate to 
L-lactate and back, pyruvate dehydrogenase kinase (PDK), inactivate the enzyme pyruvate 
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dehydrogenase, and hexokinase II (Zhao et al., 2013b), which is specific to cancer cells,  
may be more effective in cancer treatment. 
Limitation and challenges in this study  
One of limitation of the present study was inability to investigate O2 consumption, which 
is powerful test to know oxidative phosphorylation rates, due to unavailability of Seahorse 
XF Analyzer, which can measure O2 consumption directly in live cells, during studying 
time. Although we measured ATP and lactate using specific kits, which are high accurate 
for determination ATP and lactate, however, they can show changes in glycolysis but not 
oxidative phosphorylation. 
Another challenge in this study was in counting mitochondrial number using confocal 
microscopy. Due to mitochondrial overlapping it was difficult to measuring mitochondrial 
number in some non-metastatic cell line such as MCF-10A breast cancer cell and HeLa 
cell, which are characterized by high mitochondrial number in contrast to high metastatic 
MDA-MB-231 breast cancer cell line, which characterized by low number of 
mitochondria.  
Since the mitochondria are highly dynamic and the fusion-fission can be occur very fast in 
response to any changes in the medium and temperature, it made a challenge especially 
during staining. We fix this issue through adding paraformaldehyde to culture medium 
directly to fix cells before changing medium and washing the cells with PBS.  
Future study  
This thesis has contributed new insights into the role of mitochondrial morphology and 
their metabolism in regulating cancer cell migration through studying the effect of high 
glucose levels, which feature in several diseases including diabetes, obesity, 
neurodegenerative diseases, and many types of cancers, on mitochondrial dynamics in 
vitro on 2D plastic surface and several 3D cell cultures. Despite this, to confirm the 
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hyperglycaemic effect on mitochondrial morphology and their metabolism, we are 
interested in repeating this investigation on cells biopsy samples from patients with 
diabetes (type1 and type 2) to study changes in mitochondrial morphology in comparison 
with same type of cells taking from cancer patients and healthy control individuals. 
Furthermore, this study will allow us to know the mechanism that makes the diabetic cells 
to avoid cytotoxic effect of accumulated ROS, since generated and accumulated ROS in 
the cells that can be induced by factors such as hyperglycaemia, which is common 
characteristic in many diseases and disorders such as diabetes, obesity, cardiovascular 
diseases, and neurodegenerative diseases, can transform cells to neoplasia and cancer cells. 
Actually, there are reports that referred to cancer progression among diabetes type 2 and 
obesity, which are characterized by severe insulin resistance (Gristina et al., 2015; Iyengar 
et al., 2015; Wang et al., 2015c). Unfortunately, overdose or prolonged use of insulin 
therapy can decline glucose level in the blood to dangerous low levels and at the same time 
induce high uptake of glucose by cells that can causes several health complications  such 
as heart attack, stroke, cancer and eye complications (Duan et al., 2014; Sayin et al., 2015; 
Tseng, 2015).  
Since  p66shc plays an important role in reprogramming metabolism and its function and 
expression is strongly related with TRAP1, which preventing apoptosis, it will be 
interesting to repeat this investigation in other cell lines especially nerve cells as it has 
been reported that many neurodegenerative diseases are linked to hyperglycaemia and 
mitochondrial fragmentation (Rajamani, 2014, Gao et al., 2017), as well as nerve cell death 
due to that high ROS production could be responsible on several complications including 
dementia (Rossen et al., 2009, Gella and Durany, 2009).   
The effect of ZLN0005, which activates expression of PGC-1α and its  downstream protein 
Drp1, was limited to low concentrations, while, at high concentrations it did not show any 
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effect  on expression of PGC-1α or on its downstream protein Drp1, despite significant 
effect of ZLN0005 on the mitochondrial fragmentation, metabolism, and cell migration. 
Recently, α-synuclein, which localizes in cytosol and is present in mitochondria-associated 
endoplasmic reticulum membranes, has been linked to fragmentation of mitochondria 
without expression of Drp1 protein (Guardia-Laguarta et al., 2014, Nakamura et al., 2011). 
Therefore, it will be interesting to study its effect on mitochondrial morphology and 
function in regulating cancer cell migration under hyperglycaemic conditions.  
Finally, It is recommended to use Seahorse XF Analyzer for measuring ATP, lactate, and 
O2 consumption directly in live cells since the results will be more accurate and solve 
technical limitation encountered in the present study. Also it is preferred to study changes 
in mitochondrial morphology at different times as mitochondrial fusion-fission is a 
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